Mallinckrodt (MNKTQ) 10-Q 8 May 14 2014 Q2 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	6 Months Ended
	Mar. 28, 2014	2-May-14
Document And Entity Information [Abstract]	'	'
Entity Registrant Name	'Mallinckrodt plc	'
Entity Central Index Key	'0001567892	'
Trading Symbol	'MNK	'
Current Fiscal Year End Date	'--09-26	'
Entity Filer Category	'Non-accelerated Filer	'
Document Type	'10-Q	'
Document Period End Date	28-Mar-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Amendment Flag	'false	'
Ordinary Shares Outstanding	'	58,477,170

Condensed_Consolidated_and_Com

Condensed Consolidated and Combined Statements of Income (USD $)	3 Months Ended		6 Months Ended
In Millions, except Per Share data, unless otherwise specified	Mar. 28, 2014	Mar. 29, 2013	Mar. 28, 2014	Mar. 29, 2013
Income Statement [Abstract]	'	'	'	'
Net sales	$557.80	$585.30	$1,098	$1,089.30
Cost of sales	295.2	311.8	579.8	582.3
Gross profit	262.6	273.5	518.2	507
Selling, general and administrative expenses	194.1	160.7	340.3	307.5
Research and development expenses	41.4	39.2	80.4	77.6
Separation costs	2.6	14.4	4.8	26.4
Restructuring charges, net	21.7	6.4	29.7	6.6
Gains on divestiture and license	-0.9	-0.7	-13.8	-1.4
Operating income	3.7	53.5	76.8	90.3
Interest expense	-12.4	-0.1	-22.2	-0.2
Interest income	0.5	0.1	0.8	0.1
Other (expense) income, net	-0.4	0	-1	0.2
(Loss) income from continuing operations before income taxes	-8.6	53.5	54.4	90.4
Provision for income taxes	-20.3	19	-3.7	36.1
Income from continuing operations	11.7	34.5	58.1	54.3
Loss from discontinued operations, net of income taxes	-0.1	-0.5	-0.9	-1.1
Net income	$11.60	$34	$57.20	$53.20
Basic earnings (loss) per share (Note 7):	'	'	'	'
Income from continuing operations (in usd per share)	$0.20	$0.60	$1	$0.94
Loss from discontinued operations (in usd per share)	$0	($0.01)	($0.02)	($0.02)
Net income (in usd per share)	$0.20	$0.59	$0.99	$0.92
Basic weighted-averaged shares outstanding (in shares)	58.2	57.7	58	57.7
Diluted earnings (loss) per share (Note 7):	'	'	'	'
Income from continuing operations (in usd per share)	$0.20	$0.60	$0.99	$0.94
Loss from discontinued operations (in usd per share)	$0	($0.01)	($0.02)	($0.02)
Net income (in usd per share)	$0.20	$0.59	$0.97	$0.92
Diluted weighted-average shares outstanding (in shares)	59.1	57.7	58.7	57.7

Condensed_Consolidated_and_Com1

Condensed Consolidated and Combined Statements of Comprehensive Income (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Mar. 28, 2014	Mar. 29, 2013	Mar. 28, 2014	Mar. 29, 2013
Statement of Comprehensive Income [Abstract]	'	'	'	'
Net income	$11.60	$34	$57.20	$53.20
Other comprehensive loss, net of tax	'	'	'	'
Currency translation adjustments	-2.4	-8.5	-2	-8.2
Unrecognized gain (loss) on derivatives, net of $-, $-, $(0.1) and $- tax	0.1	-4	0.2	-4
Unrecognized loss on benefit plans, net of $-, $1.3, $0.1 and $1.1 tax	0	-2	-0.3	-1.7
Total other comprehensive loss, net of tax	-2.3	-14.5	-2.1	-13.9
Comprehensive income	$9.30	$19.50	$55.10	$39.30

Condensed_Consolidated_and_Com2

Condensed Consolidated and Combined Statements of Comprehensive Income (Parenthetical) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Mar. 28, 2014	Mar. 29, 2013	Mar. 28, 2014	Mar. 29, 2013
Statement of Comprehensive Income [Abstract]	'	'	'	'
Unrecognized gain (loss) derivatives, tax	$0	$0	($0.10)	$0
Unrecognized loss on benefit plans, tax	$0	$1.30	$0.10	$1.10

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Mar. 28, 2014	Sep. 27, 2013
In Millions, unless otherwise specified
Current Assets:	'	'
Cash and cash equivalents	$334.90	$275.50
Accounts receivable, less allowance for doubtful accounts of $5.1 and $4.6	334.2	400.8
Inventories	444.7	403.1
Deferred income taxes	371.7	171.1
Prepaid expenses and other current assets	147.6	134.4
Total current assets	1,633.10	1,384.90
Property, plant and equipment, net	997.5	997.4
Goodwill	853.9	532
Intangible assets, net	1,715	422.1
Other assets	255.8	220.2
Total Assets	5,455.30	3,556.60
Current Liabilities:	'	'
Current maturities of long-term debt	11.2	1.5
Accounts payable	119.9	120.9
Accrued payroll and payroll-related costs	58	66.5
Accrued branded rebates	33.6	34.6
Accrued and other current liabilities	403.1	376.7
Total current liabilities	625.8	600.2
Long-term debt	2,204.70	918.3
Pension and postretirement benefits	104	108
Environmental liabilities	63.7	39.5
Deferred income taxes	794.8	310.1
Other income tax liabilities	148.1	153.1
Other liabilities	175.8	171.8
Total Liabilities	4,116.90	2,301
Shareholders' Equity:	'	'
Preferred shares	0	0
Ordinary A shares	0	0
Ordinary shares	11.7	11.5
Ordinary shares held in treasury at cost	-1.8	0
Additional paid-in capital	1,131.40	1,102.10
Retained earnings	90.7	33.5
Accumulated other comprehensive income	106.4	108.5
Total Shareholders' Equity	1,338.40	1,255.60
Total Liabilities and Shareholders' Equity	$5,455.30	$3,556.60

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical)	Mar. 28, 2014	Mar. 28, 2014	Sep. 27, 2013	Sep. 27, 2013
In Millions, except Share data, unless otherwise specified	USD ($)	EUR (€)	USD ($)	EUR (€)
Statement of Financial Position [Abstract]	'	'	'	'
Allowance for doubtful accounts	$5.10	'	$4.60	'
Preferred shares, par value (in usd per share)	$0.20	'	$0.20	'
Preferred shares, shares authorized (in shares)	500,000,000	500,000,000	500,000,000	500,000,000
Preferred shares, shares issued (in shares)	0	0	0	0
Preferred shares, shares outstanding (in shares)	0	0	0	0
Ordinary A shares, par value (in eur per share)	'	€ 1	'	€ 1
Ordinary A shares, shares authorized (in shares)	40,000	40,000	40,000	40,000
Ordinary A shares, shares issued (in shares)	0	0	0	0
Ordinary A shares, shares outstanding (in shares)	0	0	0	0
Ordinary shares, par value (in usd per share)	$0.20	'	$0.20	'
Ordinary shares, shares authorized (in shares)	500,000,000	500,000,000	500,000,000	500,000,000
Ordinary shares, shares issued (in shares)	58,474,132	58,474,132	57,713,873	57,713,873
Ordinary shares, shares outstanding (in shares)	58,443,505	58,443,505	57,713,390	57,713,390
Ordinary shares held in treasury at cost (in shares)	30,627	30,627	483	483

Condensed_Consolidated_and_Com3

Condensed Consolidated and Combined Statements of Cash Flows (USD $)	6 Months Ended
In Millions, unless otherwise specified	Mar. 28, 2014	Mar. 29, 2013
Cash Flows From Operating Activities:	'	'
Net income	$57.20	$53.20
Loss from discontinued operations, net of income taxes	0.9	1.1
Income from continuing operations	58.1	54.3
Adjustments to reconcile net cash provided by (used in) operating activities:	'	'
Depreciation and amortization	76.7	66.9
Share-based compensation	9.4	6.6
Deferred income taxes	-12.3	3.5
Non-cash restructuring charge	2.6	0
Other non-cash items	4.1	-2.8
Changes in assets and liabilities, net of the effects of acquisitions:	'	'
Accounts receivable, net	79.6	-77.8
Inventories	-39	-23.1
Accounts payable	-34	-12
Income taxes	0.3	27.3
Accrued and other liabilities	-18	-38.4
Other	13.7	-12.3
Net cash provided by (used in) operating activities	141.2	-7.8
Cash Flows From Investing Activities:	'	'
Capital expenditures	-50.7	-76.7
Acquisitions and intangibles, net of cash acquired	-1,293.20	-88.1
Restricted cash	4.1	0.9
Other	8	-1.1
Net cash (used in) investing activities	-1,331.80	-165
Cash Flows From Financing Activities:	'	'
Issuance of external debt	1,296.80	0
Repayment of external debt	-30.1	0
Repayment of capital leases	-0.7	-0.7
Excess tax benefit from share-based compensation	4	3
Debt financing costs	-32.2	-2.3
Net transfers to parent	0	172.8
Proceeds from exercise of share options	16.1	0
Repurchase of shares	-1.8	0
Net cash provided by financing activities	1,252.10	172.8
Effect of currency rate changes on cash	-2.1	0
Net increase in cash and cash equivalents	59.4	0
Cash and cash equivalents at beginning of period	275.5	0
Cash and cash equivalents at end of period	$334.90	$0

Condensed_Consolidated_Stateme

Condensed Consolidated Statement of Changes in Shareholders' Equity Statement (USD $)	Total	Ordinary Shares	Treasury Shares	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Income
In Millions, except Share data
Beginning balance at Sep. 27, 2013	$1,255.60	$11.50	$0	$1,102.10	$33.50	$108.50
Beginning balance, ordinary shares at Sep. 27, 2013	57,713,390	57,700,000	'	'	'	'
Beginning balance, treasury shares at Sep. 27, 2013	483	'	0	'	'	'
Net income	57.2	'	'	'	57.2	'
Currency translation adjustments	-2	'	'	'	'	-2
Change in derivatives, net of tax	0.2	'	'	'	'	0.2
Minimum pension liability, net of tax	-0.3	'	'	'	'	0.3
Share options exercised (in shares)	'	400,000	'	'	'	'
Share options exercised (in usd)	20.1	0.1	'	20	'	'
Vesting of restricted shares (in shares)	'	300,000	'	'	'	'
Vesting of restricted shares (in usd)	0	0.1	'	-0.1	'	'
Share-based compensation	9.4	'	'	9.4	'	'
Repurchase of shares (in usd)	-1.8	'	-1.8	'	'	'
Ending balance at Mar. 28, 2014	$1,338.40	$11.70	($1.80)	$1,131.40	$90.70	$106.40
Ending balance, ordinary shares at Mar. 28, 2014	58,443,505	58,400,000	'	'	'	'
Ending balance, treasury shares at Mar. 28, 2014	30,627	'	0	'	'	'

Background_and_Basis_of_Presen

Background and Basis of Presentation	6 Months Ended
	Mar. 28, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Background and Basis of Presentation	'
	1	Background and Basis of Presentation
	Background
	Mallinckrodt plc, and its subsidiaries (collectively, "Mallinckrodt" or "the Company"), is a global company that develops, manufactures, markets and distributes both branded and specialty generic pharmaceuticals, active pharmaceutical ingredients ("API") and diagnostic imaging agents. These products are found in almost every hospital, standalone diagnostic imaging center or pharmacy in the United States ("U.S.") and the Company has a commercial presence in approximately 65 countries. The Company believes its extensive commercial reach and formulation expertise, coupled with its ability to navigate the highly regulated and technical nature of its business, have created compelling competitive advantages that it anticipates will sustain future revenue growth.
	The Company conducts its business in the following two segments:
	•	Specialty Pharmaceuticals produces and markets branded and specialty generic pharmaceuticals and API, comprised of medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients; and
	•	Global Medical Imaging develops, manufactures and markets contrast media and delivery systems ("CMDS") and radiopharmaceuticals (nuclear medicine).
	On June 28, 2013, the Pharmaceuticals business of Covidien plc ("Covidien") was transferred to Mallinckrodt plc, thereby completing its legal separation from Covidien ("the Separation"). On July 1, 2013, Mallinckrodt plc began regular way trading on the New York Stock Exchange under the ticker symbol "MNK."
	Basis of Presentation
	The accompanying unaudited condensed consolidated and combined financial statements reflect the consolidated financial results of the Company as an independent, publicly-traded company for the three and six months ended March 28, 2014 and the consolidated financial position as of March 28, 2014 and September 27, 2013. The three and six months ended March 29, 2013 reflect the combined results of operations of the Pharmaceuticals business of Covidien.
	The unaudited condensed consolidated and combined financial statements have been prepared in U.S. dollars and in accordance with accounting principles generally accepted in the U.S. ("GAAP"). The preparation of the unaudited condensed consolidated and combined financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses. Actual results may differ from those estimates. The unaudited condensed consolidated and combined financial statements include the accounts of the Company, its wholly-owned subsidiaries and entities in which they own or control more than fifty percent of the voting shares, or have the ability to control through similar rights. The results of entities disposed of are included in the unaudited condensed consolidated and combined financial statements up to the date of disposal and, where appropriate, these operations have been reflected as discontinued operations. Divestitures of product lines not representing businesses have been reflected in operating income. All intercompany balances and transactions have been eliminated in consolidation and, in the opinion of management, all normal recurring adjustments necessary for a fair presentation have been included in the interim results reported. The fiscal year-end balance sheet data were derived from audited consolidated financial statements, but do not include all of the annual disclosures required by GAAP; accordingly, these unaudited condensed consolidated and combined financial statements should be read in conjunction with the Company's audited annual consolidated and combined financial statements included in its Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission ("the SEC") on December 13, 2013.
	The Company's unaudited condensed combined financial statements for the three and six months ended March 29, 2013 may not be indicative of its future performance and do not necessarily reflect the results of operations and cash flows that would have been had it operated as an independent, publicly-traded company during that period. The unaudited condensed combined financial statements for the three and six months ended March 29, 2013 include expense allocations for certain functions provided by Covidien, including, but not limited to, general corporate expenses related to finance, legal, information technology, human resources, communications, employee benefits and incentives, insurance and share-based compensation. These expenses were allocated to the Company on the basis of direct usage when identifiable, with the remainder allocated on the basis of operating expenses, headcount or other measures. The amounts allocated were $13.6 million and $25.5 million during the three and six months ended March 29, 2013, respectively, and were included within selling, general and administrative expenses. Management considers the bases on which the expenses were allocated to reasonably reflect the utilization of services provided to, or the benefit received by, the Company; however, the allocations may not reflect the expense the Company would have incurred as an independent, publicly-traded company during that period. Following the Separation, the Company has performed these functions using its own resources or purchased services, certain of which are being provided by Covidien during a transitional period pursuant to a transition services agreement dated June 28, 2013, between Mallinckrodt and Covidien, particularly in relation to areas outside the U.S. The terms and prices on which such services are rendered may not be as favorable as those that were allocated to the Company by Covidien.
	Fiscal Year
	The Company reports its results based on a "52-53 week" year ending on the last Friday of September. The second fiscal quarters of 2014 and 2013 ended on March 28, 2014 and March 29, 2013, respectively. Fiscal 2013 consisted of 52 weeks and ended on September 27, 2013. Unless otherwise indicated, the three and six months ended March 28, 2014 refers to the thirteen and twenty-six week periods ended March 28, 2014 and the three and six months ended March 29, 2013 refers to the thirteen and twenty-six week periods ended March 29, 2013.

Recently_Issued_Accounting_Sta

Recently Issued Accounting Standards	6 Months Ended
	Mar. 28, 2014
Recently Issued Accounting Pronouncements [Abstract]	'
Recently Issued Accounting Standards	'
	2	Recently Issued Accounting Standards
	The Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2011-11 in December 2011, "Disclosures about Offsetting Assets and Liabilities," which was clarified in January 2013 by ASU 2013-01 "Clarifying the Scope of Disclosures about Offsetting Assets and Liabilities." This guidance provides new disclosure requirements about instruments and transactions eligible for offset in the statement of financial position, as well as instruments and transactions subject to an agreement similar to a netting agreement, to enable users of financial statements to understand the effects or potential effects of those arrangements on an entity's financial position. The guidance was effective for the Company in the first quarter of fiscal 2014. The adoption did not have a material impact on the Company's financial condition, results of operations and cash flows.
	FASB issued ASU 2013-02, "Reporting Amounts Classified out of Accumulated Other Comprehensive Income," in February 2013. This guidance requires an entity to present, either on the face of the statement of income or separately in the notes to the financial statements, the effects on net income of significant amounts reclassified out of each component of accumulated other comprehensive income, if those amounts are required to be reclassified to net income in their entirety in the same reporting period. For other amounts not required to be reclassified to net income in their entirety, an entity is required to cross-reference to other disclosures that provide additional details about those amounts. The guidance was effective for the Company in the first quarter of fiscal 2014. The adoption did not have a material impact on the Company's financial condition, results of operations and cash flows.
	FASB issued ASU 2013-11, "Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists," in July 2013. This update provides guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss or a tax credit carryforward exists, to eliminate diversity in practice in the presentation of unrecognized tax benefits in those instances. Except in certain circumstances, an unrecognized tax benefit, or a portion of an unrecognized tax benefit, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss or a tax credit carryforward. This guidance is effective for the Company in the first quarter of fiscal 2015. The Company is still assessing the impact of the pronouncement.
	FASB issued ASU 2014-04, "Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity," in April 2014. Under the new guidance, only disposals representing a strategic shift in a company's operations and financial results should be reported as discontinued operations, with expanded disclosures. In addition, disclosure of the pre-tax income attributable to a disposal of a significant part of an organization that does not qualify as a discontinued operation is required. This guidance is effective for the Company in the first quarter of fiscal 2016, with early adoption permitted. The Company is still assessing the impact of the pronouncement.

License_of_Intellectual_Proper

License of Intellectual Property	6 Months Ended
	Mar. 28, 2014
Discontinued Operations and Disposal Groups [Abstract]	'
License of Intellectual Property	'
	3	License of Intellectual Property
	The Company was involved in patent disputes with a counterparty relating to certain intellectual property relevant to extended-release oxymorphone. In December 2013, the counterparty agreed to pay the Company an upfront cash payment of $4.0 million and contractually obligated future payments of $8.0 million through July 2018, in exchange for the withdrawal of all claims associated with the intellectual property and a license to utilize the Company's intellectual property. The Company has completed the earnings process associated with the agreement and recorded an $11.7 million gain, included within gains on divestiture and license, during the six months ended March 28, 2014.

Acquisitions

Acquisitions	6 Months Ended
	Mar. 28, 2014
Acquisitions [Abstract]	'
Acquisitions	'
	4	Acquisitions
	Business Acquisitions
	Cadence Pharmaceuticals
	On March 19, 2014, the Company acquired all of the outstanding common stock of Cadence Pharmaceuticals, Inc. ("Cadence"), a biopharmaceuticals company focused on commercializing products principally for use in the hospital setting, for total consideration of $14.00 per share in cash, or approximately $1.3 billion. The acquisition was primarily funded through a $1.3 billion senior secured term loan credit facility, as further discussed in Note 11. Cadence's sole product, OFIRMEV® (acetaminophen) injection ("Ofirmev"), is a proprietary intravenous formulation of acetaminophen for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics and the reduction of fever. The acquisition of Cadence adds a growth product to the Specialty Pharmaceuticals product portfolio and provides the Company an opportunity to expand its reach into the adjacent hospital market, in which Cadence had established a strong presence.
	The following amounts represent the preliminary allocation of the fair value of the identifiable assets acquired and liabilities assumed, including preliminary goodwill and intangible assets, and the related deferred tax balances. The Company expects to complete its valuation analysis and finalize deferred tax balances as of the acquisition date no later than the fourth fiscal quarter of 2014. The changes in the purchase price allocation and preliminary goodwill based on the final valuation may include, but are not limited to, changes in deferred income taxes, intangible assets and inventory.
	Cash and cash equivalents	$	43.2
	Inventory	21
	Intangible assets	1,300.00
	Goodwill	321.9
	Other assets, current and non-current (1)	18
	Deferred tax liabilities, net	(296.6		)
	Other liabilities, current and non-current (2)	(78.3		)
	Net assets acquired	$	1,329.20
	-1	This amount includes $14.7 million of accounts receivable, which is also the gross contractual value.
	-2	This amount includes $30.0 million of pre-existing Cadence debt, which the Company repaid upon completion of the acquisition.
	Intangible assets acquired consist of the following:
		Amount			Amortization Period
	Completed technology	$	1,300.00		8 years
	The completed technology intangible asset relates to Cadence's sole product, Ofirmev, the rights to which have been in-licensed from Bristol-Myers Squibb Company ("BMS"). The fair value of the intangible asset was determined using the income approach, which is a valuation technique that provides an estimate of the fair value of the asset based on market participant expectations of the cash flows an asset would generate. The cash flows were discounted at an 13.0% rate. For more information on the BMS license agreement, refer to "License Agreement" below. Based on the Company's preliminary estimate, the excess of purchase price over net tangible and intangible assets acquired resulted in goodwill, which represents the assembled workforce, anticipated synergies and the tax-free nature of the transaction. The goodwill is not deductible for U.S. income tax purposes. All assets acquired are included within the Company's Specialty Pharmaceuticals segment.
	The condensed consolidated statements of income for both the three and six months ended March 28, 2014 included net sales of $5.3 million and a $9.0 million loss from continuing operations before income taxes. These amounts reflect the operating results and amortization expenses of Cadence since the date of acquisition. Acquisition costs included in the consolidated statements of income for the three and six months ended March 28, 2014 were $17.6 million, and were included within selling, general and administrative expenses in the consolidated statements of income.
	The following unaudited pro forma information presents a summary of the combined results of operations of the Company and of Cadence for the three and six months ended March 28, 2014 and March 29, 2013 as if the acquisition had occurred on October 1, 2012, along with certain pro forma adjustments. These pro forma adjustments consist primarily of:
	•	non-recurring costs related to the step-up in value of acquired inventory and transaction costs related to the acquisition of Cadence;
	•	increased amortization expense related to the completed technology intangible asset acquired in the acquisition of Cadence;
	•	increased interest expense to reflect the variable rate term loan and revolving credit facility entered into in connection with the acquisition of Cadence (utilizing the interest rate in effect at March 28, 2014, 3.50%), including interest and amortization of deferred financing costs and original issue discount; and
	•	the related income tax effects.
	The following unaudited pro forma information has been prepared for comparative purposes only and is not necessarily indicative of the results of operations as they would have been had the acquisition occurred on the assumed date, nor is it necessarily an indication of future operating results. In addition, the unaudited pro forma information does not reflect the cost of any integration activities, benefits from any synergies that may be derived from the acquisition or revenue growth that may be anticipated.
		Three Months Ended					Six Months Ended
		March 28,			March 29,		March 28,			March 29,
		2014			2013		2014			2013
	Net sales	$	588.2		$	608.9	$	1,163.70		$	1,130.10
	Net (loss) income	(18.4		)	4.4		(2.6		)	(35.7		)
	Basic (loss) earnings per share	$	(0.32	)	$	0.08	$	(0.04	)	$	(0.62	)
	Diluted (loss) earnings per share	(0.31		)	0.08		(0.04		)	(0.62		)
	CNS Therapeutics
	On October 1, 2012, the Company acquired all the outstanding equity of CNS Therapeutics, Inc. ("CNS Therapeutics"), a specialty pharmaceuticals company focused on developing and commercializing intrathecal products for site-specific administration to the central nervous system to treat neurological disorders and intractable chronic pain, for total consideration of $95.0 million. The total consideration was comprised of an upfront cash payment of $88.1 million (net of cash acquired of $3.6 million) and the fair value of contingent consideration of $6.9 million. This contingent consideration, which could potentially total a maximum of $9.0 million, is discussed further in Note 18. All assets acquired are included within the Company's Specialty Pharmaceuticals segment. The acquisition of CNS Therapeutics expanded the Company's branded pharmaceuticals portfolio and supports the Company's strategy of leveraging its therapeutic expertise and core capabilities in manufacturing, regulatory and commercialization to serve patients. With the acquisition, the Company now offers products for use in the management of severe spasticity of cerebal or spinal origin with a research and development pipeline of an additional presentation and concentration of GABLOFEN® (baclofen injection) ("Gablofen"), as well as other investigational pain products for intrathecal administration.
	The condensed consolidated statements of income for the three and six months ended March 28, 2014 contained $7.8 million and $15.4 million, respectively, of net sales of intrathecal products. The condensed combined statements of income for the three and six months ended March 29, 2013 contained $6.8 million and $13.3 million, respectively, of net sales of intrathecal products. Acquisition and integration costs included in the periods presented were not material.
	License Agreement
	Bristol-Myers Squibb
	As part of the Cadence acquisition, the Company acquired the exclusive development and commercialization rights to Ofirmev in the U.S. and Canada, as well as the rights to the patents and technology, which were originally in-licensed by Cadence from BMS in March 2006. BMS sublicensed these rights to Cadence under a license agreement with SCR Pharmatop S.A. ("Pharmatop"), and the Company has the right to grant sublicenses to third parties. Under this license agreement, the Company may be obligated to make future milestone payments of up to $25.0 million upon the achievement of certain levels of net sales. In addition, the Company is obligated to pay royalties on sales of the product.

Restructuring_and_Related_Char

Restructuring and Related Charges	6 Months Ended
	Mar. 28, 2014
Restructuring and Related Activities [Abstract]	'
Restructuring and Related Charges	'
	5	Restructuring and Related Charges
	During fiscal 2013, the Company launched a restructuring program designed to improve its cost structure ("the 2013 Mallinckrodt Program"). The 2013 Mallinckrodt Program includes actions across both segments, as well as within corporate functions. The Company expects to incur charges of $100.0 million to $125.0 million under this program as the specific actions required to execute on these initiatives are identified and approved, most of which are expected to be incurred by the end of fiscal 2016.
	Prior to Separation, Covidien initiated restructuring programs, which also applied to its Pharmaceuticals business. Restructuring actions associated with acquisitions made prior to the Separation are included within Other programs below. These programs were substantially completed as of September 27, 2013.
	Net restructuring and related charges by segment were as follows:
		Three Months Ended						Six Months Ended
		March 28,			March 29,			March 28,			March 29,
		2014			2013			2014			2013
	Specialty Pharmaceuticals	$	2.7		$	5.9		$	2.7		$	6.6
	Global Medical Imaging	18.5			1			26.6			1.3
	Corporate	0.5			—			0.5			—
	Restructuring and related charges, net	21.7			6.9			29.8			7.9
	Less: accelerated depreciation	—			(0.5		)	(0.1		)	(1.3		)
	Restructuring charges, net	$	21.7		$	6.4		$	29.7		$	6.6
	Net restructuring and related charges were comprised of the following:
		Three Months Ended						Six Months Ended
		March 28,			March 29,			March 28,			March 29,
		2014			2013			2014			2013
	2013 Mallinckrodt Program	$	22.6		$	—		$	30.9		$	—
	Other programs	(0.9		)	6.9			(1.1		)	7.9
	Total programs	21.7			6.9			29.8			7.9
	Less: non-cash charges, including accelerated depreciation	(2.6		)	(0.5		)	(2.7		)	(1.4		)
	Total charges expected to be settled in cash	$	19.1		$	6.4		$	27.1		$	6.5
	The following table summarizes cash activity for restructuring reserves, substantially all of which related to employee severance and benefits, with the exception of $8.4 million related to consulting costs associated with restructuring initiatives:
		2013 Mallinckrodt Program			Other Programs			Total
	Balance at September 27, 2013	$	14.9		$	10.6		$	25.5
	Charges	30			0.8			30.8
	Changes in estimate	(1.7		)	(2.0		)	(3.7		)
	Cash payments	(10.9		)	(5.3		)	(16.2		)
	Currency translation and other	(0.3		)	0.1			(0.2		)
	Balance at March 28, 2014	$	32		$	4.2		$	36.2
	Net restructuring and related charges, including associated asset impairments, incurred cumulative to date related to the 2013 Mallinckrodt Program were as follows:
	Specialty Pharmaceuticals	$	5.2
	Global Medical Imaging	36.3
	Corporate	4.3
		$	45.8
	Substantially all of the restructuring reserves were included in accrued and other current liabilities on the Company's unaudited condensed consolidated balance sheets.

Income_Taxes

Income Taxes	6 Months Ended
	Mar. 28, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	6	Income Taxes
	The Company recognized an income tax benefit of $20.3 million on loss from continuing operations before income taxes of $8.6 million for the three months ended March 28, 2014 and income tax expense of $19.0 million on income from continuing operations before income taxes of $53.5 million for the three months ended March 29, 2013. Income tax benefit was $3.7 million on income from continuing operations before income taxes of $54.4 million for the six months ended March 28, 2014 and $36.1 million on income from continuing operations before income taxes of $90.4 million for the six months ended March 29, 2013.
	The effective tax rates were impacted by the Cadence acquisition and the Separation. The rates for the three and six months ended March 28, 2014 are most notably impacted by the inclusion of a $20.7 million tax benefit associated with the Cadence acquisition, including financing and acquisition costs and amortization of the acquired intangible asset. With regard to the Separation, during the three months ended March 28, 2014, the Company received a $0.4 million tax benefit on $2.6 million of separation costs compared with a $1.0 million tax benefit on $14.4 million of separation costs for the three months ended March 29, 2013. During the six months ended March 28, 2014, the Company received a $1.1 million tax benefit on $4.8 million of separation costs compared with a $1.3 million tax benefit on $26.4 million of separation costs for the six months ended March 29, 2013. These impacts on the effective tax rate for the three and six months ended March 28, 2014 were magnified by the level of income (loss) from continuing operations before income taxes. Furthermore, the Company's effective tax rate for the six months ended March 29, 2013 reflected the business as historically managed by Covidien, rather than as an independent, publicly-traded company.
	The acquisition of Cadence resulted in a preliminary net deferred tax liability increase of $296.6 million. Significant components of this increase include $499.6 million of deferred tax liability associated with the Ofirmev intangible asset, $196.2 million of deferred tax asset associated with federal and state net operating losses, $5.8 million of deferred tax assets associated with federal and state tax credits, and a $7.3 million valuation allowance related to the uncertainty of the utilization of certain deferred tax assets.
	The Company's unrecognized tax benefits, excluding interest, totaled $105.0 million at March 28, 2014 and $100.1 million at September 27, 2013. The net increase of $4.9 million primarily resulted from increases to prior period tax positions of $11.5 million and current year activity of $1.4 million, partially offset by reductions to unrecognized tax benefits as a result of settlements of $0.2 million and the lapse of the applicable statutes of limitation of $7.8 million. Included within the $105.0 million of total unrecognized tax benefits at March 28, 2014, there are $101.2 million of unrecognized tax benefits which if favorably settled would benefit the effective tax rate. The total amount of accrued interest related to these obligations was $56.1 million at March 28, 2014 and $62.1 million at September 27, 2013.
	It is reasonably possible that within the next twelve months, as a result of the resolution of various federal, state and foreign examinations and appeals and the expiration of various statutes of limitation, that the unrecognized tax benefits will decrease by up to $44.9 million and the amount of interest and penalties will decrease by up to $26.4 million.

Earnings_Loss_per_Share

Earnings (Loss) per Share	6 Months Ended
	Mar. 28, 2014
Earnings (Loss) per Share [Abstract]	'
Earnings (Loss) per Share	'
	7	Earnings (Loss) per Share
	Basic earnings (loss) per share is computed by dividing net income by the number of weighted-average shares outstanding during the period. Diluted earnings (loss) per share is computed using the weighted-average shares outstanding and, if dilutive, potential ordinary shares outstanding during the period. Potential ordinary shares represents the incremental ordinary shares issuable for restricted share units and share option exercises. The Company calculates the dilutive effect of outstanding restricted share units and share options on earnings (loss) per share by application of the treasury stock method.
	The computations of basic and diluted earnings (loss) per share assumes that the number of shares outstanding for periods prior to June 28, 2013 was equal to the number of ordinary shares of Mallinckrodt outstanding on June 28, 2013, immediately following the distribution of one ordinary share of Mallinckrodt for every eight ordinary shares of Covidien. The dilutive effect of the Company's share-based awards that were issued as a result of the conversion of Covidien share-based awards with the Separation, the initial equity awards granted to certain of the Company's executives on July 1, 2013 and any other Company grants made since the Separation have been included in the computation of diluted earnings per share for the three and six months ended March 28, 2014, weighted appropriately for the portion of the period they were outstanding.
		Three Months Ended		Six Months Ended
		March 28,	March 29,	March 28,	March 29,
		2014	2013	2014	2013
	Weighted-average shares for basic earnings (loss) per share	58.2	57.7	58	57.7
	Effect of share options and restricted shares	0.9	—	0.7	—
	Weighted-average shares for diluted earnings (loss) per share	59.1	57.7	58.7	57.7
	The computation of diluted earnings per share for the three and six months ended March 28, 2014 includes all equity awards, as no awards were considered to be anti-dilutive.

Inventories

Inventories	6 Months Ended
	Mar. 28, 2014
Inventory, Net [Abstract]	'
Inventories	'
	8	Inventories
	Inventories were comprised of the following at the end of each period:
		March 28,		September 27,
		2014		2013
	Raw materials and supplies	$	85.7	$	68.8
	Work in process	194.9		191.5
	Finished goods	164.1		142.8
		$	444.7	$	403.1

Property_Plant_and_Equipment

Property, Plant and Equipment	6 Months Ended
	Mar. 28, 2014
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment	'
	9	Property, Plant and Equipment
	The gross carrying amount and accumulated depreciation of property, plant and equipment at the end of each period was as follows:
		March 28,			September 27, 2013
		2014
	Property, plant and equipment, gross	$	1,918.30		$	1,873.70
	Less: accumulated depreciation	(920.8		)	(876.3		)
	Property, plant and equipment, net	$	997.5		$	997.4
	Depreciation expense for property, plant and equipment was $26.1 million and $24.4 million during the three months ended March 28, 2014 and March 29, 2013, respectively and $52.4 million and $49.2 million during the six months ended March 28, 2014 and March 29, 2013, respectively. Depreciation expense included depreciation on demonstration equipment of $0.9 million and $0.9 million for the three months ended March 28, 2014 and March 29, 2013, respectively, and $2.0 million and $1.7 million for the six months ended March 28, 2014 and March 29, 2013, respectively. Demonstration equipment was included within other assets on the unaudited condensed consolidated balance sheets.

Goodwill_and_Intangible_Assets

Goodwill and Intangible Assets	6 Months Ended
	Mar. 28, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill and Intangible Assets	'
	10	Goodwill and Intangible Assets
	The carrying amount of goodwill by segment for the periods presented was as follows:
		Specialty Pharmaceuticals		Global Medical Imaging		Total
	Goodwill at September 27, 2013	$	312.3	$	219.7	$	532
	Acquisitions	321.9		—		321.9
	Goodwill at March 28, 2014	$	634.2	$	219.7	$	853.9
	The gross carrying amount and accumulated amortization of intangible assets at the end of each period were as follows:
		28-Mar-14				27-Sep-13
		Gross		Accumulated		Gross		Accumulated
		Carrying		Amortization		Carrying		Amortization
		Amount				Amount
	Amortizable:
	Completed technology	$	1,749.20	$	212.8	$	449.2	$	196.6
	Licenses	201.1		85.5		191.1		79.3
	Trademarks	7.9		3.9		7.9		3.8
	Other	7.2		1.8		—		—
	Total	$	1,965.40	$	304	$	648.2	$	279.7
	Non-Amortizable:
	Trademarks	$	35			$	35
	In-process research and development	18.6				18.6
	Total	$	53.6			$	53.6
	On March 19, 2014, the Company completed its acquisition of Cadence. With this acquisition, the Company acquired a $1.3 billion completed technology intangible asset relating to Cadence's sole product, Ofirmev, the rights to which have been in-licensed from BMS. For more information on the intangible asset, acquisition and BMS license agreement, refer to Note 4.
	In March 2014, the Company obtained approval from the U.S. Food and Drug Administration ("FDA") for XARTEMIS™ XR (oxycodone HCl and acetaminophen) extended-release tablets (CII), resulting in a milestone payment of $10.0 million. In January 2014, the Company purchased royalty rights associated with EXALGO® (hydromorphone HCl) extended-release tablets (CII) for $7.2 million.
	Intangible asset amortization expense was $15.5 million and $8.8 million during the three months ended March 28, 2014 and March 29, 2013, respectively, and $24.3 million and $17.7 million during the six months ended March 28, 2014 and March 29, 2013, respectively. The estimated aggregate amortization expense on intangible assets owned by the Company is expected to be as follows:
	Remainder of fiscal 2014	$	103.1
	Fiscal 2015	200.7
	Fiscal 2016	198.8
	Fiscal 2017	197.4
	Fiscal 2018	188.7

Debt

Debt	6 Months Ended
	Mar. 28, 2014
Debt Disclosure [Abstract]	'
Debt	'
	11	Debt
	Debt was comprised of the following at the end of each period:
		March 28,		September 27, 2013
		2014
	Current maturities of long-term debt:
	Term loan	$	9.8	$	—
	Capital lease obligation	1.4		1.4
	Loan payable	—		0.1
	Total current debt	11.2		1.5
	Long-term debt:
	Term loan	1,287.00		—
	3.50% notes due April 2018	300		299.9
	9.50% debentures due May 2022	10.4		10.4
	8.00% debentures due March 2023	8		8
	4.75% notes due April 2023	598.2		598.2
	Capital lease obligation	1.1		1.8
	Total long-term debt	2,204.70		918.3
	Total debt	$	2,215.90	$	919.8
	In March 2014, in connection with the acquisition of Cadence, Mallinckrodt International Finance S.A. ("MIFSA") and Mallinckrodt CB LLC ("MCB"), each a subsidiary of the Company, entered into senior secured credit facilities consisting of a $1.3 billion term loan facility due 2021 ("the Term Loan") and a $250.0 million revolving credit facility due 2019 ("the Revolver") (collectively, "the Facilities"). The Facilities are fully and unconditionally guaranteed by Mallinckrodt plc, certain of its direct or indirect wholly-owned U.S. subsidiaries and each of its direct or indirect wholly-owned subsidiaries that owns directly or indirectly any such wholly-owned U.S. subsidiary (collectively, "the Guarantors"). The Facilities are secured by a security interest in certain assets of MIFSA, MCB and the Guarantors. The Facilities contain customary affirmative and negative covenants, which include, among other things, restrictions on the Company's ability to declare or pay dividends, create liens, incur additional indebtedness, enter into sale and lease-back transactions, make investments, dispose of assets and merge or consolidate with any other person. In addition, the Revolver contains a financial covenant that may limit the Company's total net leverage ratio, which is defined as the ratio of (i) the Company's consolidated debt, less any unrestricted cash and cash equivalents, to (ii) the Company's adjusted consolidated EBITDA, as defined in the credit agreement. The Facilities bear interest at LIBOR plus a margin based on the Company's total net leverage ratio, and the Term Loan is subject to a minimum LIBOR level of 0.75%. Interest payment dates are variable based on the LIBOR rate utilized, but the Company generally expects interest to be payable every 90 days. The Term Loan requires quarterly principal amortization payments in an amount equal to 0.25% of the original principal amount of the Term Loan payable on the last day of each calendar quarter, commencing on June 30, 2014, with the remaining balance payable on the due date, March 19, 2021. The Company incurred an original issue discount of 0.25%, or $3.3 million, associated with the Term Loan. The Revolver contains a $150.0 million letter of credit provision, of which none had been issued as of March 28, 2014. Unused commitments on the Revolver are subject to an annual commitment fee determined by reference to the Company's public debt rating, which was 0.375% as of March 28, 2014, and the fee applied to outstanding letters of credit is based on the interest rate applied to borrowings. As of March 28, 2014, the applicable interest rate on outstanding borrowings under the Revolver would have been approximately 3.00%; however, there were no outstanding borrowings. As of March 28, 2014, the applicable interest rate for the Term Loan was 3.50% and outstanding borrowings totaled $1.3 billion.
	In conjunction with entering into the Revolver in March 2014, MIFSA terminated the $250.0 million five-year senior unsecured revolving credit facility entered into in March 2013.
	In April 2013, MIFSA issued and sold in a private placement $300.0 million aggregate principal amount of 3.50% senior unsecured notes due April 2018 and $600.0 million aggregate principal amount of 4.75% senior unsecured notes due April 2023 (collectively, "the Notes"). In connection with the initial offering, MIFSA entered into a registration rights agreement with the initial purchasers in which MIFSA agreed, among other things, to register the Notes with the SEC within one year of the issuance of the Notes. On January 16, 2014, MIFSA filed the registration statement, which was declared effective on March 5, 2014, and the bonds were exchanged in accordance with the registration statement. The Notes are subject to an indenture which contains customary affirmative and negative covenants. Mallinckrodt plc has fully and unconditionally guaranteed the Notes on an unsecured and unsubordinated basis. MIFSA pays interest on the Notes semiannually in arrears on April 15 and October 15 of each year.
	As of March 28, 2014, the Company was, and expects to remain, in compliance with the provisions and covenants associated with the Term Loan, the Revolver, the Notes and its other debt agreements.

Retirement_Plans

Retirement Plans	6 Months Ended
	Mar. 28, 2014
Compensation and Retirement Disclosure [Abstract]	'
Retirement Plans	'
	12	Retirement Plans
	The net periodic benefit cost for the Company's defined benefit pension plans was as follows:
		Three Months Ended						Six Months Ended
		March 28,			March 29,			March 28,			March 29,
		2014			2013			2014			2013
	Service cost	$	1.2		$	1.2		$	2.5		$	2.4
	Interest cost	5			4.5			9.9			9.1
	Expected return on plan assets	(6.1		)	(7.3		)	(12.2		)	(14.7		)
	Amortization of net actuarial loss	2.1			3			4.2			6
	Amortization of prior service (credit) cost	(0.2		)	0.2			(0.3		)	0.3
	Plan settlements	0.3			—			0.3			—
	Net periodic benefit cost	$	2.3		$	1.6		$	4.4		$	3.1
	The net periodic benefit credit for the Company's postretirement benefit pension plans for the three months ended March 28, 2014 and March 29, 2013 was $1.8 million and $1.5 million, respectively, and $3.6 million and $3.1 million for the six months ended March 28, 2014 and March 29, 2013, respectively. The components of the credit were not material.
	During the six months ended March 29, 2013, Covidien made a $37.5 million voluntary contribution to the Company's pension plans. The Company may elect to make voluntary contributions to its defined benefit pension plans or its postretirement benefit plans during fiscal 2014.

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Income	6 Months Ended
	Mar. 28, 2014
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]	'
Accumulated Other Comprehensive Income	'
	13	Accumulated Other Comprehensive Income
	The components of accumulated other comprehensive income were as follows:
		Currency Translation			Unrecognized Gain (Loss) on Derivatives			Unrecognized Gain (Loss) on Benefit Plans			Accumulated Other Comprehensive Income
	Balance at September 27, 2013	$	158.6		$	(7.3	)	$	(42.8	)	$	108.5
	Other comprehensive loss before reclassifications	(2.0		)	—			—			(2.0		)
	Amounts reclassified from accumulated other comprehensive income	—			0.2			(0.3		)	(0.1		)
	Net current period other comprehensive (loss) income	(2.0		)	0.2			(0.3		)	(2.1		)
	Balance at March 28, 2014	$	156.6		$	(7.1	)	$	(43.1	)	$	106.4
	The following summarizes reclassifications out of accumulated other comprehensive income for the three and six months ended March 28, 2014:
		Amount Reclassified from
		Accumulated Other Comprehensive Income
		Three Months Ended March 28, 2014			Six Months Ended March 28, 2014			Line Item in the Unaudited Condensed Consolidated
								Statement of Income
	Amortization of unrealized gain on derivatives	$	0.1		$	0.3		Interest expense
	Income tax provision	—			(0.1		)	Provision for income taxes
	Net of income taxes	0.1			0.2
	Amortization of pension and post-retirement benefit plans:
	Net actuarial loss	2.1			4.2			(1)
	Prior service credit	(2.4		)	(4.9		)	(1)
	Plan settlements	0.3			0.3			(1)
	Total before tax	—			(0.4		)
	Income tax provision	—			0.1			Provision for income taxes
	Net of income taxes	—			(0.3		)
	Total reclassifications for the period	$	0.1		$	(0.1	)
	-1
		These accumulated other comprehensive income components are included in the computation of net periodic benefit cost. See Note 12 for additional details.

Transactions_with_Former_Paren

Transactions with Former Parent Company	6 Months Ended
	Mar. 28, 2014
Related Party Transactions [Abstract]	'
Transactions with Former Parent Company	'
	14	Transactions with Former Parent Company
	Prior to the completion of the Separation on June 28, 2013, the Company was part of Covidien and, as such, transactions between Covidien and the Company were considered related party transactions. These intercompany transactions were included in the unaudited condensed combined financial statements for the three and six months ended March 29, 2013, and were considered to be effectively settled for cash at the time the transactions were recorded. The continuing relationship between Covidien and the Company is primarily governed through agreements entered into as part of the Separation, including a separation and distribution agreement, a tax matters agreement and a transition services agreement. These agreements were filed with the SEC as Exhibits 2.1, 10.1 and 10.3, respectively, to the Company's Current Report on Form 8-K filed on July 1, 2013. For further discussion on these agreements and other historical related party transactions, refer to the Company's Annual Report on Form 10-K filed with the SEC on December 13, 2013.
	Sales and Purchases
	During the three months ended March 28, 2014 and March 29, 2013, the Company sold inventory to Covidien in the amount of $11.1 million and $11.8 million, respectively, which is included in net sales in the unaudited condensed consolidated and combined statements of income. During the six months ended March 28, 2014 and March 29, 2013, the Company sold inventory to Covidien in the amount of $23.2 million and $25.9 million, respectively. The Company also purchases inventories from Covidien. The Company recognized cost of sales from these inventory purchases of $9.3 million and $9.1 million during the three months ended March 28, 2014 and March 29, 2013 and $19.3 million and $22.0 million during the six months ended March 28, 2014 and March 29, 2013, respectively.
	Allocated Expenses
	As discussed in Note 1, the unaudited condensed combined financial statements for the three and six months ended March 29, 2013 included expense allocations for certain functions provided by Covidien, including, but not limited to, general corporate expenses related to finance, legal, information technology, human resources, communications, employee benefits and incentives, insurance and share-based compensation. These expenses were allocated to the Company on the basis of direct usage when identifiable, with the remainder allocated on the basis of operating expenses, headcount or other measures. The amounts allocated were $13.6 million and $25.5 million during the three and six months ended March 29, 2013, and were included within selling, general and administrative expenses.
	Balance Sheet Impacts
	Subsequent to the Separation, the Company and Covidien maintain an ongoing relationship in which each party may provide services to the other party, including the distribution of goods. As a result of these relationships, the unaudited condensed consolidated balance sheets as of March 28, 2014 and September 27, 2013 included $64.5 million and $62.2 million, respectively, of amounts due to the Company from Covidien, within prepaid expenses and other current assets, and $74.3 million and $79.3 million, respectively, of amounts the Company owes Covidien, included within accrued and other liabilities.

Guarantees

Guarantees	6 Months Ended
	Mar. 28, 2014
Guarantees [Abstract]	'
Guarantees	'
	15	Guarantees
	In disposing of assets or businesses, the Company has historically provided representations, warranties and indemnities to cover various risks and liabilities, including unknown damage to the assets, environmental risks involved in the sale of real estate, liability to investigate and remediate environmental contamination at waste disposal sites and manufacturing facilities, and unidentified tax liabilities related to periods prior to disposition. The Company assesses the probability of potential liabilities related to such representations, warranties and indemnities and adjusts potential liabilities as a result of changes in facts and circumstances. The Company believes, given the information currently available, that their ultimate resolution will not have a material adverse effect on its financial condition, results of operations and cash flows.
	In connection with the sale of the Specialty Chemicals business (formerly known as Mallinckrodt Baker) in fiscal 2010, the Company agreed to indemnify the purchaser with respect to various matters, including certain environmental, health, safety, tax and other matters. The indemnification obligations relating to certain environmental, health and safety matters have a term of 17 years from the sale, while some of the other indemnification obligations have an indefinite term. The amount of the liability relating to all of these indemnification obligations included in other liabilities on the Company's unaudited condensed consolidated balance sheets as of March 28, 2014 and September 27, 2013 was $16.8 million and $20.1 million, respectively, of which $13.9 million and $17.2 million, respectively, related to environmental, health and safety matters. The value of the environmental, health and safety indemnity was measured based on the probability-weighted present value of the costs expected to be incurred to address environmental, health and safety claims made under the indemnity. The aggregate fair value of these indemnification obligations did not differ significantly from their aggregate carrying value at March 28, 2014 and September 27, 2013. As of March 28, 2014, the maximum future payments the Company could be required to make under these indemnification obligations was $71.4 million. The Company was required to pay $30.0 million into an escrow account as collateral to the purchaser, of which $19.4 million and $23.5 million remained in other assets on the unaudited condensed consolidated balance sheets at March 28, 2014 and September 27, 2013, respectively.
	The Company has recorded liabilities for known indemnification obligations included as part of environmental liabilities, which are discussed in Note 16. In addition, the Company is liable for product performance; however, the Company believes, given the information currently available, that their ultimate resolution will not have a material adverse effect on its financial condition, results of operations and cash flows.
	The Company is required to provide the U.S. Nuclear Regulatory Commission financial assurance demonstrating its ability to fund the decommissioning of its Maryland Heights, Missouri radiopharmaceuticals production facility upon closure, though the Company does not intend to close this facility. The Company has provided this financial assurance in the form of a $58.0 million surety bond.
	In addition, as of March 28, 2014, the Company had a $21.1 million letter of credit to guarantee decommissioning costs associated with its Saint Louis, Missouri plant. As of March 28, 2014, the Company had various other letters of credit and guarantee and surety bonds totaling $30.7 million.
	In addition, the separation and distribution agreement entered into with Covidien at the Separation provides for cross-indemnities principally designed to place financial responsibility of the obligations and liabilities of the Company's business with the Company and financial responsibility for the obligations and liabilities of Covidien's remaining business with Covidien, among other indemnities.

Commitments_and_Contingencies

Commitments and Contingencies	6 Months Ended
	Mar. 28, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	16	Commitments and Contingencies
	The Company is subject to various legal proceedings and claims, including patent infringement claims, product liability matters, environmental matters, employment disputes, contractual disputes and other commercial disputes, including those described below. The Company believes that these legal proceedings and claims likely will be resolved over an extended period of time. Although it is not feasible to predict the outcome of these matters, the Company believes, unless indicated below, given the information currently available, that their ultimate resolution will not have a material adverse effect on its financial condition, results of operations and cash flows.
	Governmental Proceedings
	On November 30, 2011 and October 22, 2012, the Company received subpoenas from the U.S. Drug Enforcement Administration requesting production of documents relating to its suspicious order monitoring programs. The Company is complying as required by the terms of the subpoenas. While it is not possible at this time to determine with certainty the outcome of these proceedings, the Company believes, given the information currently available, that their ultimate resolution will not have a material adverse effect on its financial condition, results of operations and cash flows.
	Patent/Antitrust Litigation
	Tyco Healthcare Group LP, et al. v. Mutual Pharmaceutical Company, Inc. The Company filed a patent infringement suit in the U.S. District Court for the District of New Jersey against Mutual Pharmaceutical Co., Inc., et al. (collectively, "Mutual") on March 20, 2007 pursuant to procedures set out in the Drug Price Competition and Patent Term Restoration Act of 1984, after Mutual submitted an Abbreviated New Drug Application ("ANDA") to the FDA seeking to sell a generic version of the Company's 7.5mg RESTORIL™ sleep aid product. Mutual also filed antitrust and unfair competition counterclaims. The patents at issue have since expired or been found invalid. On January 18, 2013, the trial court issued an opinion and order granting the Company's motion for summary judgment regarding Mutual's antitrust and unfair competition counterclaims. On May 1, 2013, Mutual appealed this decision to the U.S. Court of Appeals for the Federal Circuit and oral arguments were heard on February 6, 2014. While it is not possible at this time to determine with certainty the ultimate outcome of the counterclaims, the Company believes, given the information currently available, that their ultimate resolution will not have a material adverse effect on its financial condition, results of operations and cash flows.
	'222 and '218 Patent Litigation: Exela Pharma Sciences, LLC and Perrigo Company. In August 2011, Cadence, a subsidiary of the Company, and Pharmatop, the owner of the two U.S. patents and two Canadian patents licensed exclusively by Cadence, filed suit in the U.S. District Court for the District of Delaware against Exela Pharma Sciences, LLC, Exela PharmaSci, Inc. and Exela Holdings, Inc. (collectively, "Exela") and Perrigo Company, and its subsidiary, Paddock Laboratories, LLC (collectively, "Perrigo"). In the lawsuit, Cadence alleged that Exela and Perrigo infringed U.S. Patent Nos. 6,028,222 ("the '222 patent") and 6,992,218 ("the '218 patent") by filing their ANDAs seeking approval from the FDA to market a generic version of Ofirmev prior to the expiration of these patents. The '222 and '218 patents are listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. The patent infringement lawsuit was filed within 45 days of receipt of the pertinent notice letter, thereby triggering a stay of FDA approval of the Exela and Perrigo ANDAs until the earlier of the expiration of a 30-month period, the expiration of the '222 and '218 patents, the entry of a settlement order or consent decree stating that the '222 and '218 patents are invalid or not infringed, a decision in the case concerning infringement or validity that is favorable to Exela, or such shorter or longer period as the court may order. Exela filed an answer in the case that asserted, among other things, non-infringement and invalidity of the asserted patents, as well as certain counterclaims.
	In November 2012, Cadence entered into a settlement agreement and a license agreement with Perrigo to settle similar litigation. The settlement agreement includes a stipulation by the parties requesting dismissal with prejudice of the lawsuit filed by Cadence relating to the ANDA filed by Perrigo. Under the terms of the license agreement, Cadence granted to the holder of the Perrigo ANDA and its affiliates the non-exclusive right to market a generic intravenous acetaminophen product in the U.S. under the Perrigo ANDA beginning December 6, 2020, or earlier under certain circumstances. The license agreement also provides that Perrigo has been granted the exclusive right of first refusal to negotiate an agreement with Cadence to market an authorized generic version of Ofirmev (i.e., a generic version marketed under Cadence's New Drug Application ("NDA")) in the U.S., in the event that Cadence elects to launch an authorized generic version of the product.
	A bench trial for the lawsuit with Exela was held and the court ruled in favor of Cadence in November 2013 and found Exela's ANDA for a generic version of Ofirmev infringed the '222 and '218 patents. An appeal of the decision in favor of Cadence was filed by Exela on December 20, 2013. While it is not possible at this time to determine with certainty the ultimate outcome of the case, an adverse outcome could result in the launch of one or more generic versions of Ofirmev before the expiration of the last of the listed patents in June 2021 (or December 2021 if pediatric exclusivity is granted), could adversely affect the Company's ability to successfully maximize the value of Ofirmev and have an adverse effect on its financial condition, results of operations and cash flows.
	'222 and '218 Patent Litigation: Fresenius Kabi USA, LLC, Sandoz, Inc. and Wockhardt USA LLC. In January 2013 and February 2013, respectively, Cadence filed suits in the U.S. District Court for the Southern District of California against Fresenius Kabi USA, LLC ("Fresenius") and Sandoz, Inc. ("Sandoz"), following receipt of December 2012 notices from each company concerning their submissions of a NDA and an ANDA containing Paragraph IV patent certifications with the FDA for generic versions of Ofirmev. In October 2013, Cadence filed a motion to amend its complaint against Sandoz to join Sandoz AG, Neogen International N.V., APC Pharmaceuticals, LLC, and DIACO S.p.A. (collectively, "the Sandoz Parties") to the lawsuit against Sandoz due to the involvement of each of these companies with the preparation of the Sandoz ANDA and related matters.
	In the lawsuits against Fresenius and the Sandoz Parties, which were coordinated for purposes of discovery and other pretrial proceedings in the Southern District of California, Cadence alleged that Fresenius and the Sandoz Parties each infringed the '222 and '218 patents by filing a NDA, in the case of Fresenius, or an ANDA, in the case of the Sandoz Parties, seeking approval from the FDA to market a generic version of Ofirmev prior to the expiration of these patents. Both Fresenius and the Sandoz Parties filed answers in the Southern District of California asserting, among other things, non-infringement and invalidity of the asserted patents, as well as certain counterclaims. Both the Fresenius and Sandoz lawsuits were filed within 45 days of receipt of the respective notice letters, thereby triggering a stay of FDA approval of the Fresenius NDA and the Sandoz ANDA until the earlier of the expiration of a 30-month period, the expiration of the '222 and '218 patents, the entry of a settlement order or consent decree stating that the '222 and '218 patents are invalid or not infringed, a decision in the case concerning infringement or validity that is favorable to Fresenius and/or the Sandoz Parties, or such shorter or longer period as the court may order.
	In January 2014, Cadence entered into a settlement agreement and a binding term sheet for a license agreement with the Sandoz Parties. The settlement agreement includes a stipulation by the parties requesting dismissal with prejudice of the lawsuit filed by the Company relating to the ANDA filed by Sandoz. Under the terms of the license, Cadence granted to the holder of the Sandoz ANDA and its affiliates the non-exclusive right to market a generic intravenous acetaminophen product in the U.S. under the Sandoz ANDA beginning December 6, 2020, or earlier under certain circumstances. Cadence also agreed that in the event that it determines to launch an authorized generic version of Ofirmev (i.e., a generic version marketed under its NDA) in the U.S. and Perrigo elects not to exercise its right of first refusal to become the distributor of the authorized generic version of the product, Cadence will grant a similar right of first refusal to the holder of the Sandoz ANDA on substantially the same terms as those previously granted to Perrigo. Litigation remains ongoing against Fresenius, and the bench trial for such lawsuit is tentatively scheduled to commence in July 2014.
	In December 2013, Cadence received a notice from Wockhardt USA LLC ("Wockhardt"), stating that Wockhardt filed an ANDA containing a Paragraph IV patent certification with the FDA for a generic version Ofirmev. This notice stated that the Paragraph IV patent certification was made with respect to both the '222 patent and the '218 patent. Cadence filed suit against Wockhardt Limited, Wockhardt BIO AG and Wockhardt in January 2014 in the U.S. District Court of Delaware and in the U.S. District Court of New Jersey. In March 2014, Cadence entered into a settlement agreement and a license agreement with Wockhardt. The settlement agreement includes a stipulation by the parties requesting dismissal with prejudice of the lawsuit filed by Cadence relating the ANDA filed by Wockhardt. Under the terms of the license agreement, Cadence granted to the holder of Wockhardt ANDA and its affiliates the non-exclusive right to market a generic intravenous acetaminophen product in the U.S. under the Wockhardt ANDA beginning December 6, 2020, or earlier under certain circumstances.
	The Company intends to vigorously enforce its intellectual property rights relating to Ofirmev to prevent the marketing of infringing generic products prior to the expiration of the Cadence patents. The '222 patent expires in August 2017 (or February 2018 if pediatric exclusivity is granted) and the '218 patent expires in June 2021 (or December 2021 if pediatric exclusivity is granted). While it is not possible at this time to determine with certainty the ultimate outcome of the cases, an adverse outcome could result in the launch of one or more generic versions of Ofirmev before the expiration of the last of the listed patents, which could adversely affect the Company's ability to successfully maximize the value of Ofirmev and have an adverse effect on its financial condition, results of operations and cash flows.
	'222 and '218 Patents: Ex Parte Reexamination. In September 2012, Exela filed with the U.S. Patent and Trademark Office ("USPTO") a Request for Ex Parte Reexamination of the '222 patent. In December 2012, Cadence received notice that the USPTO had granted the Request for Reexamination. The reexamination process is provided for by law and requires the USPTO to consider the scope and validity of the patent based on substantial new questions of patentability raised by a third party or the USPTO. In February 2013, Cadence and Pharmatop filed with the USPTO a patent owner's statement commenting on the reexamination request, and in April 2013, Exela filed comments in response to the patent owner's statement. In a non-final, initial office action issued by the USPTO in August 2013, the USPTO rejected certain claims of the '222 patent. A response to the first office action was filed in November 2013. A supplemental amendment and response was filed in February 2014 and a next office action was issued in March 2014.
	In addition, in January 2014, an unidentified third party filed with the USPTO a Request for Ex Parte Reexamination of the '218 patent. The reexamination request was granted on March 14, 2014.
	All of the claims of the '222 and '218 patents remain valid and in force during the reexamination proceedings. Because Cadence and Pharmatop believe that the scope and validity of the patent claims in these patents are appropriate and that the USPTO's prior issuances of the patents were correct, the Company, in conjunction with Cadence and Pharmatop, will vigorously defend these patents. It is not possible at this time to determine with certainty whether Cadence and Pharmatop ultimately will succeed in maintaining the scope and validity of the claims of these patents during reexamination. If any of the patent claims in these patents ultimately are narrowed during prosecution before the USPTO, the extent of the patent coverage afforded to Ofirmev could be impaired, which could have an adverse effect on the Company's financial condition, results of operations and cash flows.
	'218 Patent Litigation: Exela Pharma Sciences, LLC. In April 2012, Exela filed suit against David J. Kappos and the USPTO in the U.S. District Court for the Eastern District of Virginia for declaratory judgment seeking a reversal of the USPTO's decision not to act on a petition by Exela to vacate the USPTO's April 2003 order reviving the international application for the '218 patent. The lawsuit followed the USPTO's rejection of Exela's petition to the USPTO filed in November 2011, which sought to vacate the April 23, 2003 order granting Pharmatop's petition to revive the '218 patent. The USPTO determined that Exela lacked standing to seek such relief. Exela also seeks declaratory judgment that the USPTO's rules and regulations that allow for revival of abandoned, international patent applications under the "unintentional" standard are invalid, and similar relief in connection with one or more counterclaims it has filed in the Delaware litigation. Cadence's motion to intervene in this lawsuit was granted in October 2012. In December 2012, the district court dismissed the case with prejudice as barred by the applicable statute of limitations. In February 2013, Exela appealed the district court's decision to the Court of Appeals for the Federal Circuit. The Court of Appeals heard oral argument on the appeal in February 2014. A decision by the Court of Appeals in favor of Exela could ultimately result in the invalidation of the '218 patent.
	Pricing Litigation
	State of Utah v. Actavis US, Inc., et al. The Company, along with numerous other pharmaceuticals companies, are defendants in this matter which was filed May 8, 2008, and is pending in the Third Judicial Circuit of Salt Lake County, Utah. The State of Utah alleges, generally, that the defendants reported false pricing information in connection with certain drugs that are reimbursable under Medicaid, resulting in overpayment by state Medicaid programs for those drugs, and is seeking monetary damages and attorneys' fees. The Company believes that it has meritorious defenses to these claims and is vigorously defending against them. While it is not possible at this time to determine with certainty the outcome of the case, the Company believes, given the information currently available, that their ultimate resolution will not have a material adverse effect on its financial condition, results of operations and cash flows.
	Environmental Remediation and Litigation Proceedings
	The Company is involved in various stages of investigation and cleanup related to environmental remediation matters at a number of sites, including those described below. The ultimate cost of site cleanup and timing of future cash outlays is difficult to predict, given the uncertainties regarding the extent of the required cleanup, the interpretation of applicable laws and regulations and alternative cleanup methods. The Company concluded that, as of March 28, 2014, it was probable that it would incur remedial costs in the range of $44.9 million to $118.6 million. The Company also concluded that, as of March 28, 2014, the best estimate within this range was $68.0 million, of which $4.3 million was included in accrued and other current liabilities and the remainder was included in environmental liabilities on the unaudited condensed consolidated balance sheet at March 28, 2014.
	Crab Orchard National Wildlife Refuge Superfund Site, near Marion, Illinois. The Company is a successor in interest to International Minerals and Chemicals Corporation ("IMC"). Between 1967 and 1982, IMC leased portions of the Additional and Uncharacterized Sites ("AUS") Operable Unit at the Crab Orchard Superfund Site ("the Site") from the government and manufactured various explosives for use in mining and other operations. In March 2002, the Department of Justice, the U.S. Department of the Interior and the U.S. Environmental Protection Agency ("EPA") (together, "the Government Agencies") issued a special notice letter to General Dynamics Ordnance and Tactical Systems, Inc. ("General Dynamics"), one of the other potentially responsible parties ("PRPs") at the Site, to compel General Dynamics to perform the remedial investigation and feasibility study ("RI/FS") for the AUS Operable Unit. General Dynamics negotiated an Administrative Order on Consent ("AOC") with the Government Agencies to conduct an extensive RI/FS at the Site under the direction of the U.S. Fish and Wildlife Service. General Dynamics asserted in August 2004 that the Company is jointly and severally liable, along with approximately eight other lessees and operators at the AUS Operable Unit, for alleged contamination of soils and groundwater resulting from historic operations, and has threatened to file a contribution claim against the Company and other parties for recovery of its costs incurred in connection with the RI/FS activities being conducted at the AUS Operable Unit. The Company and other PRPs who received demand letters from General Dynamics have explored settlement alternatives, but have not reached settlement to date. The Company and other PRPs are awaiting completion of the RI/FS by General Dynamics before the initiation of formal PRP negotiations to address resolution of these alleged claims. While it is not possible at this time to determine with certainty the ultimate outcome of this case, the Company believes, given the information currently available, that the final resolution of all known claims, after taking into account amounts already accrued, will not have a material adverse effect on its financial condition, results of operations and cash flows.
	Mallinckrodt Veterinary, Inc., Millsboro, Delaware. The Company previously operated a plant in Millsboro, Delaware ("the Millsboro Site") that manufactured various animal healthcare products. In 2005, the Delaware Department of Natural Resources and Environmental Control found trichloroethylene ("TCE") in the Millsboro public water supply at levels that exceeded the federal drinking water standards. Further investigation to identify the TCE plume in the ground water indicated that the plume has extended to property owned by a third party near the Millsboro Site. The Company, and another former owner, assumed responsibility for the Millsboro Site cleanup under the Alternative Superfund Program administered by the EPA. The Company and another PRP have entered into two AOCs with the EPA to perform investigations to abate, mitigate or eliminate the release or threat of release of hazardous substances at the Millsboro Site and to conduct an Engineering Evaluation/Cost Analysis to characterize the nature and extent of the contamination. The Company, along with the other party, continues to conduct the studies and prepare remediation plans in accordance with the AOCs. While it is not possible at this time to determine with certainty the ultimate outcome of this matter, the Company believes, given the information currently available, that the ultimate resolution of all known claims, after taking into account amounts already accrued, will not have a material adverse effect on its financial condition, results of operations and cash flows.
	Coldwater Creek, Saint Louis County, Missouri. The Company is named as a defendant in numerous tort complaints filed between February 2012 and April 2014 with numerous plaintiffs pending in the U.S. District Court for the Eastern District of Missouri. These cases allege personal injury for alleged exposure to radiological substances present in Coldwater Creek in Missouri. Plaintiffs lived in various locations in Saint Louis County, Missouri near Coldwater Creek. Radiological residues which may have been present in the creek have been remediated by the U.S. Army Corps of Engineers. The Company believes that it has meritorious defenses to these complaints and is vigorously defending against them. The Company is unable to estimate a range of reasonably possible losses for the following reasons: (i) the proceedings are in early stages; (ii) the Company has not received and reviewed complete information regarding the plaintiffs and their medical conditions; and (iii) there are significant factual issues to be resolved. While it is not possible at this time to determine with certainty the ultimate outcome of these cases, the Company believes, given the information currently available, that the ultimate resolution of all known claims will not have a material adverse effect on its financial condition, results of operations and cash flows.
	Lower Passaic River, New Jersey. The Company and approximately 70 other companies comprise the Lower Passaic Cooperating Parties Group ("the CPG") and are parties to a May 2007 AOC with the EPA to perform a RI/FS of the 17-mile stretch known as the Lower Passaic River Study Area ("the River"). The Company's potential liability stems from former operations at Lodi and Belleville, New Jersey. In June 2007, the EPA issued a draft Focused Feasibility Study ("FFS") that considered interim remedial options for the lower 8-miles of the river, in addition to a "no action" option. As an interim step related to the 2007 AOC, the CPG voluntarily entered into an AOC on June 18, 2012 with the EPA for remediation actions focused solely at mile 10.9 of the River. The Company's estimated costs related to the RI/FS and focused remediation at mile 10.9, based on interim allocations, are immaterial and have been accrued.
	On April 11, 2014, the EPA issued its revised FFS, with remedial alternatives to address cleanup of the lower 8-mile stretch of the River, which also included a "no action" option. The EPA estimates the cost for the alternatives range from $365.0 million to $3.2 billion. The EPA's preferred approach would involve bank-to-bank dredging of the lower 8-mile stretch of the River and installing an engineered cap at a discounted, estimated cost of $1.7 billion. Based on the issuance of the EPA's revised FFS, the Company recorded a $23.1 million accrual in the second quarter of fiscal 2014 representing the Company's estimate of its allocable share of the joint and several remediation liability resulting from this matter. Despite the issuance of the revised FFS, there are many uncertainties associated with the final agreed upon remediation and the Company's allocable share of the remediation. Given those uncertainties, the amounts accrued may not be indicative of the amounts for which the Company is ultimately responsible and will be refined as events in the remediation process occur.
	Products Liability Litigation
	Beginning with lawsuits brought in July 1976, the Company is also named as a defendant in personal injury lawsuits based on alleged exposure to asbestos-containing materials. A majority of the cases involve product liability claims based principally on allegations of past distribution of products containing asbestos. A limited number of the cases allege premises liability based on claims that individuals were exposed to asbestos while on the Company's property. Each case typically names dozens of corporate defendants in addition to the Company. The complaints generally seek monetary damages for personal injury or bodily injury resulting from alleged exposure to products containing asbestos. The Company's involvement in asbestos cases has been limited because it did not mine or produce asbestos. Furthermore, in the Company's experience, a large percentage of these claims have never been substantiated and have been dismissed by the courts. The Company has not suffered an adverse verdict in a trial court proceeding related to asbestos claims and intends to continue to defend these lawsuits. When appropriate, the Company settles claims; however, amounts paid to settle and defend all asbestos claims have been immaterial. As of March 28, 2014, there were approximately 11,750 asbestos-related cases pending against the Company.
	The Company estimates pending asbestos claims and claims that were incurred but not reported and related insurance recoveries, which are recorded on a gross basis in the unaudited condensed consolidated balance sheets. The Company's estimate of its liability for pending and future claims is based on claims experience over the past five years and covers claims either currently filed or expected to be filed over the next seven years. The Company believes that it has adequate amounts recorded related to these matters. While it is not possible at this time to determine with certainty the ultimate outcome of these asbestos-related proceedings, the Company believes, given the information currently available, that the ultimate resolution of all known and anticipated future claims, after taking into account amounts already accrued, along with recoveries from insurance, will not have a material adverse effect on its financial condition, results of operations and cash flows.
	Asset Retirement Obligations
	The Company has recorded asset retirement obligations for the estimated future costs primarily associated with legal obligations to decommission facilities within the Global Medical Imaging segment, including the facilities located in Petten, the Netherlands and Maryland Heights, Missouri. Substantially all of these obligations are included in other liabilities on the unaudited condensed consolidated and combined balance sheets. The following table provides a summary of the changes in the Company's asset retirement obligations:
	Balance at September 27, 2013	$	50.6
	Accretion expense	1.6
	Currency translation	0.5
	Balance at March 28, 2014	$	52.7
	The Company believes, given the information currently available, that any potential payment of such estimated amounts will not have a material adverse effect on its financial condition, results of operations and cash flows.
	Industrial Revenue Bonds
	The Company exchanged title to $27.4 million of its plant assets in return for an equal amount of Industrial Revenue Bonds ("IRB") issued by Saint Louis County. The Company also simultaneously leased such assets back from Saint Louis County under a capital lease expiring December 2025, the terms of which provide it with the right of offset against the IRBs. The lease also provides an option for the Company to repurchase the assets at the end of the lease for nominal consideration. These transactions collectively result in a ten-year property tax abatement from the date the property is placed in service. Due to right of offset, the capital lease obligation and IRB asset are recorded net in the unaudited condensed consolidated balance sheets. The Company expects that the right of offset will be applied to payments required under these arrangements.
	Tax Matters
	The income tax returns of the Company and its subsidiaries are periodically examined by various tax authorities. The resolution of these matters is subject to the conditions set forth in the tax matters agreement entered into between the Company and Covidien ("the Tax Matters Agreement"). Covidien has the right to administer, control and settle all U.S. income tax audits for periods prior to the Separation. While it is not possible at this time to determine with certainty the ultimate outcome of these matters, the Company believes, given the information currently available, that established liabilities are reasonable and that the ultimate resolution of these matters will not have a material adverse effect on its financial condition, results of operations and cash flows.
	With respect to certain tax returns filed by predecessor affiliates of the Company and Covidien, the U.S. Internal Revenue Service ("IRS") has concluded its field examination for the years 1997 through 2000 and has proposed tax adjustments. Several of the proposed adjustments could also affect both Covidien's and the Company's income tax returns for years after 2000. Certain of the IRS's proposed adjustments have been appealed, and all but one of the matters associated with the proposed tax adjustments have been resolved. The unresolved proposed adjustment asserts that substantially all of the predecessor affiliates' intercompany debt originating during the years 1997 through 2000 should not be treated as debt for U.S. federal income tax purposes, and has disallowed interest deductions related to the intercompany debt and certain tax attribute adjustments recognized on the U.S. income tax returns. This matter is subject to the Company's $200.0 million liability limitation for periods prior to September 29, 2012, as prescribed in the Tax Matters Agreement. While it is not possible at this time to determine with certainty the ultimate outcome of this matter, the Company believes, given the information available to it today, that it will not have a material adverse effect on its financial condition, results of operations and cash flows.
	Acquisition-Related Litigation
	Nine purported class action lawsuits have been filed in February 2014 and March 2014 by purported holders of Cadence common stock in connection with the Company's acquisition of Cadence, six in the Delaware Court of Chancery (consolidated under the caption In re Cadence Pharmaceuticals, Inc. Stockholders Litigation), and three in California State Court, San Diego County (Denny v. Cadence Pharmaceuticals, Inc., et al., Militello v. Cadence Pharmaceuticals, Inc., et al., and Schuon v. Cadence Pharmaceuticals, Inc., et al.). The actions bring claims against, and generally allege that, the board of directors of Cadence breached their fiduciary duties in connection with the acquisition by, among other things, failing to maximize shareholder value, and the Delaware and Schuon actions further allege that Cadence omitted to disclose allegedly material information in its Schedule 14D-9. The lawsuits also allege, among other things, that the Company aided and abetted the purported breaches of fiduciary duty. The lawsuits seek various forms of relief, including but not limited to, rescission of the transaction, damages and attorneys' fees and costs. On March 7, 2014, following expedited discovery, the parties in the consolidated Delaware action entered into a Memorandum of Understanding ("the MOU"), which sets forth the parties' agreement in principle for a settlement of those actions. The settlement contemplated by the MOU will include, among other things, a release of all claims relating to the Company's acquisition of Cadence as set forth in the MOU. The settlement is subject to a number of conditions, including, among other things, final court approval following notice to the class. There have been no substantive proceedings in any of the California actions. While it is not possible at this time to determine with certainty the ultimate outcomes of these matters, the Company believes, given the information available to it today, that they will not have a material adverse effect on its financial condition, results of operations and cash flows.
	Eight purported class action lawsuit were filed in April 2014 in the California State Court, Orange County by purported holders of Questcor Pharmaceuticals, Inc. ("Questcor") common stock in connection with the Company's proposed acquisition of Questcor (Hansen v. Thompson, et al., Heng v. Questcor Pharmaceuticals, Inc., et al., Buck v. Questcor Pharmaceuticals, Inc., et al., Yokem v. Questcor Pharmaceuticals, Inc., et al., Ellerbeck v. Questcor Pharmaceuticals, Inc., et al., Richter v. Questcor Pharmaceuticals, Inc., et al., Tramantano v. Questcor Pharmaceuticals, Inc., et al., and Crippen v. Questcor Pharmaceuticals, Inc., et al.). The actions bring claims against, and generally allege that, the board of directors of Questcor breached their fiduciary duties in connection with the acquisition by, among other things, agreeing to sell Questcor for inadequate consideration and pursuant to an inadequate process. Some of the lawsuits also allege, among other things, that the Company aided and abetted the purported breaches of fiduciary duty. The lawsuits seek various forms of relief, including but not limited to, an order enjoining the shareholder vote relating to the acquisition, rescission of the transaction if consummated, damages and attorneys' fees and costs. In addition, plantiffs in a prior-pending derivative litigation, In re Questcor Pharmaceuticals, Inc. Shareholder Derivative Litigation, pending in the U.S. District Court for the Central District of California, have filed an application to lift the stay of that action in order to file an amended complaint alleging that the board of directors of Questcor breached their fiduciary duties in connect with the acquisition. While it is not possible at this time to determine with certainty the ultimate outcomes of these matters, the Company believes, given the information available to it today, that they will not have a material adverse effect on its financial condition, results of operations and cash flows. For further information on the Company's proposed acquisition of Questcor, see Note 21.
	Other Matters
	The Company is a defendant in a number of other pending legal proceedings relating to present and former operations, acquisitions and dispositions. Given the information currently available, the Company does not expect the ultimate resolution of these proceedings, either individually or in the aggregate, to have a material adverse effect on its financial condition, results of operations and cash flows.

Derivative_Instruments

Derivative Instruments	6 Months Ended
	Mar. 28, 2014
Summary of Derivative Instruments [Abstract]	'
Derivative Instruments	'
	17	Derivative Instruments
	The Company is exposed to certain risks relating to its business operations. Foreign currency option and forward contracts are used to manage the foreign exchange exposures of operations outside the U.S. Swap contracts on commodities historically have been periodically entered into to manage the price risk associated with forecasted purchases of commodities used in the Company's manufacturing processes. Risks that relate to interest rate exposure are managed by using derivative instruments, such as interest rate lock contracts. Changes in the fair value of the derivative financial instruments are recognized in the Company's earnings unless specific hedge criteria are met.
	Foreign Exchange Exposure
	The Company has foreign exchange exposure on the translation of the financial statements and on transactions denominated in foreign currencies. The Company's policy allows for the use of various forward and option contracts to manage foreign currency exposures on accounts and notes receivable, accounts payable, intercompany loans, intercompany cash pooling arrangements and forecasted transactions that are denominated in certain foreign currencies. Existing contracts did not meet the necessary criteria to qualify for hedge accounting; accordingly, all associated changes in fair value were recognized in earnings.
	The location and amount of the net gain (loss) on foreign exchange forward and option contracts not designated as hedging instruments was recorded as follows:
		Three Months Ended						Six Months Ended
		March 28,			March 29,			March 28,			March 29,
		2014			2013			2014			2013
	Cost of sales	$	(0.2	)	$	(1.5	)	$	(0.4	)	$	(2.4	)
	Selling, general and administrative	0.3			1.2			0.3			2.3
	Other (expense) income, net	1.5			—			5.7			—
		$	1.6		$	(0.3	)	$	5.6		$	(0.1	)
	Foreign currency losses included within net income for the three and six months ended March 28, 2014 were $4.3 million and $9.3 million, respectively, and for the six months ended March 29, 2013 were $0.5 million. Foreign currency losses for the three months ended March 29, 2013 were immaterial.
	The fair value of foreign exchange forward and option contracts were included in the following captions of our unaudited condensed consolidated balance sheets at the end of each period:
		March 28,			September 27, 2013
		2014
	Prepaid expenses and other current assets	$	0.6		$	0.9
	Accrued and other current liabilities	0.6			1.4
	Commodities Exposure
	Prior to the Separation, Covidien entered into gas commodity swap contracts on behalf of the Company, which were accounted for as cash flow hedges. As of March 28, 2014, there were no outstanding gas commodity swap contracts; however, the Company may utilize such contracts in the future to mitigate price risk associated with its forecasted commodity purchases. The amounts of the net losses on these contracts recorded during the three and six months ended March 29, 2013 were as follows:
		Three Months Ended			Six Months Ended
	Cost of sales	$	0.1		$	0.2
	Selling, general and administrative	0.3			0.6
		$	0.4		$	0.8
	Interest Rate Exposure
	MIFSA entered into three forward interest rate lock contracts in March 2013 and April 2013, each with a $300.0 million notional value and designated as cash flow hedges, against the risk of variability in market interest rates in advance of its anticipated issuance of its ten-year fixed rate senior notes due April 2023. Each interest rate lock contract was considered to be highly effective and the $7.6 million loss resulting from their settlements was recorded in accumulated other comprehensive income. As of March 28, 2014, $7.0 million of this loss remains in accumulated other comprehensive income and will be amortized to interest expense over the remaining term of the ten-year notes.

Financial_Instruments_and_Fair

Financial Instruments and Fair Value Measurements	6 Months Ended
	Mar. 28, 2014
Fair Value Disclosures [Abstract]	'
Financial Instruments and Fair Value Measurements	'
	18	Financial Instruments and Fair Value Measurements
	Fair value is defined as the exit price that would be received from the sale of an asset or paid to transfer a liability, using assumptions that market participants would use in pricing an asset or liability. The fair value guidance establishes a three-level fair value hierarchy, which maximizes the use of observable inputs and minimizes the use of unobservable inputs used in measuring fair value. The levels within the hierarchy are as follows:
	Level 1— observable inputs such as quoted prices in active markets for identical assets or liabilities;
	Level 2— significant other observable inputs that are observable either directly or indirectly; and
	Level 3— significant unobservable inputs in which there is little or no market data, which requires the Company to develop its own assumptions.
	The following tables provide a summary of the significant assets and liabilities that are measured at fair value on a recurring basis at the end of each period:
		March 28,			Quoted Prices in Active Markets for Identical Assets				Significant Other Observable Inputs			Significant Unobservable Inputs
		2014			(Level 1)				(Level 2)			(Level 3)
	Assets:
	Debt and equity securities held in rabbi trusts	$	35.1		$	22.9			$	12.2		$	—
	Foreign exchange forward and option contracts	0.6			0.6				—			—
		$	35.7		$	23.5			$	12.2		$	—
	Liabilities:
	Deferred compensation liabilities	$	13.7		$	—			$	13.7		$	—
	Contingent consideration	7			—				—			7
	Foreign exchange forward and option contracts	0.6			0.6				—			—
		$	21.3		$	0.6			$	13.7		$	7
		September 27,			Quoted Prices in Active Markets for Identical Assets				Significant Other Observable Inputs			Significant Unobservable Inputs
		2013			(Level 1)				(Level 2)			(Level 3)
	Assets:
	Debt and equity securities held in rabbi trusts	$	35.3		$	22.6			$	12.7		$	—
	Foreign exchange forward and option contracts	0.9			0.9				—			—
		$	36.2		$	23.5			$	12.7		$	—
	Liabilities:
	Deferred compensation liabilities	$	13.5		$	—			$	13.5		$	—
	Contingent consideration	6.9			—				—			6.9
	Foreign exchange forward and option contracts	1.4			1.4				—			—
		$	21.8		$	1.4			$	13.5		$	6.9
	Debt and equity securities held in rabbi trust. Debt securities held in the rabbi trust primarily consist of U.S. government and agency securities and corporate bonds. When quoted prices are available in an active market, the investments are classified as level 1. When quoted market prices for a security are not available in an active market, they are classified as level 2. Equity securities held in the rabbi trust primarily consist of U.S. common stocks, which are valued using quoted market prices reported on nationally recognized securities exchanges.
	Foreign exchange forward and option contracts. Foreign currency option and forward contracts are used to economically manage the foreign exchange exposures of operations outside the U.S. Quoted prices are available in an active market; as such, these derivatives are classified as level 1.
	Deferred compensation liabilities. The Company maintains a non-qualified deferred compensation plan in the U.S., which permits eligible employees of the Company to defer a portion of their compensation. A recordkeeping account is set up for each participant and the participant chooses from a variety of funds for the deemed investment of their accounts. The measurement funds generally correspond to the funds offered in the Company's U.S. tax-qualified defined contribution retirement plan and the account balance fluctuates with the investment returns on those funds.
	Contingent consideration. In October 2012, the Company recorded contingent consideration of $6.9 million upon the acquisition of CNS Therapeutics. This contingent consideration, which could potentially total a maximum of $9.0 million, is primarily based on whether the FDA approves another concentration of Gablofen on or before December 31, 2016. The fair value of the contingent payments was measured based on the probability-weighted present value of the consideration expected to be transferred using a discount rate of 1.0%. There were no changes to the initial estimate of the fair value of the consideration during the six months ended March 28, 2014.
	Balance at September 27, 2013	$	6.9
	Accretion expense	0.1
	Balance at March 28, 2014	$	7
	Financial Instruments Not Measured at Fair Value
	The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and the majority of other current assets and liabilities approximate fair value because of their short-term nature. The Company classifies cash on hand and deposits in banks, including commercial paper, money market accounts and other investments it may hold from time to time, with an original maturity to the Company of three months or less, as cash and cash equivalents (level 1). The fair value of restricted cash is equivalent to its carrying value of $20.2 million and $24.0 million as of March 28, 2014 and September 27, 2013, respectively (level 1), substantially all of which is included in other assets on the unaudited condensed consolidated balance sheets. The Company's life insurance contracts are carried at cash surrender value, which is based on the present value of future cash flows under the terms of the contracts (level 3). Significant assumptions used in determining the cash surrender value include the amount and timing of future cash flows, interest rates and mortality charges. The fair value of these contracts approximates the carrying value of $68.7 million and $67.7 million at March 28, 2014 and September 27, 2013, respectively. These contracts are included in other assets on the unaudited condensed consolidated balance sheets.
	The carrying value of the Company's loan payable approximates fair value due to its short term nature. Since the quoted market prices for the Company's Term Loan, 8.00% and 9.50% debentures are not available in an active market, they are classified as level 2 for purposes of developing an estimate of fair value. The Company's 3.50% notes and 4.75% notes are classified as level 1, as quoted prices are available in an active market for these notes. The following table presents the carrying values and estimated fair values of the Company's long-term debt, excluding capital leases, as of the end of each period:
		March 28, 2014							September 27, 2013
		Carrying			Fair				Carrying			Fair
		Value			Value				Value			Value
	Loan payable	$	—		$	—			$	0.1		$	0.1
	Term loan	1,296.80			1,301.00				—			—
	3.50% notes due April 2018	300			296				299.9			293.7
	9.50% debentures due May 2022	10.4			14.2				10.4			14.3
	8.00% debentures due March 2023	8			10.2				8			10.2
	4.75% notes due April 2023	598.2			571.6				598.2			568.5
	Concentration of Credit and Other Risks
	Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of accounts receivable. The Company does not require collateral from customers. A portion of the Company's accounts receivable outside the U.S. includes sales to government-owned or supported healthcare systems in several countries, which are subject to payment delays. Payment is dependent upon the financial stability and creditworthiness of those countries' national economies.
	The Company routinely evaluates all government receivables for potential collection risks associated with the availability of government funding and reimbursement practices. The Company has not incurred any significant losses on government receivables; however, if the financial condition of customers or the countries' healthcare systems continue to deteriorate such that their ability to make payments is uncertain, additional allowances may be required in future periods.
	The Company's accounts receivable, net of allowance for doubtful accounts, in Spain and Italy, which the Company has been closely monitoring, at the end of each period were as follows:
		March 28,			September 27,
		2014			2013
	Spain	$	9.8		$	9.2
	Italy	10.7			12.6
	Net sales to customers in Spain and Italy totaled $12.4 million and $14.1 million for the three months ended March 28, 2014 and March 29, 2013, respectively, and $24.7 million and $26.3 million for the six months ended March 28, 2014 and March 29, 2013, respectively.
	The following table shows net sales attributable to distributors that accounted for 10% or more of the Company's total net sales:
		Three Months Ended					Six Months Ended
		March 28,		March 29,			March 28,			March 29,
		2014		2013			2014			2013
	Cardinal Health, Inc.	15	%	20	%		18	%		20	%
	McKesson Corporation	15	%	19	%		15	%		16	%
	Amerisource Bergen Corporation	10	%	6	%		11	%		7	%
The following table shows accounts receivable attributable to distributors that accounted for 10% or more of the Company's gross accounts receivable at the end of each period:
	March 28,		September 27,
	2014		2013
Cardinal Health, Inc.	20	%	18	%
McKesson Corporation	23	%	22	%
Amerisource Bergen Corporation	13	%	14	%
The following table shows net sales attributable to products that accounted for 10% or more of the Company's total net sales:
	Three Months Ended					Six Months Ended
	March 28,		March 29,			March 28,			March 29,
	2014		2013			2014			2013
Optiray™ (CMDS)	13	%	13	%		13	%		14	%
Acetaminophen products (API)	9	%	10	%		8	%		10	%
Methylphenidate ER (Specialty Generics)	8	%	11	%		9	%		7	%
Molybdenum-99 ("Mo-99") is a key raw material in the Company's Ultra-Technekow™ DTE technetium generators that are sold by its Global Medical Imaging segment. There are only eight suppliers of this raw material worldwide. The Company has agreements to obtain Mo-99 from three nuclear research reactors and relies predominantly upon two of these reactors for its Mo-99 supply. Accordingly, a disruption in the commercial supply or a significant increase in the cost of this material from these sources could have a material adverse effect on the Company's financial condition, results of operations and cash flows.

Segment_Data

Segment Data	6 Months Ended
	Mar. 28, 2014
Segment Reporting [Abstract]	'
Segment Data	'
	19	Segment Data
	Selected information by business segment was as follows:
		Three Months Ended						Six Months Ended
		March 28,			March 29,			March 28,			March 29,
		2014			2013			2014			2013
	Net sales:
	Specialty Pharmaceuticals	$	324.3		$	344.4		$	633.8		$	604.6
	Global Medical Imaging	222.4			229.1			441			458.8
	Net sales of operating segments (1)	546.7			573.5			1,074.80			1,063.40
	Other (2)	11.1			11.8			23.2			25.9
	Net sales	$	557.8		$	585.3		$	1,098.00		$	1,089.30
	Operating income:
	Specialty Pharmaceuticals	$	105.9		$	105		$	218.9		$	140
	Global Medical Imaging	10.3			18.9			14.7			68
	Segment operating income	116.2			123.9			233.6			208
	Unallocated amounts:
	Corporate and allocated expenses (3)	(72.7		)	(40.3		)	(97.9		)	(65.7		)
	Intangible asset amortization	(15.5		)	(8.8		)	(24.3		)	(17.7		)
	Restructuring and related charges, net (4)	(21.7		)	(6.9		)	(29.8		)	(7.9		)
	Separation costs	(2.6		)	(14.4		)	(4.8		)	(26.4		)
	Operating income	$	3.7		$	53.5		$	76.8		$	90.3
	-1	Amounts represent sales to external customers.
	-2	Represents products that were sold to Covidien, our former parent company, which is discussed in Note 14.
	-3	Includes administration expenses and certain compensation, environmental and other costs not charged to the Company's operating segments.
	-4	Includes restructuring-related accelerated depreciation of $0.5 million for the three months ended March 29, 2013 and $0.1 million and $1.3 million million for the six months ended March 28, 2014 and March 29, 2013, respectively. Restructuring-related accelerated depreciation for the three months ended March 28, 2014 was immaterial.

Condensed_Consolidating_and_Co

Condensed Consolidating and Combining Financial Statements	6 Months Ended
	Mar. 28, 2014
Condensed Consolidating Financial Statements [Abstract]	'
Condensed Consolidating and Combining Financial Statements	'
	20	Condensed Consolidating and Combining Financial Statements
	In November 2012, MIFSA was formed as a 100%-owned subsidiary of Covidien in connection with the Separation. MIFSA is a holding company established to own, directly or indirectly, substantially all of the operating subsidiaries of the Company, to issue debt securities and to perform treasury operations. At the time of the Separation, MIFSA became a 100%-owned subsidiary of Mallinckrodt plc.
	MIFSA is the borrower under the Notes, which are fully and unconditionally guaranteed by Mallinckrodt plc. The following information provides the composition of the Company's comprehensive income, assets, liabilities, equity and cash flows by relevant group within the Company: Mallinckrodt plc as guarantor of the Notes, MIFSA as issuer of the Notes and the operating companies that represent assets of MIFSA. There are no subsidiary guarantees related to the Notes.
	Set forth below are the unaudited condensed consolidating financial statements for the three and six months ended March 28, 2014 and as of March 28, 2014 and September 27, 2013, and the unaudited condensed combining financial statements for the three and six months ended March 29, 2013. Eliminations represent adjustments to eliminate investments in subsidiaries and intercompany balances and transactions between or among Mallinckrodt plc, MIFSA and the other subsidiaries. Unaudited condensed consolidating and combining financial information for Mallinckrodt plc and MIFSA, on a standalone basis, has been presented using the equity method of accounting for subsidiaries.
	MALLINCKRODT PLC
	CONDENSED CONSOLIDATING BALANCE SHEET
	As of March 28, 2014
	(unaudited, in millions)
		Mallinckrodt plc			Mallinckrodt International Finance S.A.			Other Subsidiaries			Eliminations			Consolidated
	Assets
	Current Assets:
	Cash and cash equivalents	$	0.2		$	86.7		$	248		$	—		$	334.9
	Accounts receivable, net	—			—			334.2			—			334.2
	Inventories	—			—			444.7			—			444.7
	Deferred income taxes	—			—			371.7			—			371.7
	Prepaid expenses and other current assets	0.5			0.2			146.9			—			147.6
	Intercompany receivable	5.9			—			8.3			(14.2		)	—
	Total current assets	6.6			86.9			1,553.80			(14.2		)	1,633.10
	Property, plant and equipment, net	—			—			997.5			—			997.5
	Goodwill	—			—			853.9			—			853.9
	Intangible assets, net	—			—			1,715.00			—			1,715.00
	Investment in subsidiaries	1,319.40			3,896.90			—			(5,216.3		)	—
	Intercompany loan receivable	21.5			—			468.4			(489.9		)	—
	Other assets	—			42			213.8			—			255.8
	Total Assets	$	1,347.50		$	4,025.80		$	5,802.40		$	(5,720.4	)	$	5,455.30
	Liabilities and Shareholders' Equity
	Current Liabilities:
	Current maturities of long-term debt	$	—		$	9.8		$	1.4		$	—		$	11.2
	Accounts payable	1.6			—			118.3			—			119.9
	Accrued payroll and payroll-related costs	0.1			—			57.9			—			58
	Accrued branded rebates	—			—			33.6			—			33.6
	Accrued and other current liabilities	1.1			21			381			—			403.1
	Intercompany payable	6.3			2.1			5.8			(14.2		)	—
	Total current liabilities	9.1			32.9			598			(14.2		)	625.8
	Long-term debt	—			2,185.20			19.5			—			2,204.70
	Pension and postretirement benefits	—			—			104			—			104
	Environmental liabilities	—			—			63.7			—			63.7
	Deferred income taxes	—			—			794.8			—			794.8
	Other income tax liabilities	—			—			148.1			—			148.1
	Intercompany loans payable	—			489.9			—			(489.9		)	—
	Other liabilities	—			—			175.8			—			175.8
	Total liabilities	9.1			2,708.00			1,903.90			(504.1		)	4,116.90
	Shareholders' equity	1,338.40			1,317.80			3,898.50			(5,216.3		)	1,338.40
	Total Liabilities and Shareholders' Equity	$	1,347.50		$	4,025.80		$	5,802.40		$	(5,720.4	)	$	5,455.30
	MALLINCKRODT PLC
	CONDENSED CONSOLIDATING BALANCE SHEET
	As of September 27, 2013
	(unaudited, in millions)
		Mallinckrodt plc			Mallinckrodt International Finance S.A.			Other Subsidiaries			Eliminations			Consolidated
	Assets
	Current Assets:
	Cash and cash equivalents	$	1.2		$	56.5		$	217.8		$	—		$	275.5
	Accounts receivable, net	—			—			400.8			—			400.8
	Inventories	—			—			403.1			—			403.1
	Deferred income taxes	—			—			171.1			—			171.1
	Prepaid expenses and other current assets	1			—			133.4			—			134.4
	Intercompany receivable	2.7			—			12.2			(14.9		)	—
	Total current assets	4.9			56.5			1,338.40			(14.9		)	1,384.90
	Property, plant and equipment, net	—			—			997.4			—			997.4
	Goodwill	—			—			532			—			532
	Intangible assets, net	—			—			422.1			—			422.1
	Investment in subsidiaries	1,266.10			2,520.40			—			(3,786.5		)	—
	Intercompany loan receivable	—			2.4			409.6			(412.0		)	—
Other assets	—			11.2			209			—			220.2
Total Assets	$	1,271.00		$	2,590.50		$	3,908.50		$	(4,213.4	)	$	3,556.60
Liabilities and Shareholders' Equity
Current Liabilities:
Current maturities of long-term debt	$	—		$	—		$	1.5		$	—		$	1.5
Accounts payable	0.1			—			120.8			—			120.9
Accrued payroll and payroll-related costs	0.1			—			66.4			—			66.5
Accrued branded rebates	—			—			34.6			—			34.6
Accrued and other current liabilities	0.6			18.3			357.8			—			376.7
Intercompany payable	12.2			—			2.7			(14.9		)	—
Total current liabilities	13			18.3			583.8			(14.9		)	600.2
Long-term debt	—			898.1			20.2			—			918.3
Pension and postretirement benefits	—			—			108			—			108
Environmental liabilities	—			—			39.5			—			39.5
Deferred income taxes	—			—			310.1			—			310.1
Other income tax liabilities	—			—			153.1			—			153.1
Intercompany loans payable	2.4			409.6			—			(412.0		)	—
Other liabilities	—			—			171.8			—			171.8
Total liabilities	15.4			1,326.00			1,386.50			(426.9		)	2,301.00
Shareholders' equity	1,255.60			1,264.50			2,522.00			(3,786.5		)	1,255.60
Total Liabilities and Shareholders' Equity	$	1,271.00		$	2,590.50		$	3,908.50		$	(4,213.4	)	$	3,556.60
MALLINCKRODT PLC
CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME
For the three months ended March 28, 2014
(unaudited, in millions)
	Mallinckrodt plc			Mallinckrodt International Finance S.A.			Other Subsidiaries			Eliminations			Consolidated
Net sales	$	—		$	—		$	557.8		$	—		$	557.8
Cost of sales	—			—			295.2			—			295.2
Gross profit	—			—			262.6			—			262.6
Selling, general and administrative expenses	7.9			0.1			186.1			—			194.1
Research and development expenses	—			—			41.4			—			41.4
Separation costs	0.6			—			2			—			2.6
Restructuring charges, net	—			—			21.7			—			21.7
Gains on divestiture and license	—			—			(0.9		)	—			(0.9		)
Operating (loss) income	(8.5		)	(0.1		)	12.3			—			3.7
Interest expense	—			(12.8		)	0.4			—			(12.4		)
Interest income	—			—			0.5			—			0.5
Other income (expense), net	22.3			—			(22.7		)	—			(0.4		)
Intercompany interest and fees	(0.9		)	—			0.9			—			—
Equity in net income of subsidiaries	(1.1		)	11.7			—			(10.6		)	—
Income (loss) from continuing operations before income taxes	11.8			(1.2		)	(8.6		)	(10.6		)	(8.6		)
Income tax expense (benefit)	0.2			(0.1		)	(20.4		)	—			(20.3		)
Income (loss) from continuing operations	11.6			(1.1		)	11.8			(10.6		)	11.7
Loss from discontinued operations, net of income taxes	—			—			(0.1		)	—			(0.1		)
Net income (loss)	11.6			(1.1		)	11.7			(10.6		)	11.6
Other comprehensive loss, net of tax	(2.3		)	(2.3		)	(2.4		)	4.7			(2.3		)
Comprehensive income (loss)	$	9.3		$	(3.4	)	$	9.3		$	(5.9	)	$	9.3
MALLINCKRODT PLC
CONDENSED COMBINING STATEMENT OF COMPREHENSIVE INCOME
For the three months ended March 29, 2013
(unaudited, in millions)
	Mallinckrodt plc			Mallinckrodt International Finance S.A.			Other Subsidiaries			Eliminations			Combined
Net sales	$	—		$	—		$	585.3		$	—		$	585.3
Cost of sales	—			—			311.8			—			311.8
Gross profit	—			—			273.5			—			273.5
Selling, general and administrative expenses	—			—			160.7			—			160.7
Research and development expenses	—			—			39.2			—			39.2
Separation costs	—			—			14.4			—			14.4
Restructuring charges, net	—			—			6.4			—			6.4
Gains on divestiture and license	—			—			(0.7		)	—			(0.7		)
Operating income	—			—			53.5			—			53.5
Interest expense	—			—			(0.1		)	—			(0.1		)
Interest income	—			—			0.1			—			0.1
Other income (expense), net	—			—			—			—			—
Intercompany interest and fees	—			—			—			—			—
Equity in net income of subsidiaries	34			34			—			(68.0		)	—
Income from continuing operations before income taxes	34			34			53.5			(68.0		)	53.5
Income tax expense	—			—			19			—			19
Income from continuing operations	34			34			34.5			(68.0		)	34.5
Loss from discontinued operations, net of income taxes	—			—			(0.5		)	—			(0.5		)
Net income	34			34			34			(68.0		)	34
Other comprehensive loss, net of tax	(14.5		)	(14.5		)	(10.5		)	25			(14.5		)
Comprehensive income	$	19.5		$	19.5		$	23.5		$	(43.0	)	$	19.5
MALLINCKRODT PLC
CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME
For the six months ended March 28, 2014
(unaudited, in millions)
	Mallinckrodt plc			Mallinckrodt International Finance S.A.			Other Subsidiaries			Eliminations			Consolidated
Net sales	$	—		$	—		$	1,098.00		$	—		$	1,098.00
Cost of sales	—			—			579.8			—			579.8
Gross profit	—			—			518.2			—			518.2
Selling, general and administrative expenses	11.9			0.2			328.2			—			340.3
Research and development expenses	—			—			80.4			—			80.4
Separation costs	1.4			—			3.4			—			4.8
Restructuring charges, net	—			—			29.7			—			29.7
Gains on divestiture and license	—			—			(13.8		)	—			(13.8		)
Operating (loss) income	(13.3		)	(0.2		)	90.3			—			76.8
Interest expense	—			(23.3		)	1.1			—			(22.2		)
Interest income	—			—			0.8			—			0.8
Other income (expense), net	23			—			(24.0		)	—			(1.0		)
Intercompany interest and fees	(4.0		)	—			4			—			—
Equity in net income of subsidiaries	51.5			74.9			—			(126.4		)	—
Income from continuing operations before income taxes	57.2			51.4			72.2			(126.4		)	54.4
Income tax (benefit) expense	—			(0.1		)	(3.6		)	—			(3.7		)
Income from continuing operations	57.2			51.5			75.8			(126.4		)	58.1
Loss from discontinued operations, net of income taxes	—			—			(0.9		)	—			(0.9		)
Net income	57.2			51.5			74.9			(126.4		)	57.2
Other comprehensive loss, net of tax	(2.1		)	(2.1		)	(2.3		)	4.4			(2.1		)
Comprehensive income	$	55.1		$	49.4		$	72.6		$	(122.0	)	$	55.1
MALLINCKRODT PLC
CONDENSED COMBINING STATEMENT OF COMPREHENSIVE INCOME
For the six months ended March 29, 2013
(unaudited, in millions)
	Mallinckrodt plc			Mallinckrodt International Finance S.A.			Other Subsidiaries			Eliminations			Combined
Net sales	$	—		$	—		$	1,089.30		$	—		$	1,089.30
Cost of sales	—			—			582.3			—			582.3
Gross profit	—			—			507			—			507
Selling, general and administrative expenses	—			—			307.5			—			307.5
Research and development expenses	—			—			77.6			—			77.6
Separation costs	—			—			26.4			—			26.4
Restructuring charges, net	—			—			6.6			—			6.6
Gains on divestiture and license	—			—			(1.4		)	—			(1.4		)
Operating income	—			—			90.3			—			90.3
Interest expense	—			—			(0.2		)	—			(0.2		)
Interest income	—			—			0.1			—			0.1
Other income (expense), net	—			—			0.2			—			0.2
Intercompany interest and fees	—			—			—			—			—
Equity in net income of subsidiaries	53.2			53.2			—			(106.4		)	—
Income from continuing operations before income taxes	53.2			53.2			90.4			(106.4		)	90.4
Income tax expense	—			—			36.1			—			36.1
Income from continuing operations	53.2			53.2			54.3			(106.4		)	54.3
Loss from discontinued operations, net of income taxes	—			—			(1.1		)	—			(1.1		)
Net income	53.2			53.2			53.2			(106.4		)	53.2
Other comprehensive loss, net of tax	(13.9		)	(13.9		)	(9.9		)	23.8			(13.9		)
Comprehensive income	$	39.3		$	39.3		$	43.3		$	(82.6	)	$	39.3
MALLINCKRODT PLC
CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS
For the six months ended March 28, 2014
(unaudited, in millions)
	Mallinckrodt plc			Mallinckrodt International Finance S.A.			Other Subsidiaries			Eliminations			Consolidated
Cash Flows From Operating Activities:
Net cash (used in) provided by operating activities	$	8.6		$	(17.1	)	$	149.7		$	—		$	141.2
Cash Flows From Investing Activities:
Capital expenditures	—			—			(50.7		)	—			(50.7		)
Acquisitions and intangibles, net of cash acquired	—			—			(1,293.2		)	—			(1,293.2		)
Intercompany loan investment	(21.5		)	—			(58.8		)	80.3			—
Repayment of intercompany loan investment	—			2.4			—			(2.4		)	—
Investment in subsidiary	—			(1,300.0		)	—			1,300.00			—
Restricted cash	—			—			4.1			—			4.1
Other	—			—			8			—			8
Net cash (used in) investing activities	(21.5		)	(1,297.6		)	(1,390.6		)	1,377.90			(1,331.8		)
Cash Flows From Financing Activities:
Issuance of external debt	—			1,296.80			—			—			1,296.80
Repayment of external debt	—			—			(30.1		)	—			(30.1		)
Repayment of capital leases	—			—			(0.7		)	—			(0.7		)
Debt financing costs	—			(32.2		)	—			—			(32.2		)
Excess tax benefit from share-based compensation	—			—			4			—			4
Proceeds from exercise of share options	16.1			—			—			—			16.1
Purchase of treasury shares	(1.8		)	—			—			—			(1.8		)
Advances from intercompany borrowings	—			80.3			—			(80.3		)	—
Payment on intercompany borrowings	(2.4		)	—			—			2.4			—
Capital contribution	—			—			1,300.00			(1,300.0		)	—
Net cash provided by (used in) financing activities	11.9			1,344.90			1,273.20			(1,377.9		)	1,252.10
Effect of currency rate changes on cash	—			—			(2.1		)	—			(2.1		)
Net increase in cash and cash equivalents	(1.0		)	30.2			30.2			—			59.4
Cash and cash equivalents at beginning of period	1.2			56.5			217.8			—			275.5
Cash and cash equivalents at end of period	$	0.2		$	86.7		$	248		$	—		$	334.9
MALLINCKRODT PLC
CONDENSED COMBINING STATEMENT OF CASH FLOWS
For the six months ended March 29, 2013
(unaudited, in millions)
	Mallinckrodt plc			Mallinckrodt International Finance S.A.			Other Subsidiaries			Eliminations			Combined
Cash Flows From Operating Activities:
Net cash (used in) provided by operating activities	$	—		$	(4.8	)	$	(3.0	)	$	—		$	(7.8	)
Cash Flows From Investing Activities:
Capital expenditures	—			—			(76.7		)	—			(76.7		)
Acquisition, net of cash acquired	—			—			(88.1		)	—			(88.1		)
Restricted cash	—			—			0.9			—			0.9
Other	—			—			(1.1		)	—			(1.1		)
Net cash (used in) investing activities	—			—			(165.0		)	—			(165.0		)
Cash Flows From Financing Activities:
Repayment of capital leases	—			—			(0.7		)	—			(0.7		)
Debt financing costs	—			—			(2.3		)	—			(2.3		)
Excess tax benefit from share-based compensation	—			—			3			—			3
Net transfers from (to) parent	—			4.8			168			—			172.8
Net cash provided by (used in) financing activities	—			4.8			168			—			172.8
Effect of currency rate changes on cash	—			—			—			—			—
Net increase in cash and cash equivalents	—			—			—			—			—
Cash and cash equivalents at beginning of period	—			—			—			—			—
Cash and cash equivalents at end of period	$	—		$	—		$	—		$	—		$	—

Subsequent_Events

Subsequent Events	6 Months Ended
	Mar. 28, 2014
Subsequent Events [Abstract]	'
Subsequent Events	'
	21	Subsequent Events
	Questcor Pharmaceuticals
	On April 5, 2014, the Company entered into a definitive merger agreement to acquire Questcor, a high-growth biopharmaceutical company, for approximately $5.6 billion. Questcor shareholders will receive $30.00 per share in cash and 0.897 shares of the Company for each share of Questcor common stock owned. The Company has entered into debt financing commitments that, together with cash on hand, are expected to be sufficient to provide the funds necessary to consummate the transaction. The Company expects that the financing will consist of a combination of a senior secured term loan facility and senior notes. The acquisition is expected to provide a strong and sustainable platform for future revenue and earnings growth within the Company's Specialty Pharmaceuticals segment. Subject to customary closing conditions, the transaction is currently expected to be completed in the fourth fiscal quarter of 2014.
	Lower Passaic River Environmental Reserve
	On April 11, 2014, the EPA issued its revised FFS, with remedial alternatives to address cleanup of the lower 8-mile stretch of the River, which also included a "no action" option. The EPA estimates the cost for the alternatives range from $365.0 million to $3.2 billion. The EPA's preferred approach would involve bank-to-bank dredging of the lower 8-mile stretch of the River and installing an engineered cap at a discounted, estimated cost of $1.7 billion. Based on the issuance of the EPA's revised FFS, the Company recorded a $23.1 million accrual in the second quarter of fiscal 2014 representing the Company's estimate of its allocable share of the joint and several remediation liability resulting from this matter. Despite the issuance of the revised FFS, there are many uncertainties associated with the final agreed upon remediation and the Company's allocable share of the remediation. Given those uncertainties, the amounts accrued may not be indicative of the amounts for which the Company is ultimately responsible and will be refined as events in the remediation process occur.

Acquisitions_Tables

Acquisitions (Tables)	6 Months Ended
	Mar. 28, 2014
Acquisitions [Abstract]	'
Schedule of Fair Value of Identifiable Assets Acquired and Liabilities Assumed	'
	Cash and cash equivalents	$	43.2
	Inventory	21
	Intangible assets	1,300.00
	Goodwill	321.9
	Other assets, current and non-current (1)	18
	Deferred tax liabilities, net	(296.6		)
	Other liabilities, current and non-current (2)	(78.3		)
	Net assets acquired	$	1,329.20
	-1	This amount includes $14.7 million of accounts receivable, which is also the gross contractual value.
	-2	This amount includes $30.0 million of pre-existing Cadence debt, which the Company repaid upon completion of the acquisition.
Schedule of Intangible Assets Acquired	'
	Intangible assets acquired consist of the following:
		Amount			Amortization Period
	Completed technology	$	1,300.00		8 years
Schedule of Unaudited Pro Forma Information	'
		Three Months Ended					Six Months Ended
		March 28,			March 29,		March 28,			March 29,
		2014			2013		2014			2013
	Net sales	$	588.2		$	608.9	$	1,163.70		$	1,130.10
	Net (loss) income	(18.4		)	4.4		(2.6		)	(35.7		)
	Basic (loss) earnings per share	$	(0.32	)	$	0.08	$	(0.04	)	$	(0.62	)
	Diluted (loss) earnings per share	(0.31		)	0.08		(0.04		)	(0.62		)

Restructuring_and_Related_Char1

Restructuring and Related Charges (Tables)	6 Months Ended
	Mar. 28, 2014
Restructuring and Related Activities [Abstract]	'
Schedule of Restructuring and Related Charges by Segment	'
	Net restructuring and related charges by segment were as follows:
		Three Months Ended						Six Months Ended
		March 28,			March 29,			March 28,			March 29,
		2014			2013			2014			2013
	Specialty Pharmaceuticals	$	2.7		$	5.9		$	2.7		$	6.6
	Global Medical Imaging	18.5			1			26.6			1.3
	Corporate	0.5			—			0.5			—
	Restructuring and related charges, net	21.7			6.9			29.8			7.9
	Less: accelerated depreciation	—			(0.5		)	(0.1		)	(1.3		)
	Restructuring charges, net	$	21.7		$	6.4		$	29.7		$	6.6
Schedule of Net Restructuring and Related Charges	'
	Net restructuring and related charges were comprised of the following:
		Three Months Ended						Six Months Ended
		March 28,			March 29,			March 28,			March 29,
		2014			2013			2014			2013
	2013 Mallinckrodt Program	$	22.6		$	—		$	30.9		$	—
	Other programs	(0.9		)	6.9			(1.1		)	7.9
	Total programs	21.7			6.9			29.8			7.9
	Less: non-cash charges, including accelerated depreciation	(2.6		)	(0.5		)	(2.7		)	(1.4		)
	Total charges expected to be settled in cash	$	19.1		$	6.4		$	27.1		$	6.5
Schedule of Restructuring Reserves by Type of Cost	'
	The following table summarizes cash activity for restructuring reserves, substantially all of which related to employee severance and benefits, with the exception of $8.4 million related to consulting costs associated with restructuring initiatives:
		2013 Mallinckrodt Program			Other Programs			Total
	Balance at September 27, 2013	$	14.9		$	10.6		$	25.5
	Charges	30			0.8			30.8
	Changes in estimate	(1.7		)	(2.0		)	(3.7		)
	Cash payments	(10.9		)	(5.3		)	(16.2		)
	Currency translation and other	(0.3		)	0.1			(0.2		)
	Balance at March 28, 2014	$	32		$	4.2		$	36.2
Schedule of Restructuring Charges Incurred Cumulative to Date	'
	Net restructuring and related charges, including associated asset impairments, incurred cumulative to date related to the 2013 Mallinckrodt Program were as follows:
	Specialty Pharmaceuticals	$	5.2
	Global Medical Imaging	36.3
	Corporate	4.3
		$	45.8

Earnings_Loss_per_Share_Tables

Earnings (Loss) per Share (Tables)	6 Months Ended
	Mar. 28, 2014
Earnings (Loss) per Share [Abstract]	'
Schedule of Earnings (Loss) per Share	'
		Three Months Ended		Six Months Ended
		March 28,	March 29,	March 28,	March 29,
		2014	2013	2014	2013
	Weighted-average shares for basic earnings (loss) per share	58.2	57.7	58	57.7
	Effect of share options and restricted shares	0.9	—	0.7	—
	Weighted-average shares for diluted earnings (loss) per share	59.1	57.7	58.7	57.7

Inventories_Tables

Inventories (Tables)	6 Months Ended
	Mar. 28, 2014
Inventory, Net [Abstract]	'
Schedule of Inventories	'
	Inventories were comprised of the following at the end of each period:
		March 28,		September 27,
		2014		2013
	Raw materials and supplies	$	85.7	$	68.8
	Work in process	194.9		191.5
	Finished goods	164.1		142.8
		$	444.7	$	403.1

Property_Plant_and_Equipment_T

Property, Plant and Equipment (Tables)	6 Months Ended
	Mar. 28, 2014
Property, Plant and Equipment [Abstract]	'
Schedule of Property, Plant and Equipment	'
	The gross carrying amount and accumulated depreciation of property, plant and equipment at the end of each period was as follows:
		March 28,			September 27, 2013
		2014
	Property, plant and equipment, gross	$	1,918.30		$	1,873.70
	Less: accumulated depreciation	(920.8		)	(876.3		)
	Property, plant and equipment, net	$	997.5		$	997.4

Goodwill_and_Intangible_Assets1

Goodwill and Intangible Assets (Tables)	6 Months Ended
	Mar. 28, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Goodwill	'
	The carrying amount of goodwill by segment for the periods presented was as follows:
		Specialty Pharmaceuticals		Global Medical Imaging		Total
	Goodwill at September 27, 2013	$	312.3	$	219.7	$	532
	Acquisitions	321.9		—		321.9
	Goodwill at March 28, 2014	$	634.2	$	219.7	$	853.9
Schedule of Intangible Assets	'
	The gross carrying amount and accumulated amortization of intangible assets at the end of each period were as follows:
		28-Mar-14				27-Sep-13
		Gross		Accumulated		Gross		Accumulated
		Carrying		Amortization		Carrying		Amortization
		Amount				Amount
	Amortizable:
	Completed technology	$	1,749.20	$	212.8	$	449.2	$	196.6
	Licenses	201.1		85.5		191.1		79.3
	Trademarks	7.9		3.9		7.9		3.8
	Other	7.2		1.8		—		—
	Total	$	1,965.40	$	304	$	648.2	$	279.7
	Non-Amortizable:
	Trademarks	$	35			$	35
	In-process research and development	18.6				18.6
	Total	$	53.6			$	53.6
Schedule of Future Amortization Expense, Intangible Assets	'
	The estimated aggregate amortization expense on intangible assets owned by the Company is expected to be as follows:
	Remainder of fiscal 2014	$	103.1
	Fiscal 2015	200.7
	Fiscal 2016	198.8
	Fiscal 2017	197.4
	Fiscal 2018	188.7

Debt_Tables

Debt (Tables)	6 Months Ended
	Mar. 28, 2014
Debt Disclosure [Abstract]	'
Schedule of Long-term Debt including Capital Lease Obligation	'
	Debt was comprised of the following at the end of each period:
		March 28,		September 27, 2013
		2014
	Current maturities of long-term debt:
	Term loan	$	9.8	$	—
	Capital lease obligation	1.4		1.4
	Loan payable	—		0.1
	Total current debt	11.2		1.5
	Long-term debt:
	Term loan	1,287.00		—
	3.50% notes due April 2018	300		299.9
	9.50% debentures due May 2022	10.4		10.4
	8.00% debentures due March 2023	8		8
	4.75% notes due April 2023	598.2		598.2
	Capital lease obligation	1.1		1.8
	Total long-term debt	2,204.70		918.3
	Total debt	$	2,215.90	$	919.8

Retirement_Plans_Tables

Retirement Plans (Tables) (Pension Benefits)	6 Months Ended
	Mar. 28, 2014
Pension Benefits	'
Defined Benefit Plan Disclosure [Line Items]	'
Schedule of Net Periodic Benefit Cost	'
	The net periodic benefit cost for the Company's defined benefit pension plans was as follows:
		Three Months Ended						Six Months Ended
		March 28,			March 29,			March 28,			March 29,
		2014			2013			2014			2013
	Service cost	$	1.2		$	1.2		$	2.5		$	2.4
	Interest cost	5			4.5			9.9			9.1
	Expected return on plan assets	(6.1		)	(7.3		)	(12.2		)	(14.7		)
	Amortization of net actuarial loss	2.1			3			4.2			6
	Amortization of prior service (credit) cost	(0.2		)	0.2			(0.3		)	0.3
	Plan settlements	0.3			—			0.3			—
	Net periodic benefit cost	$	2.3		$	1.6		$	4.4		$	3.1

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Income (Tables)	6 Months Ended
	Mar. 28, 2014
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]	'
Schedule of Accumulated Other Comprehensive Income	'
	The components of accumulated other comprehensive income were as follows:
		Currency Translation			Unrecognized Gain (Loss) on Derivatives			Unrecognized Gain (Loss) on Benefit Plans			Accumulated Other Comprehensive Income
	Balance at September 27, 2013	$	158.6		$	(7.3	)	$	(42.8	)	$	108.5
	Other comprehensive loss before reclassifications	(2.0		)	—			—			(2.0		)
	Amounts reclassified from accumulated other comprehensive income	—			0.2			(0.3		)	(0.1		)
	Net current period other comprehensive (loss) income	(2.0		)	0.2			(0.3		)	(2.1		)
	Balance at March 28, 2014	$	156.6		$	(7.1	)	$	(43.1	)	$	106.4
Schedule of Reclassifications out of Accumulated Other Comprehensive Income	'
	The following summarizes reclassifications out of accumulated other comprehensive income for the three and six months ended March 28, 2014:
		Amount Reclassified from
		Accumulated Other Comprehensive Income
		Three Months Ended March 28, 2014			Six Months Ended March 28, 2014			Line Item in the Unaudited Condensed Consolidated
								Statement of Income
	Amortization of unrealized gain on derivatives	$	0.1		$	0.3		Interest expense
	Income tax provision	—			(0.1		)	Provision for income taxes
	Net of income taxes	0.1			0.2
	Amortization of pension and post-retirement benefit plans:
	Net actuarial loss	2.1			4.2			(1)
	Prior service credit	(2.4		)	(4.9		)	(1)
	Plan settlements	0.3			0.3			(1)
	Total before tax	—			(0.4		)
	Income tax provision	—			0.1			Provision for income taxes
	Net of income taxes	—			(0.3		)
	Total reclassifications for the period	$	0.1		$	(0.1	)
	-1
		These accumulated other comprehensive income components are included in the computation of net periodic benefit cost. See Note 12 for additional details.

Commitment_and_Contingencies_T

Commitment and Contingencies (Tables)	6 Months Ended
	Mar. 28, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Schedule of Changes in Asset Retirement Obligations	'
	The following table provides a summary of the changes in the Company's asset retirement obligations:
	Balance at September 27, 2013	$	50.6
	Accretion expense	1.6
	Currency translation	0.5
	Balance at March 28, 2014	$	52.7

Derivative_Instruments_Tables

Derivative Instruments (Tables)	6 Months Ended
	Mar. 28, 2014
Summary of Derivative Instruments [Abstract]	'
Schedule of Net Gain (Loss) on Foreign Exchange Contracts	'
	The location and amount of the net gain (loss) on foreign exchange forward and option contracts not designated as hedging instruments was recorded as follows:
		Three Months Ended						Six Months Ended
		March 28,			March 29,			March 28,			March 29,
		2014			2013			2014			2013
	Cost of sales	$	(0.2	)	$	(1.5	)	$	(0.4	)	$	(2.4	)
	Selling, general and administrative	0.3			1.2			0.3			2.3
	Other (expense) income, net	1.5			—			5.7			—
		$	1.6		$	(0.3	)	$	5.6		$	(0.1	)
Schedule of Fair Value of Foreign Exchange Contracts	'
	The fair value of foreign exchange forward and option contracts were included in the following captions of our unaudited condensed consolidated balance sheets at the end of each period:
		March 28,			September 27, 2013
		2014
	Prepaid expenses and other current assets	$	0.6		$	0.9
	Accrued and other current liabilities	0.6			1.4
Schedule of Net Losses on Gas Commodity Swap Contracts	'
	The amounts of the net losses on these contracts recorded during the three and six months ended March 29, 2013 were as follows:
		Three Months Ended			Six Months Ended
	Cost of sales	$	0.1		$	0.2
	Selling, general and administrative	0.3			0.6
		$	0.4		$	0.8

Financial_Instruments_and_Fair1

Financial Instruments and Fair Value Measurements (Tables)	6 Months Ended
	Mar. 28, 2014
Fair Value Disclosures [Abstract]	'
Schedule of Fair Value of Assets and Liabilities Measured on a Recurring Basis	'
	The following tables provide a summary of the significant assets and liabilities that are measured at fair value on a recurring basis at the end of each period:
		March 28,			Quoted Prices in Active Markets for Identical Assets				Significant Other Observable Inputs			Significant Unobservable Inputs
		2014			(Level 1)				(Level 2)			(Level 3)
	Assets:
	Debt and equity securities held in rabbi trusts	$	35.1		$	22.9			$	12.2		$	—
	Foreign exchange forward and option contracts	0.6			0.6				—			—
		$	35.7		$	23.5			$	12.2		$	—
	Liabilities:
	Deferred compensation liabilities	$	13.7		$	—			$	13.7		$	—
	Contingent consideration	7			—				—			7
	Foreign exchange forward and option contracts	0.6			0.6				—			—
		$	21.3		$	0.6			$	13.7		$	7
		September 27,			Quoted Prices in Active Markets for Identical Assets				Significant Other Observable Inputs			Significant Unobservable Inputs
		2013			(Level 1)				(Level 2)			(Level 3)
	Assets:
	Debt and equity securities held in rabbi trusts	$	35.3		$	22.6			$	12.7		$	—
	Foreign exchange forward and option contracts	0.9			0.9				—			—
		$	36.2		$	23.5			$	12.7		$	—
	Liabilities:
	Deferred compensation liabilities	$	13.5		$	—			$	13.5		$	—
	Contingent consideration	6.9			—				—			6.9
	Foreign exchange forward and option contracts	1.4			1.4				—			—
		$	21.8		$	1.4			$	13.5		$	6.9
Schedule of Reconciliation of Changes in Fair Value of Contingent Consideration	'
	Balance at September 27, 2013	$	6.9
	Accretion expense	0.1
	Balance at March 28, 2014	$	7
Schedule of Carrying Amount and Fair Value of Long-term Debt	'
	The following table presents the carrying values and estimated fair values of the Company's long-term debt, excluding capital leases, as of the end of each period:
		March 28, 2014							September 27, 2013
		Carrying			Fair				Carrying			Fair
		Value			Value				Value			Value
	Loan payable	$	—		$	—			$	0.1		$	0.1
	Term loan	1,296.80			1,301.00				—			—
	3.50% notes due April 2018	300			296				299.9			293.7
	9.50% debentures due May 2022	10.4			14.2				10.4			14.3
	8.00% debentures due March 2023	8			10.2				8			10.2
	4.75% notes due April 2023	598.2			571.6				598.2			568.5
Schedule of Accounts Receivable Concentration Risk	'
	The Company's accounts receivable, net of allowance for doubtful accounts, in Spain and Italy, which the Company has been closely monitoring, at the end of each period were as follows:
		March 28,			September 27,
		2014			2013
	Spain	$	9.8		$	9.2
	Italy	10.7			12.6
Schedules of Concentration of Risk	'
	The following table shows net sales attributable to distributors that accounted for 10% or more of the Company's total net sales:
		Three Months Ended					Six Months Ended
		March 28,		March 29,			March 28,			March 29,
		2014		2013			2014			2013
	Cardinal Health, Inc.	15	%	20	%		18	%		20	%
	McKesson Corporation	15	%	19	%		15	%		16	%
	Amerisource Bergen Corporation	10	%	6	%		11	%		7	%
	The following table shows accounts receivable attributable to distributors that accounted for 10% or more of the Company's gross accounts receivable at the end of each period:
		March 28,		September 27,
		2014		2013
	Cardinal Health, Inc.	20	%	18	%
	McKesson Corporation	23	%	22	%
	Amerisource Bergen Corporation	13	%	14	%
	The following table shows net sales attributable to products that accounted for 10% or more of the Company's total net sales:
		Three Months Ended					Six Months Ended
		March 28,		March 29,			March 28,			March 29,
		2014		2013			2014			2013
	Optiray™ (CMDS)	13	%	13	%		13	%		14	%
	Acetaminophen products (API)	9	%	10	%		8	%		10	%
	Methylphenidate ER (Specialty Generics)	8	%	11	%		9	%		7	%

Segment_Data_Tables

Segment Data (Tables)	6 Months Ended
	Mar. 28, 2014
Segment Reporting [Abstract]	'
Schedule of Segment Reporting Information by Business Segment	'
	Selected information by business segment was as follows:
		Three Months Ended						Six Months Ended
		March 28,			March 29,			March 28,			March 29,
		2014			2013			2014			2013
	Net sales:
	Specialty Pharmaceuticals	$	324.3		$	344.4		$	633.8		$	604.6
	Global Medical Imaging	222.4			229.1			441			458.8
	Net sales of operating segments (1)	546.7			573.5			1,074.80			1,063.40
	Other (2)	11.1			11.8			23.2			25.9
	Net sales	$	557.8		$	585.3		$	1,098.00		$	1,089.30
	Operating income:
	Specialty Pharmaceuticals	$	105.9		$	105		$	218.9		$	140
	Global Medical Imaging	10.3			18.9			14.7			68
	Segment operating income	116.2			123.9			233.6			208
	Unallocated amounts:
	Corporate and allocated expenses (3)	(72.7		)	(40.3		)	(97.9		)	(65.7		)
	Intangible asset amortization	(15.5		)	(8.8		)	(24.3		)	(17.7		)
	Restructuring and related charges, net (4)	(21.7		)	(6.9		)	(29.8		)	(7.9		)
	Separation costs	(2.6		)	(14.4		)	(4.8		)	(26.4		)
	Operating income	$	3.7		$	53.5		$	76.8		$	90.3
	-1	Amounts represent sales to external customers.
	-2	Represents products that were sold to Covidien, our former parent company, which is discussed in Note 14.
	-3	Includes administration expenses and certain compensation, environmental and other costs not charged to the Company's operating segments.
	-4	Includes restructuring-related accelerated depreciation of $0.5 million for the three months ended March 29, 2013 and $0.1 million and $1.3 million million for the six months ended March 28, 2014 and March 29, 2013, respectively. Restructuring-related accelerated depreciation for the three months ended March 28, 2014 was immaterial.

Condensed_Consolidating_and_Co1

Condensed Consolidating and Combining Financial Statements (Tables)	6 Months Ended
	Mar. 28, 2014
Condensed Consolidating Financial Statements [Abstract]	'
Schedule of Condensed Consolidating Balance Sheets	'
	MALLINCKRODT PLC
	CONDENSED CONSOLIDATING BALANCE SHEET
	As of March 28, 2014
	(unaudited, in millions)
		Mallinckrodt plc			Mallinckrodt International Finance S.A.			Other Subsidiaries			Eliminations			Consolidated
	Assets
	Current Assets:
	Cash and cash equivalents	$	0.2		$	86.7		$	248		$	—		$	334.9
	Accounts receivable, net	—			—			334.2			—			334.2
	Inventories	—			—			444.7			—			444.7
	Deferred income taxes	—			—			371.7			—			371.7
	Prepaid expenses and other current assets	0.5			0.2			146.9			—			147.6
	Intercompany receivable	5.9			—			8.3			(14.2		)	—
	Total current assets	6.6			86.9			1,553.80			(14.2		)	1,633.10
	Property, plant and equipment, net	—			—			997.5			—			997.5
	Goodwill	—			—			853.9			—			853.9
	Intangible assets, net	—			—			1,715.00			—			1,715.00
	Investment in subsidiaries	1,319.40			3,896.90			—			(5,216.3		)	—
	Intercompany loan receivable	21.5			—			468.4			(489.9		)	—
	Other assets	—			42			213.8			—			255.8
	Total Assets	$	1,347.50		$	4,025.80		$	5,802.40		$	(5,720.4	)	$	5,455.30
	Liabilities and Shareholders' Equity
	Current Liabilities:
	Current maturities of long-term debt	$	—		$	9.8		$	1.4		$	—		$	11.2
	Accounts payable	1.6			—			118.3			—			119.9
	Accrued payroll and payroll-related costs	0.1			—			57.9			—			58
	Accrued branded rebates	—			—			33.6			—			33.6
	Accrued and other current liabilities	1.1			21			381			—			403.1
	Intercompany payable	6.3			2.1			5.8			(14.2		)	—
	Total current liabilities	9.1			32.9			598			(14.2		)	625.8
	Long-term debt	—			2,185.20			19.5			—			2,204.70
	Pension and postretirement benefits	—			—			104			—			104
	Environmental liabilities	—			—			63.7			—			63.7
	Deferred income taxes	—			—			794.8			—			794.8
	Other income tax liabilities	—			—			148.1			—			148.1
	Intercompany loans payable	—			489.9			—			(489.9		)	—
	Other liabilities	—			—			175.8			—			175.8
	Total liabilities	9.1			2,708.00			1,903.90			(504.1		)	4,116.90
	Shareholders' equity	1,338.40			1,317.80			3,898.50			(5,216.3		)	1,338.40
	Total Liabilities and Shareholders' Equity	$	1,347.50		$	4,025.80		$	5,802.40		$	(5,720.4	)	$	5,455.30
	MALLINCKRODT PLC
	CONDENSED CONSOLIDATING BALANCE SHEET
	As of September 27, 2013
	(unaudited, in millions)
		Mallinckrodt plc			Mallinckrodt International Finance S.A.			Other Subsidiaries			Eliminations			Consolidated
	Assets
	Current Assets:
	Cash and cash equivalents	$	1.2		$	56.5		$	217.8		$	—		$	275.5
	Accounts receivable, net	—			—			400.8			—			400.8
	Inventories	—			—			403.1			—			403.1
	Deferred income taxes	—			—			171.1			—			171.1
	Prepaid expenses and other current assets	1			—			133.4			—			134.4
	Intercompany receivable	2.7			—			12.2			(14.9		)	—
	Total current assets	4.9			56.5			1,338.40			(14.9		)	1,384.90
	Property, plant and equipment, net	—			—			997.4			—			997.4
	Goodwill	—			—			532			—			532
	Intangible assets, net	—			—			422.1			—			422.1
	Investment in subsidiaries	1,266.10			2,520.40			—			(3,786.5		)	—
	Intercompany loan receivable	—			2.4			409.6			(412.0		)	—
	Other assets	—			11.2			209			—			220.2
	Total Assets	$	1,271.00		$	2,590.50		$	3,908.50		$	(4,213.4	)	$	3,556.60
	Liabilities and Shareholders' Equity
	Current Liabilities:
Current maturities of long-term debt	$	—		$	—		$	1.5		$	—		$	1.5
Accounts payable	0.1			—			120.8			—			120.9
Accrued payroll and payroll-related costs	0.1			—			66.4			—			66.5
Accrued branded rebates	—			—			34.6			—			34.6
Accrued and other current liabilities	0.6			18.3			357.8			—			376.7
Intercompany payable	12.2			—			2.7			(14.9		)	—
Total current liabilities	13			18.3			583.8			(14.9		)	600.2
Long-term debt	—			898.1			20.2			—			918.3
Pension and postretirement benefits	—			—			108			—			108
Environmental liabilities	—			—			39.5			—			39.5
Deferred income taxes	—			—			310.1			—			310.1
Other income tax liabilities	—			—			153.1			—			153.1
Intercompany loans payable	2.4			409.6			—			(412.0		)	—
Other liabilities	—			—			171.8			—			171.8
Total liabilities	15.4			1,326.00			1,386.50			(426.9		)	2,301.00
Shareholders' equity	1,255.60			1,264.50			2,522.00			(3,786.5		)	1,255.60
Total Liabilities and Shareholders' Equity	$	1,271.00		$	2,590.50		$	3,908.50		$	(4,213.4	)	$	3,556.60
Schedule of Condensed Consolidating and Combining Statements of Comprehensive Income	'
	MALLINCKRODT PLC
	CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME
	For the three months ended March 28, 2014
	(unaudited, in millions)
		Mallinckrodt plc			Mallinckrodt International Finance S.A.			Other Subsidiaries			Eliminations			Consolidated
	Net sales	$	—		$	—		$	557.8		$	—		$	557.8
	Cost of sales	—			—			295.2			—			295.2
	Gross profit	—			—			262.6			—			262.6
	Selling, general and administrative expenses	7.9			0.1			186.1			—			194.1
	Research and development expenses	—			—			41.4			—			41.4
	Separation costs	0.6			—			2			—			2.6
	Restructuring charges, net	—			—			21.7			—			21.7
	Gains on divestiture and license	—			—			(0.9		)	—			(0.9		)
	Operating (loss) income	(8.5		)	(0.1		)	12.3			—			3.7
	Interest expense	—			(12.8		)	0.4			—			(12.4		)
	Interest income	—			—			0.5			—			0.5
	Other income (expense), net	22.3			—			(22.7		)	—			(0.4		)
	Intercompany interest and fees	(0.9		)	—			0.9			—			—
	Equity in net income of subsidiaries	(1.1		)	11.7			—			(10.6		)	—
	Income (loss) from continuing operations before income taxes	11.8			(1.2		)	(8.6		)	(10.6		)	(8.6		)
	Income tax expense (benefit)	0.2			(0.1		)	(20.4		)	—			(20.3		)
	Income (loss) from continuing operations	11.6			(1.1		)	11.8			(10.6		)	11.7
	Loss from discontinued operations, net of income taxes	—			—			(0.1		)	—			(0.1		)
	Net income (loss)	11.6			(1.1		)	11.7			(10.6		)	11.6
	Other comprehensive loss, net of tax	(2.3		)	(2.3		)	(2.4		)	4.7			(2.3		)
	Comprehensive income (loss)	$	9.3		$	(3.4	)	$	9.3		$	(5.9	)	$	9.3
	MALLINCKRODT PLC
	CONDENSED COMBINING STATEMENT OF COMPREHENSIVE INCOME
	For the three months ended March 29, 2013
	(unaudited, in millions)
		Mallinckrodt plc			Mallinckrodt International Finance S.A.			Other Subsidiaries			Eliminations			Combined
	Net sales	$	—		$	—		$	585.3		$	—		$	585.3
	Cost of sales	—			—			311.8			—			311.8
	Gross profit	—			—			273.5			—			273.5
	Selling, general and administrative expenses	—			—			160.7			—			160.7
	Research and development expenses	—			—			39.2			—			39.2
	Separation costs	—			—			14.4			—			14.4
	Restructuring charges, net	—			—			6.4			—			6.4
	Gains on divestiture and license	—			—			(0.7		)	—			(0.7		)
	Operating income	—			—			53.5			—			53.5
	Interest expense	—			—			(0.1		)	—			(0.1		)
	Interest income	—			—			0.1			—			0.1
	Other income (expense), net	—			—			—			—			—
	Intercompany interest and fees	—			—			—			—			—
	Equity in net income of subsidiaries	34			34			—			(68.0		)	—
	Income from continuing operations before income taxes	34			34			53.5			(68.0		)	53.5
	Income tax expense	—			—			19			—			19
	Income from continuing operations	34			34			34.5			(68.0		)	34.5
	Loss from discontinued operations, net of income taxes	—			—			(0.5		)	—			(0.5		)
	Net income	34			34			34			(68.0		)	34
	Other comprehensive loss, net of tax	(14.5		)	(14.5		)	(10.5		)	25			(14.5		)
	Comprehensive income	$	19.5		$	19.5		$	23.5		$	(43.0	)	$	19.5
	MALLINCKRODT PLC
	CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME
	For the six months ended March 28, 2014
	(unaudited, in millions)
		Mallinckrodt plc			Mallinckrodt International Finance S.A.			Other Subsidiaries			Eliminations			Consolidated
	Net sales	$	—		$	—		$	1,098.00		$	—		$	1,098.00
	Cost of sales	—			—			579.8			—			579.8
	Gross profit	—			—			518.2			—			518.2
	Selling, general and administrative expenses	11.9			0.2			328.2			—			340.3
	Research and development expenses	—			—			80.4			—			80.4
	Separation costs	1.4			—			3.4			—			4.8
Restructuring charges, net	—			—			29.7			—			29.7
Gains on divestiture and license	—			—			(13.8		)	—			(13.8		)
Operating (loss) income	(13.3		)	(0.2		)	90.3			—			76.8
Interest expense	—			(23.3		)	1.1			—			(22.2		)
Interest income	—			—			0.8			—			0.8
Other income (expense), net	23			—			(24.0		)	—			(1.0		)
Intercompany interest and fees	(4.0		)	—			4			—			—
Equity in net income of subsidiaries	51.5			74.9			—			(126.4		)	—
Income from continuing operations before income taxes	57.2			51.4			72.2			(126.4		)	54.4
Income tax (benefit) expense	—			(0.1		)	(3.6		)	—			(3.7		)
Income from continuing operations	57.2			51.5			75.8			(126.4		)	58.1
Loss from discontinued operations, net of income taxes	—			—			(0.9		)	—			(0.9		)
Net income	57.2			51.5			74.9			(126.4		)	57.2
Other comprehensive loss, net of tax	(2.1		)	(2.1		)	(2.3		)	4.4			(2.1		)
Comprehensive income	$	55.1		$	49.4		$	72.6		$	(122.0	)	$	55.1
MALLINCKRODT PLC
CONDENSED COMBINING STATEMENT OF COMPREHENSIVE INCOME
For the six months ended March 29, 2013
(unaudited, in millions)
	Mallinckrodt plc			Mallinckrodt International Finance S.A.			Other Subsidiaries			Eliminations			Combined
Net sales	$	—		$	—		$	1,089.30		$	—		$	1,089.30
Cost of sales	—			—			582.3			—			582.3
Gross profit	—			—			507			—			507
Selling, general and administrative expenses	—			—			307.5			—			307.5
Research and development expenses	—			—			77.6			—			77.6
Separation costs	—			—			26.4			—			26.4
Restructuring charges, net	—			—			6.6			—			6.6
Gains on divestiture and license	—			—			(1.4		)	—			(1.4		)
Operating income	—			—			90.3			—			90.3
Interest expense	—			—			(0.2		)	—			(0.2		)
Interest income	—			—			0.1			—			0.1
Other income (expense), net	—			—			0.2			—			0.2
Intercompany interest and fees	—			—			—			—			—
Equity in net income of subsidiaries	53.2			53.2			—			(106.4		)	—
Income from continuing operations before income taxes	53.2			53.2			90.4			(106.4		)	90.4
Income tax expense	—			—			36.1			—			36.1
Income from continuing operations	53.2			53.2			54.3			(106.4		)	54.3
Loss from discontinued operations, net of income taxes	—			—			(1.1		)	—			(1.1		)
Net income	53.2			53.2			53.2			(106.4		)	53.2
Other comprehensive loss, net of tax	(13.9		)	(13.9		)	(9.9		)	23.8			(13.9		)
Comprehensive income	$	39.3		$	39.3		$	43.3		$	(82.6	)	$	39.3
Schedule of Condensed Consolidating and Combining Statements of Cash Flows	'
	MALLINCKRODT PLC
	CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS
	For the six months ended March 28, 2014
	(unaudited, in millions)
		Mallinckrodt plc			Mallinckrodt International Finance S.A.			Other Subsidiaries			Eliminations			Consolidated
	Cash Flows From Operating Activities:
	Net cash (used in) provided by operating activities	$	8.6		$	(17.1	)	$	149.7		$	—		$	141.2
	Cash Flows From Investing Activities:
	Capital expenditures	—			—			(50.7		)	—			(50.7		)
	Acquisitions and intangibles, net of cash acquired	—			—			(1,293.2		)	—			(1,293.2		)
	Intercompany loan investment	(21.5		)	—			(58.8		)	80.3			—
	Repayment of intercompany loan investment	—			2.4			—			(2.4		)	—
	Investment in subsidiary	—			(1,300.0		)	—			1,300.00			—
	Restricted cash	—			—			4.1			—			4.1
	Other	—			—			8			—			8
	Net cash (used in) investing activities	(21.5		)	(1,297.6		)	(1,390.6		)	1,377.90			(1,331.8		)
	Cash Flows From Financing Activities:
	Issuance of external debt	—			1,296.80			—			—			1,296.80
	Repayment of external debt	—			—			(30.1		)	—			(30.1		)
	Repayment of capital leases	—			—			(0.7		)	—			(0.7		)
	Debt financing costs	—			(32.2		)	—			—			(32.2		)
	Excess tax benefit from share-based compensation	—			—			4			—			4
	Proceeds from exercise of share options	16.1			—			—			—			16.1
	Purchase of treasury shares	(1.8		)	—			—			—			(1.8		)
	Advances from intercompany borrowings	—			80.3			—			(80.3		)	—
	Payment on intercompany borrowings	(2.4		)	—			—			2.4			—
	Capital contribution	—			—			1,300.00			(1,300.0		)	—
	Net cash provided by (used in) financing activities	11.9			1,344.90			1,273.20			(1,377.9		)	1,252.10
	Effect of currency rate changes on cash	—			—			(2.1		)	—			(2.1		)
	Net increase in cash and cash equivalents	(1.0		)	30.2			30.2			—			59.4
	Cash and cash equivalents at beginning of period	1.2			56.5			217.8			—			275.5
	Cash and cash equivalents at end of period	$	0.2		$	86.7		$	248		$	—		$	334.9
	MALLINCKRODT PLC
	CONDENSED COMBINING STATEMENT OF CASH FLOWS
	For the six months ended March 29, 2013
	(unaudited, in millions)
		Mallinckrodt plc			Mallinckrodt International Finance S.A.			Other Subsidiaries			Eliminations			Combined
	Cash Flows From Operating Activities:
	Net cash (used in) provided by operating activities	$	—		$	(4.8	)	$	(3.0	)	$	—		$	(7.8	)
	Cash Flows From Investing Activities:
	Capital expenditures	—			—			(76.7		)	—			(76.7		)
	Acquisition, net of cash acquired	—			—			(88.1		)	—			(88.1		)
	Restricted cash	—			—			0.9			—			0.9
	Other	—			—			(1.1		)	—			(1.1		)
	Net cash (used in) investing activities	—			—			(165.0		)	—			(165.0		)
	Cash Flows From Financing Activities:
	Repayment of capital leases	—			—			(0.7		)	—			(0.7		)
	Debt financing costs	—			—			(2.3		)	—			(2.3		)
	Excess tax benefit from share-based compensation	—			—			3			—			3
	Net transfers from (to) parent	—			4.8			168			—			172.8
	Net cash provided by (used in) financing activities	—			4.8			168			—			172.8
	Effect of currency rate changes on cash	—			—			—			—			—
	Net increase in cash and cash equivalents	—			—			—			—			—
	Cash and cash equivalents at beginning of period	—			—			—			—			—
	Cash and cash equivalents at end of period	$	—		$	—		$	—		$	—		$	—

Background_and_Basis_of_Presen1

Background and Basis of Presentation (Details) (USD $)	Mar. 28, 2014	Mar. 29, 2013	Mar. 29, 2013
In Millions, unless otherwise specified	Country	Covidien	Covidien
		Selling, general and administrative	Selling, general and administrative
Schedule of Basis of Presenation [Line Items]	'	'	'
Number of countries in which entity has a commercial presence	65	'	'
Allocated expenses	'	$13.60	$25.50

License_of_Intellectual_Proper1

License of Intellectual Property (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Mar. 28, 2014	Mar. 29, 2013	Mar. 28, 2014	Mar. 29, 2013
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'	'	'	'
Gains on divestiture and license	$0.90	$0.70	$13.80	$1.40
Oxymorphone ER	'	'	'	'
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'	'	'	'
Upfront cash received	'	'	4	'
Contractually obligated future cash receipts	'	'	8	'
Gains on divestiture and license	'	'	$11.70	'

Acquisitions_Narrative_Details

Acquisitions (Narrative) (Details) (USD $)

3 Months Ended

6 Months Ended

0 Months Ended

3 Months Ended

6 Months Ended

0 Months Ended

3 Months Ended

6 Months Ended

0 Months Ended

Mar. 28, 2014

Mar. 29, 2013

Mar. 28, 2014

Mar. 29, 2013

Oct. 01, 2012

Mar. 19, 2014

Mar. 28, 2014

Mar. 28, 2014

Oct. 01, 2012

Mar. 28, 2014

Mar. 29, 2013

Mar. 28, 2014

Mar. 29, 2013

Mar. 28, 2014

Mar. 28, 2014

Mar. 19, 2014

Mar. 19, 2014

CNS Therapeutics, Inc.

Specialty Pharmaceuticals

Specialty Pharmaceuticals

Specialty Pharmaceuticals

Specialty Pharmaceuticals

Specialty Pharmaceuticals

Specialty Pharmaceuticals

Specialty Pharmaceuticals

Specialty Pharmaceuticals

Licensing Agreements

Secured Debt

Secured Debt

Completed Technology

Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals, Inc.

CNS Therapeutics, Inc.

CNS Therapeutics, Inc.

CNS Therapeutics, Inc.

CNS Therapeutics, Inc.

CNS Therapeutics, Inc.

Ofirmev

Term Loan

Term Loan

Ofirmev

Specialty Pharmaceuticals

Specialty Pharmaceuticals

Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals, Inc.

Business Acquisition [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash paid per Cadence share

'

'

'

'

'

$14

'

'

'

'

'

'

'

'

'

'

'

Total consideration

'

'

'

'

'

1,300,000,000

'

'

95,000,000

'

'

'

'

'

'

'

'

Acquisition funding, term loan, face amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,300,000,000

'

Discount rate used, completed technology

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

13.00%

Net sales

557,800,000

585,300,000

1,098,000,000

1,089,300,000

'

'

5,300,000

5,300,000

'

7,800,000

6,800,000

15,400,000

13,300,000

'

'

'

'

(Loss) income from continuing operations before income taxes

-8,600,000

53,500,000

54,400,000

90,400,000

'

'

-9,000,000

-9,000,000

'

'

'

'

'

'

'

'

'

Acquisition costs

'

'

'

'

'

17,600,000

'

'

'

'

'

'

'

'

'

'

'

Interest rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3.50%

'

'

Cash payment, net of cash acquired

'

'

1,293,200,000

88,100,000

'

'

'

'

88,100,000

'

'

'

'

'

'

'

'

Cash and cash equivalents

'

'

'

'

'

43,200,000

'

'

3,600,000

'

'

'

'

'

'

'

'

Contingent consideration

'

'

'

'

6,900,000

'

'

'

6,900,000

'

'

'

'

'

'

'

'

Contingent consideration, potential maximum

'

'

'

'

9,000,000

'

'

'

9,000,000

'

'

'

'

'

'

'

'

Future milestone payments

'

'

'

'

'

'

'

'

'

'

'

'

'

$25,000,000

'

'

'

Acquisitions_Schedule_of_Fair_

Acquisitions (Schedule of Fair Value of Identifiable Assets Acquired and Liabilities Assumed) (Details) (USD $)	Mar. 28, 2014	Sep. 27, 2013	Mar. 28, 2014	Sep. 27, 2013	Mar. 19, 2014
In Millions, unless otherwise specified			Specialty Pharmaceuticals	Specialty Pharmaceuticals	Specialty Pharmaceuticals
					Cadence Pharmaceuticals, Inc.
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest [Abstract]	'	'	'	'	'
Cash and cash equivalents	'	'	'	'	$43.20
Inventory	'	'	'	'	21
Intangible assets	'	'	'	'	1,300
Goodwill	853.9	532	634.2	312.3	321.9
Other assets, current and non-current	'	'	'	'	18	[1]
Deferred tax liabilities, net	'	'	'	'	-296.6
Other liabilities, current and non-current	'	'	'	'	-78.3	[2]
Net assets acquired	'	'	'	'	1,329.20
Acquired accounts receivable	'	'	'	'	14.7
Acquired debt	'	'	'	'	$30
[1]	This amount includes $14.7 million of accounts receivable, which is also the gross contractual value.
[2]	This amount includes $30.0 million of pre-existing Cadence debt, which the Company repaid upon completion of the acquisition.

Acquisitions_Schedule_of_Intan

Acquisitions (Schedule of Intangible Assets Acquired) (Details) (Ofirmev, Specialty Pharmaceuticals, Cadence Pharmaceuticals, Inc., Completed Technology, USD $)	0 Months Ended
In Millions, unless otherwise specified	Mar. 19, 2014
Ofirmev | Specialty Pharmaceuticals | Cadence Pharmaceuticals, Inc. | Completed Technology	'
Intangible Assets Acquired as Part of Business Combination [Line Items]	'
Completed technology	$1,300
Intangible assets acquired, amortization period	'8 years

Acquisitions_Schedule_of_Unaud

Acquisitions (Schedule of Unaudited Pro Forma Information) (Details) (Cadence Pharmaceuticals, Inc., Specialty Pharmaceuticals, USD $)	3 Months Ended		6 Months Ended
In Millions, except Per Share data, unless otherwise specified	Mar. 28, 2014	Mar. 29, 2013	Mar. 28, 2014	Mar. 29, 2013
Cadence Pharmaceuticals, Inc. | Specialty Pharmaceuticals	'	'	'	'
Business Acquisition, Pro Forma Information [Line Items]	'	'	'	'
Net sales, pro forma	$588.20	$608.90	$1,163.70	$1,130.10
Net (loss) income, pro forma	($18.40)	$4.40	($2.60)	($35.70)
Basic (loss) earnings per share, pro forma (in usd per share)	($0.32)	$0.08	($0.04)	($0.62)
Diluted (loss) earnings per share, pro forma (in usd per share)	($0.31)	$0.08	($0.04)	($0.62)

Restructuring_and_Related_Char2

Restructuring and Related Charges (Narrative) (Details) (2013 Mallinckrodt program, USD $)	6 Months Ended
In Millions, unless otherwise specified	Mar. 28, 2014
Minimum	'
Restructuring Cost and Reserve [Line Items]	'
2013 Mallinckrodt program expected cost range	$100
Maximum	'
Restructuring Cost and Reserve [Line Items]	'
2013 Mallinckrodt program expected cost range	$125

Restructuring_and_Related_Char3

Restructuring and Related Charges (Schedule of Restructuring and Related Charges by Segment) (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Mar. 28, 2014	Mar. 29, 2013	Mar. 28, 2014	Mar. 29, 2013
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Total restructuring and related charges	$21.70	$6.90	$29.80	$7.90
Less: accelerated depreciation	0	-0.5	-0.1	-1.3
Restructuring charges, net	21.7	6.4	29.7	6.6
Specialty Pharmaceuticals	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Total restructuring and related charges	2.7	5.9	2.7	6.6
Global Medical Imaging	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Total restructuring and related charges	18.5	1	26.6	1.3
Corporate	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Total restructuring and related charges	$0.50	$0	$0.50	$0

Restructuring_and_Related_Char4

Restructuring and Related Charges (Schedule of Net Restructuring and Related Charges) (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Mar. 28, 2014	Mar. 29, 2013	Mar. 28, 2014	Mar. 29, 2013
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Total restructuring and related charges	$21.70	$6.90	$29.80	$7.90
Less: non-cash charges, including accelerated depreciation	-2.6	-0.5	-2.7	-1.4
Total charges expected to be settled in cash	19.1	6.4	27.1	6.5
2013 Mallinckrodt program	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Total restructuring and related charges	22.6	0	30.9	0
Other programs	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Total restructuring and related charges	($0.90)	$6.90	($1.10)	$7.90

Restructuring_and_Related_Char5

Restructuring and Related Charges (Schedule of Restructuring Reserves by Type of Cost) (Details) (USD $)	6 Months Ended
In Millions, unless otherwise specified	Mar. 28, 2014
Restructuring Reserve [Roll Forward]	'
Beginning Balance	$25.50
Charges	30.8
Changes in estimate	-3.7
Cash payments	-16.2
Currency translation and other	-0.2
Ending Balance	36.2
2013 Mallinckrodt program	'
Restructuring Reserve [Roll Forward]	'
Beginning Balance	14.9
Charges	30
Changes in estimate	-1.7
Cash payments	-10.9
Currency translation and other	-0.3
Ending Balance	32
Other programs	'
Restructuring Reserve [Roll Forward]	'
Beginning Balance	10.6
Charges	0.8
Changes in estimate	-2
Cash payments	-5.3
Currency translation and other	0.1
Ending Balance	4.2
Consulting Costs	'
Restructuring Reserve [Roll Forward]	'
Ending Balance	$8.40

Restructuring_and_Related_Char6

Restructuring and Related Charges (Schedule of Restructuring Charges Incurred Cumulative to Date) (Details) (2013 Mallinckrodt program, USD $)	18 Months Ended
In Millions, unless otherwise specified	Mar. 28, 2014
Restructuring Cost and Reserve [Line Items]	'
Restructuring costs incurred cumulative to date	$45.80
Specialty Pharmaceuticals	'
Restructuring Cost and Reserve [Line Items]	'
Restructuring costs incurred cumulative to date	5.2
Global Medical Imaging	'
Restructuring Cost and Reserve [Line Items]	'
Restructuring costs incurred cumulative to date	36.3
Corporate	'
Restructuring Cost and Reserve [Line Items]	'
Restructuring costs incurred cumulative to date	$4.30

Income_Taxes_Details

Income Taxes (Details) (USD $)

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

In Millions, unless otherwise specified

Mar. 28, 2014

Mar. 29, 2013

Mar. 28, 2014

Mar. 29, 2013

Sep. 27, 2013

Mar. 28, 2014

Mar. 29, 2013

Mar. 28, 2014

Mar. 29, 2013

Mar. 28, 2014

Mar. 28, 2014

Mar. 19, 2014

Mar. 19, 2014

Separation Costs

Separation Costs

Separation Costs

Separation Costs

Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals, Inc.

Completed Technology

Ofirmev

Cadence Pharmaceuticals, Inc.

Income Taxes [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

Provision for income taxes

($20.30)

$19

($3.70)

$36.10

'

'

'

'

'

'

'

'

'

(Loss) income from continuing operations before income taxes

-8.6

53.5

54.4

90.4

'

'

'

'

'

'

'

'

'

Tax benefit on special items

'

'

'

'

'

0.4

1

1.1

1.3

20.7

20.7

'

'

Separation costs

2.6

14.4

4.8

26.4

'

'

'

'

'

'

'

'

'

Deferred tax liability, net increase due to acquisition

'

'

'

'

'

'

'

'

'

'

'

296.6

'

Deferred tax liabilities, acquired intangible asset

'

'

'

'

'

'

'

'

'

'

'

'

499.6

Deferred tax assets, acquired NOLs

'

'

'

'

'

'

'

'

'

'

'

196.2

'

Deferred tax asset, acquired federal and state tax credits

'

'

'

'

'

'

'

'

'

'

'

5.8

'

Deferred tax assets, acquired valuation allowance

'

'

'

'

'

'

'

'

'

'

'

7.3

'

Unrecognized tax benefits

105

'

105

'

100.1

'

'

'

'

'

'

'

'

Unrecognized tax benefits, net increase

'

'

4.9

'

'

'

'

'

'

'

'

'

'

Unrecognized tax benefits, additions related to prior period tax positions

'

'

11.5

'

'

'

'

'

'

'

'

'

'

Unrecognized tax benefits, additions related to current year tax positions

'

'

1.4

'

'

'

'

'

'

'

'

'

'

Unrecognized tax benefits, decrease related to settlements

'

'

0.2

'

'

'

'

'

'

'

'

'

'

Unrecognized tax benefits, lapse of statute of limitations

'

'

7.8

'

'

'

'

'

'

'

'

'

'

Unrecognized tax benefits, which if favorably settled would benefit the effective tax rate

101.2

'

101.2

'

'

'

'

'

'

'

'

'

'

Interest accrued on unrecognized tax benefits

56.1

'

56.1

'

62.1

'

'

'

'

'

'

'

'

Unrecognized tax benefits that would impact effective tax rate, upper bound of change

44.9

'

44.9

'

'

'

'

'

'

'

'

'

'

Income tax penalties and interest accrued that would impact effective tax rate, upper bound of change

$26.40

'

$26.40

'

'

'

'

'

'

'

'

'

'

Earnings_Loss_per_Share_Detail

Earnings (Loss) per Share (Details)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Mar. 28, 2014	Mar. 29, 2013	Mar. 28, 2014	Mar. 29, 2013
Earnings (Loss) per Share [Abstract]	'	'	'	'
Distribution ratio	0.125	'	0.125	'
Weighted-average shares for basic earnings (loss) per share (in shares)	58.2	57.7	58	57.7
Effect of share options and restricted shares (in shares)	0.9	0	0.7	0
Weighted-average shares for diluted earnings (loss) per share (in shares)	59.1	57.7	58.7	57.7

Inventories_Details

Inventories (Details) (USD $)	Mar. 28, 2014	Sep. 27, 2013
In Millions, unless otherwise specified
Inventory, Net [Abstract]	'	'
Raw materials and supplies	$85.70	$68.80
Work in process	194.9	191.5
Finished goods	164.1	142.8
Inventories	$444.70	$403.10

Property_Plant_and_Equipment_S

Property, Plant and Equipment (Schedule of Property, Plant and Equipment) (Details) (USD $)	Mar. 28, 2014	Sep. 27, 2013
In Millions, unless otherwise specified
Property, Plant and Equipment [Abstract]	'	'
Property, plant and equipment, gross	$1,918.30	$1,873.70
Less: accumulated depreciation	-920.8	-876.3
Property, plant and equipment, net	$997.50	$997.40

Property_Plant_and_Equipment_N

Property, Plant and Equipment (Narrative) (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Mar. 28, 2014	Mar. 29, 2013	Mar. 28, 2014	Mar. 29, 2013
Property, Plant and Equipment [Line Items]	'	'	'	'
Depreciation	$26.10	$24.40	$52.40	$49.20
Demonstration Equipment	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'
Depreciation	$0.90	$0.90	$2	$1.70

Goodwill_and_Intangible_Assets2

Goodwill and Intangible Assets (Schedule Of Goodwill) (Details) (USD $)	6 Months Ended
In Millions, unless otherwise specified	Mar. 28, 2014
Goodwill [Roll Forward]	'
Beginning balance	$532
Acquisitions	321.9
Ending balance	853.9
Specialty Pharmaceuticals	'
Goodwill [Roll Forward]	'
Beginning balance	312.3
Acquisitions	321.9
Ending balance	634.2
Global Medical Imaging	'
Goodwill [Roll Forward]	'
Beginning balance	219.7
Acquisitions	0
Ending balance	$219.70

Goodwill_and_Intangible_Assets3

Goodwill and Intangible Assets (Schedule Of Intangible Assets) (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Mar. 28, 2014	Mar. 29, 2013	Mar. 28, 2014	Mar. 29, 2013	Sep. 27, 2013
Schedule of Intangible Asset by Major Class [Line Items]	'	'	'	'	'
Finite-lived intangible assets, gross	$1,965.40	'	$1,965.40	'	$648.20
Accumulated amortization	304	'	304	'	279.7
Indefinitie-lived intangible assets, gross	53.6	'	53.6	'	53.6
Intangible asset amortization	15.5	8.8	24.3	17.7	'
Trademarks	'	'	'	'	'
Schedule of Intangible Asset by Major Class [Line Items]	'	'	'	'	'
Indefinitie-lived intangible assets, gross	35	'	35	'	35
In-process Research and Development	'	'	'	'	'
Schedule of Intangible Asset by Major Class [Line Items]	'	'	'	'	'
Indefinitie-lived intangible assets, gross	18.6	'	18.6	'	18.6
Completed Technology	'	'	'	'	'
Schedule of Intangible Asset by Major Class [Line Items]	'	'	'	'	'
Finite-lived intangible assets, gross	1,749.20	'	1,749.20	'	449.2
Accumulated amortization	212.8	'	212.8	'	196.6
Licensing Agreements	'	'	'	'	'
Schedule of Intangible Asset by Major Class [Line Items]	'	'	'	'	'
Finite-lived intangible assets, gross	201.1	'	201.1	'	191.1
Accumulated amortization	85.5	'	85.5	'	79.3
Trademarks	'	'	'	'	'
Schedule of Intangible Asset by Major Class [Line Items]	'	'	'	'	'
Finite-lived intangible assets, gross	7.9	'	7.9	'	7.9
Accumulated amortization	3.9	'	3.9	'	3.8
Other	'	'	'	'	'
Schedule of Intangible Asset by Major Class [Line Items]	'	'	'	'	'
Finite-lived intangible assets, gross	7.2	'	7.2	'	0
Accumulated amortization	$1.80	'	$1.80	'	$0

Goodwill_and_Intangible_Assets4

Goodwill and Intangible Assets (Narrative) (Details) (USD $)	Mar. 28, 2014	Sep. 27, 2013
In Millions, unless otherwise specified
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-lived intangible assets, gross	$1,965.40	$648.20
Completed Technology	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-lived intangible assets, gross	1,749.20	449.2
Licensing Agreements	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-lived intangible assets, gross	201.1	191.1
Other Intangible Assets	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-lived intangible assets, gross	7.2	0
Ofirmev | Cadence Pharmaceuticals, Inc. | Completed Technology	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-lived intangible assets, gross	1,300	'
Xartemis XR | Licensing Agreements	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-lived intangible assets, gross	10	'
Exalgo | Other Intangible Assets	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-lived intangible assets, gross	$7.20	'

Goodwill_and_Intangible_Assets5

Goodwill and Intangible Assets (Schedule of Future Amortization Expense, Intangible Assets) (Details) (USD $)	Mar. 28, 2014
In Millions, unless otherwise specified
Goodwill and Intangible Assets Disclosure [Abstract]	'
Remainder of fiscal 2014	$103.10
Fiscal 2015	200.7
Fiscal 2016	198.8
Fiscal 2017	197.4
Fiscal 2018	$188.70

Debt_Schedule_of_Longterm_Debt

Debt (Schedule of Long-term Debt including Capital Lease Obligation) (Details) (USD $)	Mar. 28, 2014	Sep. 27, 2013
In Millions, unless otherwise specified
Current maturities of long-term debt:	'	'
Capital lease obligation	$1.40	$1.40
Total current debt	11.2	1.5
Long-term debt:	'	'
Capital lease obligation	1.1	1.8
Long-term debt	2,204.70	918.3
Total debt	2,215.90	919.8
Secured Debt | Term Loan	'	'
Current maturities of long-term debt:	'	'
Long term debt, current maturities	9.8	0
Long-term debt:	'	'
Long term debt, excluding current maturities	1,287	0
Senior Notes | 3.50% Senior Note	'	'
Long-term debt:	'	'
Long term debt, excluding current maturities	300	299.9
Senior Notes | 4.75% Senior Note	'	'
Long-term debt:	'	'
Long term debt, excluding current maturities	598.2	598.2
Debentures | 9.50% Debenture	'	'
Long-term debt:	'	'
Long term debt, excluding current maturities	10.4	10.4
Debentures | 8.00% Debenture	'	'
Long-term debt:	'	'
Long term debt, excluding current maturities	8	8
Loans Payable	'	'
Current maturities of long-term debt:	'	'
Loan payable	$0	$0.10

Debt_Narrative_Details

Debt (Narrative) (Details) (USD $)

6 Months Ended

1 Months Ended

6 Months Ended

Mar. 28, 2014

Mar. 28, 2014

Mar. 19, 2014

Mar. 31, 2013

Mar. 28, 2014

Mar. 19, 2014

Mar. 28, 2014

Apr. 30, 2013

Apr. 30, 2013

Mar. 19, 2014

Mar. 28, 2014

Mar. 19, 2014

Secured Debt

Secured Debt

Line of Credt

Line of Credt

Line of Credt

Senior Notes

Senior Notes

Senior Notes

LIBOR

Letter of Credit

Letter of Credit

Term Loan

Term Loan

3.50% Senior Note

4.75% Senior Note

Secured Debt

Line of Credt

Line of Credt

Term Loan

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Face amount

'

'

$1,300,000,000

'

'

'

'

$300,000,000

$600,000,000

'

'

'

Maximum borrowing capacity

'

'

'

250,000,000

'

250,000,000

'

'

'

'

'

150,000,000

Minimum LIBOR

'

'

'

'

'

'

'

'

'

0.75%

'

'

Quarterly principal amortization payments

'

'

0.25%

'

'

'

'

'

'

'

'

'

Original issue discount, percentage

'

'

0.25%

'

'

'

'

'

'

'

'

'

Original issue discount, amount

'

'

3,300,000

'

'

'

'

'

'

'

'

'

Letters of credit outstanding

'

'

'

'

'

'

'

'

'

'

0

'

Annual commitment fee

0.38%

'

'

'

'

'

'

'

'

'

'

'

Interest rate

'

3.50%

'

'

3.00%

'

'

'

'

'

'

'

Borrowings outstanding

'

'

'

'

0

'

'

'

'

'

'

'

Borrowings outstanding, term loan

'

$1,300,000,000

'

'

'

'

'

'

'

'

'

'

Term of debt instrument

'

'

'

'5 years

'

'

'10 years

'

'

'

'

'

Stated interest rate

'

'

'

'

'

'

'

3.50%

4.75%

'

'

'

Retirement_Plans_Schedule_of_N

Retirement Plans (Schedule of Net Periodic Benefit Cost) (Details) (Pension Benefits, USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Mar. 28, 2014	Mar. 29, 2013	Mar. 28, 2014	Mar. 29, 2013
Pension Benefits	'	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'	'
Service cost	$1.20	$1.20	$2.50	$2.40
Interest cost	5	4.5	9.9	9.1
Expected return on plan assets	-6.1	-7.3	-12.2	-14.7
Amortization of net actuarial loss	2.1	3	4.2	6
Amortization of prior service (credit) cost	-0.2	0.2	-0.3	0.3
Plan settlements	0.3	0	0.3	0
Net periodic benefit cost	$2.30	$1.60	$4.40	$3.10

Retirement_Plans_Narrative_Det

Retirement Plans (Narrative) (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Mar. 28, 2014	Mar. 29, 2013	Mar. 28, 2014	Mar. 29, 2013
Covidien	'	'	'	'
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]	'	'	'	'
Company contributions to pension plans	'	'	'	$37.50
Postretirement Benefits	'	'	'	'
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]	'	'	'	'
Net periodic benefit credit	$1.80	$1.50	$3.60	$3.10

Accumulated_Other_Comprehensiv2

Accumulated Other Comprehensive Income (Schedule of Accumulated Other Comprehensive Income) (Details) (USD $)	6 Months Ended
In Millions, unless otherwise specified	Mar. 28, 2014
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]	'
Beginning balance	$108.50
Other comprehensive loss before reclassifications	-2
Amounts reclassified from accumulated other comprehensive income	-0.1
Net current period other comprehensive (loss) income	-2.1
Ending balance	106.4
Currency Translation	'
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]	'
Beginning balance	158.6
Other comprehensive loss before reclassifications	-2
Amounts reclassified from accumulated other comprehensive income	0
Net current period other comprehensive (loss) income	-2
Ending balance	156.6
Unrecognized Gain (Loss) on Derivatives	'
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]	'
Beginning balance	-7.3
Other comprehensive loss before reclassifications	0
Amounts reclassified from accumulated other comprehensive income	0.2
Net current period other comprehensive (loss) income	0.2
Ending balance	-7.1
Unrecognized Gain (Loss) on Benefit Plans	'
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]	'
Beginning balance	-42.8
Other comprehensive loss before reclassifications	0
Amounts reclassified from accumulated other comprehensive income	-0.3
Net current period other comprehensive (loss) income	-0.3
Ending balance	($43.10)

Accumulated_Other_Comprehensiv3

Accumulated Other Comprehensive Income (Schedule of Reclassifications out of Accumulated Other Comprehensive Income) (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Mar. 28, 2014		Mar. 28, 2014
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]	'		'
Total reclassifications for the period	'		($0.10)
Reclassification out of Accumulated Other Comprehensive Income	'		'
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]	'		'
Amortization of unrealized gain on derivatives, tax	0		-0.1
Amortization of unrealized gain on derivatives, net of tax	0.1		0.2
Amortization of pension and post-retirement plans, net actuarial loss	2.1	[1]	4.2	[1]
Amortization of pension and post-retirement plans, prior service cost	-2.4	[1]	-4.9	[1]
Amortization of pension and post-retirement plans, plan settlements	0.3	[1]	0.3	[1]
Amortization of pension and post-retirement plans, before tax	0		-0.4
Amortization of pension and post-retirement plans, tax	0		0.1
Amortization of pension and post-retirement plans, net of tax	0		-0.3
Total reclassifications for the period	0.1		-0.1
Reclassification out of Accumulated Other Comprehensive Income | Interest Expense	'		'
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]	'		'
Amortization of unrealized gain on derivatives, before tax	$0.10		$0.30
[1]	These accumulated other comprehensive income components are included in the computation of net periodic benefit cost. See Note 12 for additional details.

Transactions_with_Former_Paren1

Transactions with Former Parent Company (Details) (Covidien, USD $)

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

In Millions, unless otherwise specified

Mar. 28, 2014

Mar. 29, 2013

Mar. 28, 2014

Mar. 29, 2013

Mar. 28, 2014

Mar. 29, 2013

Mar. 28, 2014

Mar. 29, 2013

Mar. 29, 2013

Mar. 29, 2013

Mar. 28, 2014

Sep. 27, 2013

Mar. 28, 2014

Sep. 27, 2013

Net sales

Net sales

Net sales

Net sales

Cost of sales

Cost of sales

Cost of sales

Cost of sales

Selling, general and administrative

Selling, general and administrative

Prepaid expenses and other current assets

Prepaid expenses and other current assets

Accrued and other liabilities

Accrued and other liabilities

Related Party Transaction [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Inventory sold

$11.10

$11.80

$23.20

$25.90

'

'

'

'

'

'

'

'

'

'

Inventory purchases

'

'

'

'

9.3

9.1

19.3

22

'

'

'

'

'

'

Allocated expenses

'

'

'

'

'

'

'

'

13.6

25.5

'

'

'

'

Due from related parties

'

'

'

'

'

'

'

'

'

'

64.5

62.2

'

'

Due to related parties

'

'

'

'

'

'

'

'

'

'

'

'

$74.30

$79.30

Guarantees_Details

Guarantees (Details) (USD $)	Mar. 28, 2014	Mar. 28, 2014	Mar. 28, 2014	Mar. 28, 2014	Mar. 28, 2014	Sep. 27, 2013	Mar. 28, 2014	Sep. 27, 2013	Mar. 28, 2014	Sep. 27, 2013
In Millions, unless otherwise specified	Others	Maryland Heights, Missouri	Saint Louis, Missouri	Mallinckrodt Baker	Mallinckrodt Baker	Mallinckrodt Baker	Mallinckrodt Baker	Mallinckrodt Baker	Mallinckrodt Baker	Mallinckrodt Baker
		Surety Bond	Letter of Credit	Indemnification Agreement	Indemnification Agreement	Indemnification Agreement	Indemnification Agreement	Indemnification Agreement	Environmental, Health and Safety Matters	Environmental, Health and Safety Matters
					Other Liabilities	Other Liabilities	Other Assets	Other Assets	Indemnification Agreement	Indemnification Agreement
									Other Liabilities	Other Liabilities
Guarantor Obligations [Line Items]	'	'	'	'	'	'	'	'	'	'
Guarantor obligations, obligation term	'	'	'	'17 years	'	'	'	'	'	'
Guarantors obligation	'	'	'	'	$16.80	$20.10	'	'	$13.90	$17.20
Maximum future payments	30.7	58	21.1	71.4	'	'	'	'	'	'
Escrow	'	'	'	$30	'	'	$19.40	$23.50	'	'

Commitments_and_Contingencies_

Commitments and Contingencies (Narrative) (Details) (USD $)	6 Months Ended
	Mar. 28, 2014
	Defendent
Loss Contingencies [Line Items]	'
Remedial cost range, minimum	$44,900,000
Remedial cost range, maximum	118,600,000
Environmental liabilities	68,000,000
Lower Passaic River, New Jersey	'
Loss Contingencies [Line Items]	'
Remedial cost range, minimum	365,000,000
Remedial cost range, maximum	3,200,000,000
Remedial cost, estimate	1,700,000,000
Environmental liabilities	23,100,000
Companies comprising the Lower Passaic Cooperating Parties Group (in defendants)	70
Asbestos Matters	'
Loss Contingencies [Line Items]	'
Asbestos related pending cases	11,750
Estimation of liability, historical term	'5 years
Estimation of liability, expected future term of claims	'7 years
Accrued and other current liabilities	'
Loss Contingencies [Line Items]	'
Environmental liabilities, current	4,300,000
Cadence Shareholder Litigation	'
Loss Contingencies [Line Items]	'
Number of cases	9
Questcor Shareholder Litigation	'
Loss Contingencies [Line Items]	'
Number of cases	8
Tax Matters Agreement | Covidien	'
Loss Contingencies [Line Items]	'
Tax agreement, tax threshold	200,000,000
Industrial Revenue Bonds	'
Loss Contingencies [Line Items]	'
Plant assets exchanged for IRBs	$27,400,000
United States	'
Loss Contingencies [Line Items]	'
Ofirmev patents	2
Canada	'
Loss Contingencies [Line Items]	'
Ofirmev patents	2

Commitments_and_Contingencies_1

Commitments and Contingencies (Schedule of Changes in Asset Retirement Obligations) (Details) (USD $)	6 Months Ended
In Millions, unless otherwise specified	Mar. 28, 2014
Asset Retirement Obligation, Roll Forward Analysis [Roll Forward]	'
Beginning balance	$50.60
Accretion expense	1.6
Currency translation	0.5
Ending balance	$52.70

Derivative_Instruments_Schedul

Derivative Instruments (Schedule of Net Gain (Loss) on Foreign Exchange Contracts) (Details) (Not Designated as Hedging Instrument, Foreign Exchange Forward and Option, USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Mar. 28, 2014	Mar. 29, 2013	Mar. 28, 2014	Mar. 29, 2013
Derivative Instruments, (Loss) Gain [Line Items]	'	'	'	'
Net gain (loss) on foreign exchange forward and option contracts not designated as hedging instruments	$1.60	($0.30)	$5.60	($0.10)
Cost of sales	'	'	'	'
Derivative Instruments, (Loss) Gain [Line Items]	'	'	'	'
Net gain (loss) on foreign exchange forward and option contracts not designated as hedging instruments	-0.2	-1.5	-0.4	-2.4
Selling, general and administrative	'	'	'	'
Derivative Instruments, (Loss) Gain [Line Items]	'	'	'	'
Net gain (loss) on foreign exchange forward and option contracts not designated as hedging instruments	0.3	1.2	0.3	2.3
Other (expense) income, net	'	'	'	'
Derivative Instruments, (Loss) Gain [Line Items]	'	'	'	'
Net gain (loss) on foreign exchange forward and option contracts not designated as hedging instruments	$1.50	$0	$5.70	$0

Derivative_Instruments_Schedul1

Derivative Instruments (Schedule of Fair Value of Foreign Exchange Contracts) (Details) (Foreign Exchange Forward and Option, Not Designated as Hedging Instrument, USD $)	Mar. 28, 2014	Sep. 27, 2013
In Millions, unless otherwise specified
Prepaid expenses and other current assets	'	'
Derivatives, Fair Value [Line Items]	'	'
Foreign exchange forward and option contracts, asset	$0.60	$0.90
Accrued and other current liabilities	'	'
Derivatives, Fair Value [Line Items]	'	'
Foreign exchange forward and option contracts, liability	$0.60	$1.40

Derivative_Instruments_Schedul2

Derivative Instruments (Schedule of Net Losses on Gas Commodity Swap Contracts) (Details) (Cash Flow Hedges, Designated as Hedging Instrument, Gas Commodity Swap Contract, USD $)	3 Months Ended	6 Months Ended
In Millions, unless otherwise specified	Mar. 29, 2013	Mar. 29, 2013
Derivative Instruments, Gain (Loss) [Line Items]	'	'
Net loss on commodity swap contracts	$0.40	$0.80
Cost of sales	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'
Net loss on commodity swap contracts	0.1	0.2
Selling, general and administrative	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'
Net loss on commodity swap contracts	$0.30	$0.60

Derivative_Instruments_Narrati

Derivative Instruments (Narrative) (Details) (USD $)	3 Months Ended	6 Months Ended
In Millions, unless otherwise specified	Mar. 28, 2014	Mar. 28, 2014	Mar. 29, 2013	Mar. 28, 2014	Mar. 28, 2014	Mar. 31, 2013
				Senior Notes	Designated as Hedging Instrument	Designated as Hedging Instrument
					Forward Interest Rate Lock Contract	Forward Interest Rate Lock Contract
					Cash Flow Hedges	Cash Flow Hedges
						contract
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'	'	'	'
Foreign currency loss	$4.30	$9.30	$0.50	'	'	'
Forward interest rate lock contracts, number	'	'	'	'	'	3
Forward interest rate lock contracts, notional amount	'	'	'	'	'	300
Term of debt instrument	'	'	'	'10 years	'	'
Losses resulting from terminated derivatives, recorded in AOCI	'	'	'	'	7.6	'
Loss included within AOCI related to terminated interest rate lock contracts	'	'	'	'	$7	'

Financial_Instruments_and_Fair2

Financial Instruments and Fair Value Measurements (Narrative) (Details) (USD $)

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

In Millions, unless otherwise specified

Mar. 28, 2014

Mar. 29, 2013

Mar. 28, 2014

Mar. 29, 2013

Mar. 28, 2014

Mar. 29, 2013

Mar. 28, 2014

Mar. 29, 2013

Mar. 28, 2014

Oct. 01, 2012

Mar. 28, 2014

Mar. 28, 2014

Apr. 30, 2013

Mar. 28, 2014

Apr. 30, 2013

Mar. 28, 2014

Mar. 28, 2014

Sep. 27, 2013

Mar. 28, 2014

Sep. 27, 2013

Spain and Italy

Spain and Italy

Spain and Italy

Spain and Italy

CNS Therapeutics, Inc.

CNS Therapeutics, Inc.

Debentures

Debentures

Senior Notes

Senior Notes

Senior Notes

Senior Notes

Other Assets

Other Assets

Other Assets

Other Assets

8.00% Debenture

9.50% Debenture

3.50% Senior Note

3.50% Senior Note

4.75% Senior Note

4.75% Senior Note

Carrying Value

Carrying Value

Carrying Value

Carrying Value

Level 2

Level 2

Level 1

Level 1

Level 1

Level 1

Level 3

Level 3

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of contingent consideration upon acquisition

'

'

'

'

'

'

'

'

'

$6.90

'

'

'

'

'

'

'

'

'

'

Maximum contingent payments for acquisition

'

'

'

'

'

'

'

'

'

9

'

'

'

'

'

'

'

'

'

'

Discount rate

'

'

'

'

'

'

'

'

1.00%

'

'

'

'

'

'

'

'

'

'

'

Restricted cash

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20.2

24

'

'

Cash surrender value of life insurance

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

68.7

67.7

Stated interest rate

'

'

'

'

'

'

'

'

'

'

8.00%

9.50%

3.50%

3.50%

4.75%

4.75%

'

'

'

'

Net sales

$557.80

$585.30

$1,098

$1,089.30

$12.40

$14.10

$24.70

$26.30

'

'

'

'

'

'

'

'

'

'

'

'

Financial_Instruments_and_Fair3

Financial Instruments and Fair Value Measurements (Schedule of Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details) (Recurring, USD $)	Mar. 28, 2014	Sep. 27, 2013
In Millions, unless otherwise specified
Total	'	'
Assets:	'	'
Debt and equity securities held in rabbi trusts	$35.10	$35.30
Foreign exchange forward and option contracts	0.6	0.9
Total assets at fair value	35.7	36.2
Liabilities:	'	'
Deferred compensation liabilities	13.7	13.5
Contingent consideration	7	6.9
Foreign exchange forward and option contracts	0.6	1.4
Total liabilities at fair value	21.3	21.8
Quoted Prices in Active Markets for Identical Assets (Level 1)	'	'
Assets:	'	'
Debt and equity securities held in rabbi trusts	22.9	22.6
Foreign exchange forward and option contracts	0.6	0.9
Total assets at fair value	23.5	23.5
Liabilities:	'	'
Deferred compensation liabilities	0	0
Contingent consideration	0	0
Foreign exchange forward and option contracts	0.6	1.4
Total liabilities at fair value	0.6	1.4
Significant Other Observable Inputs (Level 2)	'	'
Assets:	'	'
Debt and equity securities held in rabbi trusts	12.2	12.7
Foreign exchange forward and option contracts	0	0
Total assets at fair value	12.2	12.7
Liabilities:	'	'
Deferred compensation liabilities	13.7	13.5
Contingent consideration	0	0
Foreign exchange forward and option contracts	0	0
Total liabilities at fair value	13.7	13.5
Significant Unobservable Inputs (Level 3)	'	'
Assets:	'	'
Debt and equity securities held in rabbi trusts	0	0
Foreign exchange forward and option contracts	0	0
Total assets at fair value	0	0
Liabilities:	'	'
Deferred compensation liabilities	0	0
Contingent consideration	7	6.9
Foreign exchange forward and option contracts	0	0
Total liabilities at fair value	$7	$6.90

Financial_Instruments_and_Fair4

Financial Instruments and Fair Value Measurements (Schedule of Reconciliation of Changes in Fair Value of Contingent Consideration) (Details) (Recurring, Contingent Consideration, CNS Therapeutics, Inc., USD $)	6 Months Ended
In Millions, unless otherwise specified	Mar. 28, 2014
Recurring | Contingent Consideration | CNS Therapeutics, Inc.	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]	'
Beginning balance	$6.90
Accretion expense	0.1
Ending balance	$7

Financial_Instruments_and_Fair5

Financial Instruments and Fair Value Measurements (Schedule of Carrying Amount and Fair Value of Long-term Debt) (Details) (USD $)	Mar. 28, 2014	Sep. 27, 2013
In Millions, unless otherwise specified
Carrying Value	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Loans payable	$0	$0.10
Carrying Value | Secured Debt | Term Loan	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Long term debt	1,296.80	0
Carrying Value | Senior Notes | 3.50% Senior Note	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Long term debt	300	299.9
Carrying Value | Senior Notes | 4.75% Senior Note	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Long term debt	598.2	598.2
Carrying Value | Debentures | 9.50% Debenture	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Long term debt	10.4	10.4
Carrying Value | Debentures | 8.00% Debenture	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Long term debt	8	8
Fair Value	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Loans payable	0	0.1
Fair Value | Secured Debt | Term Loan	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Long term debt	1,301	0
Fair Value | Senior Notes | 3.50% Senior Note	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Long term debt	296	293.7
Fair Value | Senior Notes | 4.75% Senior Note	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Long term debt	571.6	568.5
Fair Value | Debentures | 9.50% Debenture	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Long term debt	14.2	14.3
Fair Value | Debentures | 8.00% Debenture	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Long term debt	$10.20	$10.20

Financial_Instruments_and_Fair6

Financial Instruments and Fair Value Measurements (Schedule of Accounts Receivable Concentration Risk) (Details) (USD $)	Mar. 28, 2014	Sep. 27, 2013
In Millions, unless otherwise specified
Spain	'	'
Segment Reporting Information [Line Items]	'	'
Accounts receivable	$9.80	$9.20
Italy	'	'
Segment Reporting Information [Line Items]	'	'
Accounts receivable	$10.70	$12.60

Financial_Instruments_and_Fair7

Financial Instruments and Fair Value Measurements (Schedules of Concentration of Risk) (Details)

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

Mar. 28, 2014

Mar. 29, 2013

Mar. 28, 2014

Mar. 29, 2013

Mar. 28, 2014

Mar. 29, 2013

Mar. 28, 2014

Mar. 29, 2013

Mar. 28, 2014

Mar. 29, 2013

Mar. 28, 2014

Mar. 29, 2013

Mar. 28, 2014

Sep. 27, 2013

Mar. 28, 2014

Sep. 27, 2013

Mar. 28, 2014

Sep. 27, 2013

Mar. 28, 2014

Mar. 29, 2013

Mar. 28, 2014

Mar. 29, 2013

Mar. 28, 2014

Mar. 29, 2013

Mar. 28, 2014

Mar. 29, 2013

Mar. 28, 2014

Mar. 29, 2013

Mar. 28, 2014

Mar. 29, 2013

Distributor Concentration Risk

Distributor Concentration Risk

Distributor Concentration Risk

Distributor Concentration Risk

Distributor Concentration Risk

Distributor Concentration Risk

Distributor Concentration Risk

Distributor Concentration Risk

Distributor Concentration Risk

Distributor Concentration Risk

Distributor Concentration Risk

Distributor Concentration Risk

Distributor Concentration Risk

Distributor Concentration Risk

Distributor Concentration Risk

Distributor Concentration Risk

Distributor Concentration Risk

Distributor Concentration Risk

Product Concentration Risk

Product Concentration Risk

Product Concentration Risk

Product Concentration Risk

Product Concentration Risk

Product Concentration Risk

Product Concentration Risk

Product Concentration Risk

Product Concentration Risk

Product Concentration Risk

Product Concentration Risk

Product Concentration Risk

Net Sales Attributable to Distributors

Net Sales Attributable to Distributors

Net Sales Attributable to Distributors

Net Sales Attributable to Distributors

Net Sales Attributable to Distributors

Net Sales Attributable to Distributors

Net Sales Attributable to Distributors

Net Sales Attributable to Distributors

Net Sales Attributable to Distributors

Net Sales Attributable to Distributors

Net Sales Attributable to Distributors

Net Sales Attributable to Distributors

Accounts Receivable Attributable to Distributors

Accounts Receivable Attributable to Distributors

Accounts Receivable Attributable to Distributors

Accounts Receivable Attributable to Distributors

Accounts Receivable Attributable to Distributors

Accounts Receivable Attributable to Distributors

Net Sales Attributable to Products

Net Sales Attributable to Products

Net Sales Attributable to Products

Net Sales Attributable to Products

Net Sales Attributable to Products

Net Sales Attributable to Products

Net Sales Attributable to Products

Net Sales Attributable to Products

Net Sales Attributable to Products

Net Sales Attributable to Products

Net Sales Attributable to Products

Net Sales Attributable to Products

Cardinal Health, Inc.

Cardinal Health, Inc.

Cardinal Health, Inc.

Cardinal Health, Inc.

McKesson Corporation

McKesson Corporation

McKesson Corporation

McKesson Corporation

Amerisource Bergen Corporation

Amerisource Bergen Corporation

Amerisource Bergen Corporation

Amerisource Bergen Corporation

Cardinal Health, Inc.

Cardinal Health, Inc.

McKesson Corporation

McKesson Corporation

Amerisource Bergen Corporation

Amerisource Bergen Corporation

Optiray (CMDS)

Optiray (CMDS)

Optiray (CMDS)

Optiray (CMDS)

Acetaminophen Products (API) [Member]

Acetaminophen Products (API) [Member]

Acetaminophen Products (API) [Member]

Acetaminophen Products (API) [Member]

Methylphenidate ER (Specialty Generics)

Methylphenidate ER (Specialty Generics)

Methylphenidate ER (Specialty Generics)

Methylphenidate ER (Specialty Generics)

Concentration Risk [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Concentration risk, percentage

15.00%

20.00%

18.00%

20.00%

15.00%

19.00%

15.00%

16.00%

10.00%

6.00%

11.00%

7.00%

20.00%

18.00%

23.00%

22.00%

13.00%

14.00%

13.00%

13.00%

13.00%

14.00%

9.00%

10.00%

8.00%

10.00%

8.00%

11.00%

9.00%

7.00%

Segment_Data_Schedule_of_Segme

Segment Data (Schedule of Segment Reporting Information by Business Segment) (Details) (USD $)	3 Months Ended				6 Months Ended
In Millions, unless otherwise specified	Mar. 28, 2014		Mar. 29, 2013		Mar. 28, 2014		Mar. 29, 2013
Net sales	$557.80		$585.30		$1,098		$1,089.30
Operating income	3.7		53.5		76.8		90.3
Intangible asset amortization	-15.5		-8.8		-24.3		-17.7
Restructuring and related charges, net	-21.7		-6.9		-29.8		-7.9
Separation costs	-2.6		-14.4		-4.8		-26.4
Restructuring related accelerated depreciation	0		-0.5		-0.1		-1.3
Specialty Pharmaceuticals	'		'		'		'
Restructuring and related charges, net	-2.7		-5.9		-2.7		-6.6
Global Medical Imaging	'		'		'		'
Restructuring and related charges, net	-18.5		-1		-26.6		-1.3
Operating Segments	'		'		'		'
Net sales	546.7	[1]	573.5	[1]	1,074.80	[1]	1,063.40	[1]
Operating income	116.2		123.9		233.6		208
Operating Segments | Specialty Pharmaceuticals	'		'		'		'
Net sales	324.3		344.4		633.8		604.6
Operating income	105.9		105		218.9		140
Operating Segments | Global Medical Imaging	'		'		'		'
Net sales	222.4		229.1		441		458.8
Operating income	10.3		18.9		14.7		68
Corporate, Non-Segment	'		'		'		'
Net sales	11.1	[2]	11.8	[2]	23.2	[2]	25.9	[2]
Corporate and allocated expenses	-72.7	[3]	-40.3	[3]	-97.9	[3]	-65.7	[3]
Intangible asset amortization	-15.5		-8.8		-24.3		-17.7
Restructuring and related charges, net	-21.7	[4]	-6.9	[4]	-29.8	[4]	-7.9	[4]
Separation costs	($2.60)		($14.40)		($4.80)		($26.40)
[1]	Amounts represent sales to external customers.
[2]	Represents products that were sold to Covidien, our former parent company, which is discussed in Note 14.
[3]	Includes administration expenses and certain compensation, environmental and other costs not charged to the Company's operating segments.
[4]	Includes restructuring-related accelerated depreciation of $0.5 million for the three months ended MarchB 29, 2013 and $0.1 million and $1.3 million million for the six months ended MarchB 28, 2014 and MarchB 29, 2013, respectively. Restructuring-related accelerated depreciation for the three months ended MarchB 28, 2014 was immaterial.

Condensed_Consolidating_and_Co2

Condensed Consolidating and Combining Financial Statements (Narrative) (Details)	Mar. 28, 2014	Nov. 30, 2012
	Mallinckrodt International Finance S.A.	Covidien
Condensed Consolidating Financial Statements	'	'
Percentage of ownership in MIFSA	100.00%	100.00%

Condensed_Consolidating_and_Co3

Condensed Consolidating and Combining Financial Statements (Schedule of Condensed Consolidating Balance Sheets) (Details) (USD $)	Mar. 28, 2014	Sep. 27, 2013	Mar. 29, 2013	Sep. 28, 2012
In Millions, unless otherwise specified
Current Assets:	'	'	'	'
Cash and cash equivalents	$334.90	$275.50	$0	$0
Accounts receivable, net	334.2	400.8	'	'
Inventories	444.7	403.1	'	'
Deferred income taxes	371.7	171.1	'	'
Prepaid expenses and other current assets	147.6	134.4	'	'
Intercompany receivable	0	0	'	'
Total current assets	1,633.10	1,384.90	'	'
Property, plant and equipment, net	997.5	997.4	'	'
Goodwill	853.9	532	'	'
Intangible assets, net	1,715	422.1	'	'
Investment in subsidiaries	0	0	'	'
Intercompany loan receivable	0	0	'	'
Other assets	255.8	220.2	'	'
Total Assets	5,455.30	3,556.60	'	'
Current Liabilities:	'	'	'	'
Current maturities of long-term debt	11.2	1.5	'	'
Accounts payable	119.9	120.9	'	'
Accrued payroll and payroll-related costs	58	66.5	'	'
Accrued branded rebates	33.6	34.6	'	'
Accrued and other current liabilities	403.1	376.7	'	'
Intercompany payable	0	0	'	'
Total current liabilities	625.8	600.2	'	'
Long-term debt	2,204.70	918.3	'	'
Pension and postretirement benefits	104	108	'	'
Environmental liabilities	63.7	39.5	'	'
Deferred income taxes	794.8	310.1	'	'
Other income tax liabilities	148.1	153.1	'	'
Intercompany loans payable	0	0	'	'
Other liabilities	175.8	171.8	'	'
Total liabilities	4,116.90	2,301	'	'
Shareholders' equity	1,338.40	1,255.60	'	'
Total Liabilities and Shareholders' Equity	5,455.30	3,556.60	'	'
Mallinckrodt plc	'	'	'	'
Current Assets:	'	'	'	'
Cash and cash equivalents	0.2	1.2	0	0
Accounts receivable, net	0	0	'	'
Inventories	0	0	'	'
Deferred income taxes	0	0	'	'
Prepaid expenses and other current assets	0.5	1	'	'
Intercompany receivable	5.9	2.7	'	'
Total current assets	6.6	4.9	'	'
Property, plant and equipment, net	0	0	'	'
Goodwill	0	0	'	'
Intangible assets, net	0	0	'	'
Investment in subsidiaries	1,319.40	1,266.10	'	'
Intercompany loan receivable	21.5	0	'	'
Other assets	0	0	'	'
Total Assets	1,347.50	1,271	'	'
Current Liabilities:	'	'	'	'
Current maturities of long-term debt	0	0	'	'
Accounts payable	1.6	0.1	'	'
Accrued payroll and payroll-related costs	0.1	0.1	'	'
Accrued branded rebates	0	0	'	'
Accrued and other current liabilities	1.1	0.6	'	'
Intercompany payable	6.3	12.2	'	'
Total current liabilities	9.1	13	'	'
Long-term debt	0	0	'	'
Pension and postretirement benefits	0	0	'	'
Environmental liabilities	0	0	'	'
Deferred income taxes	0	0	'	'
Other income tax liabilities	0	0	'	'
Intercompany loans payable	0	2.4	'	'
Other liabilities	0	0	'	'
Total liabilities	9.1	15.4	'	'
Shareholders' equity	1,338.40	1,255.60	'	'
Total Liabilities and Shareholders' Equity	1,347.50	1,271	'	'
Mallinckrodt International Finance S.A.	'	'	'	'
Current Assets:	'	'	'	'
Cash and cash equivalents	86.7	56.5	0	0
Accounts receivable, net	0	0	'	'
Inventories	0	0	'	'
Deferred income taxes	0	0	'	'
Prepaid expenses and other current assets	0.2	0	'	'
Intercompany receivable	0	0	'	'
Total current assets	86.9	56.5	'	'
Property, plant and equipment, net	0	0	'	'
Goodwill	0	0	'	'
Intangible assets, net	0	0	'	'
Investment in subsidiaries	3,896.90	2,520.40	'	'
Intercompany loan receivable	0	2.4	'	'
Other assets	42	11.2	'	'
Total Assets	4,025.80	2,590.50	'	'
Current Liabilities:	'	'	'	'
Current maturities of long-term debt	9.8	0	'	'
Accounts payable	0	0	'	'
Accrued payroll and payroll-related costs	0	0	'	'
Accrued branded rebates	0	0	'	'
Accrued and other current liabilities	21	18.3	'	'
Intercompany payable	2.1	0	'	'
Total current liabilities	32.9	18.3	'	'
Long-term debt	2,185.20	898.1	'	'
Pension and postretirement benefits	0	0	'	'
Environmental liabilities	0	0	'	'
Deferred income taxes	0	0	'	'
Other income tax liabilities	0	0	'	'
Intercompany loans payable	489.9	409.6	'	'
Other liabilities	0	0	'	'
Total liabilities	2,708	1,326	'	'
Shareholders' equity	1,317.80	1,264.50	'	'
Total Liabilities and Shareholders' Equity	4,025.80	2,590.50	'	'
Other Subsidiaries	'	'	'	'
Current Assets:	'	'	'	'
Cash and cash equivalents	248	217.8	0	0
Accounts receivable, net	334.2	400.8	'	'
Inventories	444.7	403.1	'	'
Deferred income taxes	371.7	171.1	'	'
Prepaid expenses and other current assets	146.9	133.4	'	'
Intercompany receivable	8.3	12.2	'	'
Total current assets	1,553.80	1,338.40	'	'
Property, plant and equipment, net	997.5	997.4	'	'
Goodwill	853.9	532	'	'
Intangible assets, net	1,715	422.1	'	'
Investment in subsidiaries	0	0	'	'
Intercompany loan receivable	468.4	409.6	'	'
Other assets	213.8	209	'	'
Total Assets	5,802.40	3,908.50	'	'
Current Liabilities:	'	'	'	'
Current maturities of long-term debt	1.4	1.5	'	'
Accounts payable	118.3	120.8	'	'
Accrued payroll and payroll-related costs	57.9	66.4	'	'
Accrued branded rebates	33.6	34.6	'	'
Accrued and other current liabilities	381	357.8	'	'
Intercompany payable	5.8	2.7	'	'
Total current liabilities	598	583.8	'	'
Long-term debt	19.5	20.2	'	'
Pension and postretirement benefits	104	108	'	'
Environmental liabilities	63.7	39.5	'	'
Deferred income taxes	794.8	310.1	'	'
Other income tax liabilities	148.1	153.1	'	'
Intercompany loans payable	0	0	'	'
Other liabilities	175.8	171.8	'	'
Total liabilities	1,903.90	1,386.50	'	'
Shareholders' equity	3,898.50	2,522	'	'
Total Liabilities and Shareholders' Equity	5,802.40	3,908.50	'	'
Eliminations	'	'	'	'
Current Assets:	'	'	'	'
Cash and cash equivalents	0	0	0	0
Accounts receivable, net	0	0	'	'
Inventories	0	0	'	'
Deferred income taxes	0	0	'	'
Prepaid expenses and other current assets	0	0	'	'
Intercompany receivable	-14.2	-14.9	'	'
Total current assets	-14.2	-14.9	'	'
Property, plant and equipment, net	0	0	'	'
Goodwill	0	0	'	'
Intangible assets, net	0	0	'	'
Investment in subsidiaries	-5,216.30	-3,786.50	'	'
Intercompany loan receivable	-489.9	-412	'	'
Other assets	0	0	'	'
Total Assets	-5,720.40	-4,213.40	'	'
Current Liabilities:	'	'	'	'
Current maturities of long-term debt	0	0	'	'
Accounts payable	0	0	'	'
Accrued payroll and payroll-related costs	0	0	'	'
Accrued branded rebates	0	0	'	'
Accrued and other current liabilities	0	0	'	'
Intercompany payable	-14.2	-14.9	'	'
Total current liabilities	-14.2	-14.9	'	'
Long-term debt	0	0	'	'
Pension and postretirement benefits	0	0	'	'
Environmental liabilities	0	0	'	'
Deferred income taxes	0	0	'	'
Other income tax liabilities	0	0	'	'
Intercompany loans payable	-489.9	-412	'	'
Other liabilities	0	0	'	'
Total liabilities	-504.1	-426.9	'	'
Shareholders' equity	-5,216.30	-3,786.50	'	'
Total Liabilities and Shareholders' Equity	($5,720.40)	($4,213.40)	'	'

Condensed_Consolidating_and_Co4

Condensed Consolidating and Combining Financial Statements (Schedule of Condensed Consolidating and Combining Statements of Comprehensive Income) (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Mar. 28, 2014	Mar. 29, 2013	Mar. 28, 2014	Mar. 29, 2013
Condensed Consolidating Financial Statements	'	'	'	'
Net sales	$557.80	$585.30	$1,098	$1,089.30
Cost of sales	295.2	311.8	579.8	582.3
Gross profit	262.6	273.5	518.2	507
Selling, general and administrative expenses	194.1	160.7	340.3	307.5
Research and development expenses	41.4	39.2	80.4	77.6
Separation costs	2.6	14.4	4.8	26.4
Restructuring charges, net	21.7	6.4	29.7	6.6
Gains on divestiture and license	-0.9	-0.7	-13.8	-1.4
Operating (loss) income	3.7	53.5	76.8	90.3
Interest expense	-12.4	-0.1	-22.2	-0.2
Interest income	0.5	0.1	0.8	0.1
Other income (expense), net	-0.4	0	-1	0.2
Intercompany interest and fees	0	0	0	0
Equity in net income of subsidiaries	0	0	0	0
Income (loss) from continuing operations before income taxes	-8.6	53.5	54.4	90.4
Income tax expense (benefit)	-20.3	19	-3.7	36.1
Income (loss) from continuing operations	11.7	34.5	58.1	54.3
Loss from discontinued operations, net of income taxes	-0.1	-0.5	-0.9	-1.1
Net income (loss)	11.6	34	57.2	53.2
Other comprehensive loss, net of tax	-2.3	-14.5	-2.1	-13.9
Comprehensive income (loss)	9.3	19.5	55.1	39.3
Mallinckrodt plc	'	'	'	'
Condensed Consolidating Financial Statements	'	'	'	'
Net sales	0	0	0	0
Cost of sales	0	0	0	0
Gross profit	0	0	0	0
Selling, general and administrative expenses	7.9	0	11.9	0
Research and development expenses	0	0	0	0
Separation costs	0.6	0	1.4	0
Restructuring charges, net	0	0	0	0
Gains on divestiture and license	0	0	0	0
Operating (loss) income	-8.5	0	-13.3	0
Interest expense	0	0	0	0
Interest income	0	0	0	0
Other income (expense), net	22.3	0	23	0
Intercompany interest and fees	-0.9	0	-4	0
Equity in net income of subsidiaries	-1.1	34	51.5	53.2
Income (loss) from continuing operations before income taxes	11.8	34	57.2	53.2
Income tax expense (benefit)	0.2	0	0	0
Income (loss) from continuing operations	11.6	34	57.2	53.2
Loss from discontinued operations, net of income taxes	0	0	0	0
Net income (loss)	11.6	34	57.2	53.2
Other comprehensive loss, net of tax	-2.3	-14.5	-2.1	-13.9
Comprehensive income (loss)	9.3	19.5	55.1	39.3
Mallinckrodt International Finance S.A.	'	'	'	'
Condensed Consolidating Financial Statements	'	'	'	'
Net sales	0	0	0	0
Cost of sales	0	0	0	0
Gross profit	0	0	0	0
Selling, general and administrative expenses	0.1	0	0.2	0
Research and development expenses	0	0	0	0
Separation costs	0	0	0	0
Restructuring charges, net	0	0	0	0
Gains on divestiture and license	0	0	0	0
Operating (loss) income	-0.1	0	-0.2	0
Interest expense	-12.8	0	-23.3	0
Interest income	0	0	0	0
Other income (expense), net	0	0	0	0
Intercompany interest and fees	0	0	0	0
Equity in net income of subsidiaries	11.7	34	74.9	53.2
Income (loss) from continuing operations before income taxes	-1.2	34	51.4	53.2
Income tax expense (benefit)	-0.1	0	-0.1	0
Income (loss) from continuing operations	-1.1	34	51.5	53.2
Loss from discontinued operations, net of income taxes	0	0	0	0
Net income (loss)	-1.1	34	51.5	53.2
Other comprehensive loss, net of tax	-2.3	-14.5	-2.1	-13.9
Comprehensive income (loss)	-3.4	19.5	49.4	39.3
Other Subsidiaries	'	'	'	'
Condensed Consolidating Financial Statements	'	'	'	'
Net sales	557.8	585.3	1,098	1,089.30
Cost of sales	295.2	311.8	579.8	582.3
Gross profit	262.6	273.5	518.2	507
Selling, general and administrative expenses	186.1	160.7	328.2	307.5
Research and development expenses	41.4	39.2	80.4	77.6
Separation costs	2	14.4	3.4	26.4
Restructuring charges, net	21.7	6.4	29.7	6.6
Gains on divestiture and license	-0.9	-0.7	-13.8	-1.4
Operating (loss) income	12.3	53.5	90.3	90.3
Interest expense	0.4	-0.1	1.1	-0.2
Interest income	0.5	0.1	0.8	0.1
Other income (expense), net	-22.7	0	-24	0.2
Intercompany interest and fees	0.9	0	4	0
Equity in net income of subsidiaries	0	0	0	0
Income (loss) from continuing operations before income taxes	-8.6	53.5	72.2	90.4
Income tax expense (benefit)	-20.4	19	-3.6	36.1
Income (loss) from continuing operations	11.8	34.5	75.8	54.3
Loss from discontinued operations, net of income taxes	-0.1	-0.5	-0.9	-1.1
Net income (loss)	11.7	34	74.9	53.2
Other comprehensive loss, net of tax	-2.4	-10.5	-2.3	-9.9
Comprehensive income (loss)	9.3	23.5	72.6	43.3
Eliminations	'	'	'	'
Condensed Consolidating Financial Statements	'	'	'	'
Net sales	0	0	0	0
Cost of sales	0	0	0	0
Gross profit	0	0	0	0
Selling, general and administrative expenses	0	0	0	0
Research and development expenses	0	0	0	0
Separation costs	0	0	0	0
Restructuring charges, net	0	0	0	0
Gains on divestiture and license	0	0	0	0
Operating (loss) income	0	0	0	0
Interest expense	0	0	0	0
Interest income	0	0	0	0
Other income (expense), net	0	0	0	0
Intercompany interest and fees	0	0	0	0
Equity in net income of subsidiaries	-10.6	-68	-126.4	-106.4
Income (loss) from continuing operations before income taxes	-10.6	-68	-126.4	-106.4
Income tax expense (benefit)	0	0	0	0
Income (loss) from continuing operations	-10.6	-68	-126.4	-106.4
Loss from discontinued operations, net of income taxes	0	0	0	0
Net income (loss)	-10.6	-68	-126.4	-106.4
Other comprehensive loss, net of tax	4.7	25	4.4	23.8
Comprehensive income (loss)	($5.90)	($43)	($122)	($82.60)

Condensed_Consolidating_and_Co5

Condensed Consolidating and Combining Financial Statements (Schedule of Condensed Consolidating and Combining Statements of Cash Flows) (Details) (USD $)	6 Months Ended
In Millions, unless otherwise specified	Mar. 28, 2014	Mar. 29, 2013
Cash Flows From Operating Activities:	'	'
Net cash (used in) provided by operating activities	$141.20	($7.80)
Cash Flows From Investing Activities:	'	'
Capital expenditures	-50.7	-76.7
Acquisitions and intangibles, net of cash acquired	-1,293.20	-88.1
Intercompany loan investment	0	'
Repayment of intercompany loan investment	0	'
Investment in subsidiary	0	'
Restricted cash	4.1	0.9
Other	8	-1.1
Net cash (used in) investing activities	-1,331.80	-165
Cash Flows From Financing Activities:	'	'
Issuance of external debt	1,296.80	0
Repayment of external debt	-30.1	0
Repayment of capital leases	-0.7	-0.7
Debt financing costs	-32.2	-2.3
Excess tax benefit from share-based compensation	4	3
Proceeds from exercise of share options	16.1	0
Purchase of treasury shares	1.8	0
Net transfers from (to) parent	0	172.8
Advances from intercompany borrowings	0	'
Payment on intercompany borrowings	0	'
Capital contribution	0	'
Net cash provided by (used in) financing activities	1,252.10	172.8
Effect of currency rate changes on cash	-2.1	0
Net increase in cash and cash equivalents	59.4	0
Cash and cash equivalents at beginning of period	275.5	0
Cash and cash equivalents at end of period	334.9	0
Mallinckrodt plc	'	'
Cash Flows From Operating Activities:	'	'
Net cash (used in) provided by operating activities	8.6	0
Cash Flows From Investing Activities:	'	'
Capital expenditures	0	0
Acquisitions and intangibles, net of cash acquired	0	0
Intercompany loan investment	-21.5	'
Repayment of intercompany loan investment	0	'
Investment in subsidiary	0	'
Restricted cash	0	0
Other	0	0
Net cash (used in) investing activities	-21.5	0
Cash Flows From Financing Activities:	'	'
Issuance of external debt	0	'
Repayment of external debt	0	'
Repayment of capital leases	0	0
Debt financing costs	0	0
Excess tax benefit from share-based compensation	0	0
Proceeds from exercise of share options	16.1	'
Purchase of treasury shares	1.8	'
Net transfers from (to) parent	'	0
Advances from intercompany borrowings	0	'
Payment on intercompany borrowings	-2.4	'
Capital contribution	0	'
Net cash provided by (used in) financing activities	11.9	0
Effect of currency rate changes on cash	0	0
Net increase in cash and cash equivalents	-1	0
Cash and cash equivalents at beginning of period	1.2	0
Cash and cash equivalents at end of period	0.2	0
Mallinckrodt International Finance S.A.	'	'
Cash Flows From Operating Activities:	'	'
Net cash (used in) provided by operating activities	-17.1	-4.8
Cash Flows From Investing Activities:	'	'
Capital expenditures	0	0
Acquisitions and intangibles, net of cash acquired	0	0
Intercompany loan investment	0	'
Repayment of intercompany loan investment	2.4	'
Investment in subsidiary	-1,300	'
Restricted cash	0	0
Other	0	0
Net cash (used in) investing activities	-1,297.60	0
Cash Flows From Financing Activities:	'	'
Issuance of external debt	1,296.80	'
Repayment of external debt	0	'
Repayment of capital leases	0	0
Debt financing costs	-32.2	0
Excess tax benefit from share-based compensation	0	0
Proceeds from exercise of share options	0	'
Purchase of treasury shares	0	'
Net transfers from (to) parent	'	4.8
Advances from intercompany borrowings	80.3	'
Payment on intercompany borrowings	0	'
Capital contribution	0	'
Net cash provided by (used in) financing activities	1,344.90	4.8
Effect of currency rate changes on cash	0	0
Net increase in cash and cash equivalents	30.2	0
Cash and cash equivalents at beginning of period	56.5	0
Cash and cash equivalents at end of period	86.7	0
Other Subsidiaries	'	'
Cash Flows From Operating Activities:	'	'
Net cash (used in) provided by operating activities	149.7	-3
Cash Flows From Investing Activities:	'	'
Capital expenditures	-50.7	-76.7
Acquisitions and intangibles, net of cash acquired	-1,293.20	-88.1
Intercompany loan investment	-58.8	'
Repayment of intercompany loan investment	0	'
Investment in subsidiary	0	'
Restricted cash	4.1	0.9
Other	8	-1.1
Net cash (used in) investing activities	-1,390.60	-165
Cash Flows From Financing Activities:	'	'
Issuance of external debt	0	'
Repayment of external debt	-30.1	'
Repayment of capital leases	-0.7	-0.7
Debt financing costs	0	-2.3
Excess tax benefit from share-based compensation	4	3
Proceeds from exercise of share options	0	'
Purchase of treasury shares	0	'
Net transfers from (to) parent	'	168
Advances from intercompany borrowings	0	'
Payment on intercompany borrowings	0	'
Capital contribution	1,300	'
Net cash provided by (used in) financing activities	1,273.20	168
Effect of currency rate changes on cash	-2.1	0
Net increase in cash and cash equivalents	30.2	0
Cash and cash equivalents at beginning of period	217.8	0
Cash and cash equivalents at end of period	248	0
Eliminations	'	'
Cash Flows From Operating Activities:	'	'
Net cash (used in) provided by operating activities	0	0
Cash Flows From Investing Activities:	'	'
Capital expenditures	0	0
Acquisitions and intangibles, net of cash acquired	0	0
Intercompany loan investment	80.3	'
Repayment of intercompany loan investment	-2.4	'
Investment in subsidiary	1,300	'
Restricted cash	0	0
Other	0	0
Net cash (used in) investing activities	1,377.90	0
Cash Flows From Financing Activities:	'	'
Issuance of external debt	0	'
Repayment of external debt	0	'
Repayment of capital leases	0	0
Debt financing costs	0	0
Excess tax benefit from share-based compensation	0	0
Proceeds from exercise of share options	0	'
Purchase of treasury shares	0	'
Net transfers from (to) parent	'	0
Advances from intercompany borrowings	-80.3	'
Payment on intercompany borrowings	2.4	'
Capital contribution	-1,300	'
Net cash provided by (used in) financing activities	-1,377.90	0
Effect of currency rate changes on cash	0	0
Net increase in cash and cash equivalents	0	0
Cash and cash equivalents at beginning of period	0	0
Cash and cash equivalents at end of period	$0	$0

Subsequent_Events_Details

Subsequent Events (Details) (USD $)	Mar. 28, 2014	Apr. 05, 2014	Mar. 28, 2014	Apr. 11, 2014
		Questcor Pharmaceuticals, Inc.	Lower Passaic River, New Jersey	Lower Passaic River, New Jersey
		Business Acquisition		Loss Contingency
Subsequent Event [Line Items]	'	'	'	'
Date of subsequent event	'	5-Apr-14	'	11-Apr-14
Total consideration to be paid	'	$5,600,000,000	'	'
Cash to be paid per Questcor share	'	30	'	'
Mallinckrodt shares to be issued per Questcor share	'	0.897	'	'
Remedial cost range, minimum	44,900,000	'	365,000,000	365,000,000
Remedial cost range, maximum	118,600,000	'	3,200,000,000	3,200,000,000
Remedial cost, estimate	'	'	1,700,000,000	1,700,000,000
Environmental liabilities	$68,000,000	'	$23,100,000	$23,100,000